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Abstract 
Although Facioscapulohumeral Muscular Dystrophy (FSHD) was first described in 1885, an 
effective treatment is yet to be developed. FSHD is an autosomal dominant disorder 
characterized by distinct chromatin changes including DNA hypomethylation of the D4Z4 
macrosatellite repeat array on a disease-permissive 4qA allele and aberrant expression of the 
D4Z4-embedded DUX4 retrogene in skeletal muscle. Compelling evidence indicates that this 
mutation-induced DUX4 expression plays a key role in disease pathogenesis.  
We initially performed bioinformatic studies which predicted the presence of novel nucleic 
acid regulatory elements, namely G-quadruplexes (GQs), in the DUX4 genomic locus and 
transcript. GQ motifs were identified in transcriptional regulatory elements such as DUX4 
myogenic enhancer and promoter regions, as well as near splice sites of DUX4 transcript. The 
structural characteristics of these putative GQs were characterised and confirmed using 
circular dichroism and nuclear magnetic resonance spectroscopy. Using a reporter gene 
system and cell transfection, mutation of GQ sequences in the DUX4 promoter led to 
decreased reporter gene expression indicating a role in transcription. In addition, when 
expression from the DUX4 genomic sequence was driven by the CMV promoter (lacking GQs) 
expression was also downregulated when transfected cells were treated with the GQ specific, 
small-molecule drug, berberine. The downregulation of DUX4 mRNA expression by berberine 
treatment was also confirmed in FSHD patient muscle cell cultures. High affinity of berberine 
binding to the GQ sequences within the DUX4 enhancer, promoter and transcript, was 
determined using UV, visible light and fluorescence spectroscopic techniques. Although the 
specific molecular mechanisms involved remain as yet to be fully unravelled, these data 
demonstrate for the first time that GQs are present in DUX4 locus sequences and that 
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targeting them can reduce DUX4 expression, and thus that their pharmacological modulation 
may provide a novel therapeutic strategy for the treatment of FSHD. 
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1. Introduction 
1.1. Facioscapulohumeral muscular dystrophy: clinical description 
 Disease discovery 
The first picture published of an affected Facioscapulohumeral (FSHD) patient was 
reported by Duchenne de Boulogne in his Album de photographies pathologiques in 
1862 (Duchenne 1862). Later, in 1869 Duchenne released a more detailed description 
of the disease in Archives of General Medicine (Duchenne 1869), which is often regarded 
as the first reference of FSHD. However, the term Facioscapulohumeral was first devised 
in 1885, when Landouzy and Dejerine described cases of more advanced stages of the 
disease (Landouzy and Dejerine 1885). They highlight the progressive muscle atrophy of 
the face, shoulder girdle and upper arms, followed by weakening of abdominal muscles 
resulting in lumbar hyperlordosis, and of tibialis anterior muscles with steppage gait. 
The first modern clinical characterisation of FSHD was performed by Padberg in 1982 
that involved 107 individuals from 19 families of which 73 subjects showed clinical 
hallmarks of FSHD. Padberg’s studies give the first evidence for extensive clinical 
variability of patients with FSHD, even from the same family (Padberg 1982). 
 Clinical features 
FSHD is a progressive disease that weakens and destroys skeletal muscles. The typical 
clinical manifestation at first involve facial weakness that progresses to shoulder girdle, 
humeral, truncal and anterior leg muscles.  
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Facial weakness is reported in up to 90% of patients, of which over 50% of cases show 
to have the facial muscle affected in an asymmetrical fashion- a trait found useful in 
differential diagnosis of FSHD (Figure 1.1.D) (Padberg 1982). Shoulder girdle weakens is 
reported as the first symptom by around 80% of patients (Padberg 1982) and it is a result 
of atrophy of the scapula fixator and pectoralis muscles (Figure 1.1). The scapula 
weakness is usually asymmetrical and locates to the right side of the body, 
independently of the handedness (Brouwer et al. 1993). Significant number of patients 
(up to 30%) do not develop further symptoms past the shoulder weakness. (Padberg 
1982). In the next stage of the disease a foot extensor or pelvic girdle weakness is 
reported in 80% and 20% of cases, respectively (Padberg 1982). Usually, abdominal 
muscle weakness is reported at this stage that results in lumbar lordosis. Roughly 10% 
of all the patients and 20% of patients past their 50’s will become wheelchair-bound. 
Extraocular, masticatory and cardiac muscles are not considered to be involved in FSHD 
and should be considered for other diagnoses (Padberg 1982; Laforet et al. 1998; A. J. 
van der Kooi et al. 2000). Serum creatine kinase (CK) level is typically less than five times 
the upper limit. Electromyography (EMG) and muscle histology examination show 
myopathic changes that are not FSHD specific (Padberg 2004; Dorobek et al. 2013).  
Non-muscular disease manifestations, include: scoliosis that is present in around 30% of 
patients and might lead to respiratory problems; retinal vasculopathy found in 
approximately 60% of patients that leads to visual loss in less than 1% of cases; high-
tone hearing loss which occurs prominently in early-onset patients (Padberg 1982; 
Padberg et al. 1995; Rogers et al. 2002).  
3 
 
FSHD is an autosomal dominant disease with an age dependent penetrance estimate of 
>95% at 20 years of age (Lemmers and van der Maarel 1993). The prevalence of the 
condition was calculated to be around 1 in 8000 persons (Deenen et al. 2014). However, 
the disease pattern of progression can vary as infantile cases have been reported (Bailey, 
Marzulo, and Hans 1986). In addition, a gender bias manifested by higher penetrance in 
males (95%) vs. females (65%) that carry the FSHD allele has also been found (Zatz et al. 
1998). The underlying reasons why the FSHD does not follow a classical autosomal 
dominant Mendelian chronology is not clearly understood.
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A. 
 
B. 
 
C. 
 
D. 
 
 Figure 1.1 Clinical manifestations of FSHD 
(A.) asymmetrical facial weakness; (B.) and (C.) elevated scapulae and shoulder girdle weakness; D) asymmetric muscle wasting. Images 
were acquired from Padberg, 2004 
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1.2. Genetic basis of FSHD 
The genetic mechanisms behind FSHD are as fascinating as they are complex. This 
autosomal dominant disorder originates from the loss of epigenetic marks within the 
polymorphic D4Z4 macrosatellite repeat on a FSHD-permissive haplotype located at the 
telomeric end of chromosome 4q. The most common form of the disease (FSHD1) is 
caused by a deletion of a large region of the D4Z4 repeat array. In rare cases, mutations 
in Structural Maintenance of Chromosomes Hinge Domain Containing 1 (SMCHD1) gene 
that methylates the D4Z4 region leads to FSHD2. The mutations in both forms of the 
disease results in partial relaxation of D4Z4 chromatin that consequently allows 
expression of a DUX4 transcription factor found to be extremely toxic in skeletal muscle.  
 Contraction of D4Z4 repeat array in FSHD1 
The polymorphic D4Z4 macrosatellite repeat array consist of GC-rich 3.3 kb D4Z4 units 
arranged in head-to-tail fashion in the subtelomeric region of chromosome 4q located 
around 40kb from the telomere repeat (Figure 1.2) (van Deutekom et al. 1993; 
Wijmenga et al. 1992; R. J. L. F. Lemmers et al. 2002). In non-affected individuals, the 
size of the D4Z4 array ranges from 11 to 100 units. A virtually identical repeat array 
localizes to the subtelomeric region of chromosome 10q. In addition, two major variants 
of distant chromosome 4q have been identified, namely 4qA and 4qB. However, only 
contracted 4qA form, with 1-10 repeat units left, can lead to FSHD1. This D4Z4 repeat 
contraction causes chromatin structure relaxation in somatic cells as demonstrated by 
the decreased levels of CpG methylation and loss of histone modification markers within 
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the array (Balog et al. 2012; Zeng et al. 2009). Within each of the D4Z4 unit an open 
reading frame sequence for a retrogene called DUX4 is present. Interestingly, only the 
distal unit can produce a stable DUX4 transcript, since only the last D4Z4 unit is directly 
proceeded by the pLAM region that provides two facultative introns and a crucial 
polyadenylation sequence (ATTAAA) that is specific to 4qA variant only. D4Z4 repeat 
present in other than 4qA chromosome configurations and the homologous sequences 
located at the chromosome 10q that lack the pLAM sequence, even when contracted, 
do not express the DUX4 in somatic skeletal muscle and therefore do not result in FSHD.  
 Role of SMCHD1 in FSHD2 
The FSHD2 term is used to ascribe 5% of FSHD that do not exhibit the D4Z4 repeat 
contraction in the permissive chromosome 4. Despite normal size of the D4Z4 array, 
DNA methylation of D4Z4 is strongly reduced in FSHD2, just as it is in FSHD1, indicating 
a similar epigenetic silencing impairment in both forms of the disease. Whole exome 
sequencing in selected FSHD2 patients has recently identified mutations in (SMCHD1) 
gene located in the chromosome 18 (R. J. L. F. Lemmers et al. 2012). FSHD2 is a complex 
digenic disease where the SMCHD1 mutations are segregated independently from the 
FSHD-permissive chromosome 4q that encodes stable DUX4 transcript. Interestingly, 
SMUCH1 mutations account for approximately 85% of all FSHD2 patients, indicating that 
an FSHD3 locus may be yet to be discovered (Winston et al. 2015; Tawil et al. 2014).  
SMCHD1 is a member of a condensin/cohesin protein complex mediating chromatin 
compaction and has been found to directly bind to D4Z4 repeat array, indicating its 
important role in epigenetic suppression of the FSHD-permissive chromosome 4q (R. J. 
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L. F. Lemmers et al. 2012). SMDCH1 shows preferential binding to longer telomeres in 
human cell lines. A similar mechanism of binding of the protein with affinities dictated 
by the size of the D4Z4 repeats was proposed (Daxinger et al. 2015). However, the exact 
molecular mechanism of SMCH1 binding to D4Z4 repeat array is to be established. 
Interestingly, recent studies suggest that SMCHD1 can act as a disease severity 
regulator, especially in FSHD families that carry the upper-limit of 7-10 within their 
permissive alleles (Sacconi et al. 2013). In these cases, the combined effect of a D4Z4 
array contraction with SMCUH1 mutation results in faster disease progression and 
earlier onset (Sacconi et al. 2013). 
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Figure 1.2 The genetic and molecular mechanism behind the FSHD1 and 2 
In normal, unaffected cases there are 11-100 tightly condensed D4Z4 microsatellite repeat units (triangles) on the sub-telomeric region of 4q35 
chromosome. Large deletion of the D4Z4 repeat units in FSHD1 leaving only 10-1 repeats, leads to chromatin relaxation and allows expression of DUX4 
from the last D4Z4 repeat unit. Non-permissive chromosome alleles do not carry a functional poly(A) signal (green bar) that is essential for transcription 
of a stable DUX4 mRNA. Only the alleles that carry the functional poly(A) sequence (red box) distal to the repeat array can produce stable DUX4 
transcripts that can be translated into toxic DUX4 transcription factor protein. Methylation of D4Z4 repeat array is regulated by SMCHD1. In FSHD2, 
the SMCHD1 becomes mutated and unable to methylate the D4Z4 region, resulting in open chromatin conformation and consequently DUX4 
expression. Abbreviations: FSHD, facioscapulohumeral dystrophy; DUX4, double homeobox 4; SMCHD1, structural maintenance of chromosomes 
flexible hinge domain-containing protein. Images of the patient and muscle histology acquired from the FSH Society website. 
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1.3. DUX4 gene, transcript and protein.  
FSHD1 and FSHD2 are clinically indistinguishable (de Greef et al. 2010). Despite the 
differences in the underlying genetic mechanism behind the FSHD1 and FSHD2, they 
both seem to be a result of an impaired suppression of DUX4 expression in skeletal 
muscle (R. J. L. F. Lemmers et al. 2012). However, due to the complex nature of DUX4 
transcription, it took over a decade to determine its expression by RT-PCR after its open 
reading frame (ORF) was first found within the D4Z4 repeat unit (Hewitt et al. 1994; Dixit 
et al. 2007a).  
 DUX4 gene 
Until relatively recently, repeated DNA elements have been considered as ‘junk’ DNA. 
However, due to recent advances in high throughput technologies, a range of RNAs 
expressed from these repeat elements have been found to play an important role in cell 
biology (Trofimova and Krasikova 2016). Similarly, initial sequence analysis of D4Z4 
region revealed a large ORF of a double homeodomain protein that however lacked a 
promoter, introns and polyadenylation sequences, indicating that it most likely encoded 
a non-functional retrotransposed pseudogene (Hewitt et al. 1994; Lyle et al. 1995; Yip 
and Picketts 2003; Alexiadis et al. 2007). However, subsequent studies have identified a 
functional promoter within the larger ORF and suggested a smaller double homeobox 
DUX4 transcription factor (TF) gene (Gabriels et al. 1999b). Since homeodomain-
containing TFs bind DNA and often regulate embryonic development (Gehring et al. 
1994), and a large number of genes have been found misregulated in FSHD patient 
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muscle cells in initial studies, and the DUX4 gene has become an interesting candidate 
that could help explain genetic mechanism behind the disease (Tupler et al. 1996).  
Detection of a specific DUX4 mRNA has proven to be extremely difficult due to its high 
GC content, very low expression in skeletal muscles and high level of sequence 
alignment with other DUX homologous genes distributed across the human genome 
(Beckers et al. 2001). The first RT-PCR study that could reliably detect DUX4 expression 
in FSHD myoblast confirmed that the gene is expressed from the distal D4Z4 unit 
extending to the pLAM region that contain an intron and a critical polyadenylation 
sequence (Figure 1.3.1) uu. Further publications have provided a detailed standardised 
protocol for RT-PCR that has proven useful to others in the field in confirming expression 
of a stable DUX4 transcript (Snider et al. 2009a; R. J. L. F. Lemmers et al. 2010). The 
complexity of DUX4 detection was also demonstrated by a dilution series experiment 
showing that a small fraction of 1 in a 1000 FSHD myoblasts express DUX4 in vitro (Snider 
et al. 2010).  
Expression of DUX4 mRNA seems to be induced after initiation of the differentiation 
process, as all FSHD myotubes and only a fraction of proliferating cells shows to be 
positive for DUX4 in proliferating myoblast cultures (Dixit et al. 2007a; Snider et al. 
2010a). Interestingly, expression of DUX4 mRNA could not be found in the patient 
muscle biopsies (Snider et al. 2010a), most likely confirming a low abundance of the 
transcript. It was proposed that DUX4 might be preferentially expressed during 
regeneration process, in activated satellite cells and their progenitors that constitute a 
small minority of the total muscle biopsy (Saccone and Puri 2010). Therefore, it would 
be considerably more challenging to detect DUX4 in the adult FSHD biopsies, compared 
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to pathological, highly regenerating or foetal muscles (Richards et al. 2012). Since 
nucleosomes become disrupted during DNA replication in some of the activated satellite 
cells and their progenitors, it could contribute to the relaxed chromatin structure that 
leads to DUX4 de-repression in FSHD cells (Richards et al. 2012). 
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Figure 1.3 DUX4 genomic features and its mRNA variants 
(Top) Schematic representation of the most distal D4Z4 repeat unit, followed by the 
adjacent pLAM region and distal exons. The DUX4 ORF was mapped to the first exon. 
Two poly-A signals were found to be present in exon 3 and distal exon 7, respectively. 
The pLAM region provides an intron and a functional poly-A signal on chromosome 4, 
whereas on chromosome 10 the poly-A sequence is lost. Stop codon maps at the end 
of the exon 1.  
(Bottom) Graphic representation of DUX4 mRNA variants. In all currently investigated 
FSHD myoblasts, only the full length DUX4 (DUX4-fl) ending in exon 3 could be found. 
In addition, DUX4-fl was reported in FSHD embryoid bodies, FSHD fibroblast, and in 
control and FSHD fibroblast-derived IPSC. Germ line tissue also expresses some DUX4-
fl ending in exon 3 and others ending in exon 7. The shorter DUX4 (DUX4-s) isoform 
was reported in muscle and other somatic tissues. All of the above DUX4 mRNA variants 
derive specifically from the chromosome 4 
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 DUX4 transcript 
Increasing evidence indicates that DUX4 transcripts could also play a role in FSHD. It has 
been found that the D4Z4 repeat array is transcribed in bi-directional fashion that forms 
sense and antisense DUX4 mRNA as well as additional small RNAs (Snider et al. 2009a). 
These types of transcript have been implicated in recruitment of Heterochromatin 
Protein 1 that could be involved in maintenance of heterochromatic state of the D4Z4 
repeat unit (Snider et al. 2009a). Moreover, the bi-directional transcription was also 
reported in mouse DUX paralogue (Clapp et al. 2007).  
Location of introns within the 3’UTR of DUX4 could also indicate that levels of the 
transcript might be regulated by the process of nonsense-mediated decay (NMD), as 
suggested by the recent experiments showing that NMD endogenously downregulates 
the DUX4 mRNA levels in muscle (Feng et al. 2015). An increased level of RNAs with 
premature stop codon has been found by the RNA-seq analysis in DUX4-induced 
myoblast cells implying defective NMD. The increased DUX4 expression has also resulted 
in downregulation of UPF1 that most likely directly led to the NMD-mediated 
downregulation (Feng et al. 2015).  
Three DUX4 isoforms have been reported and these include: two full length transcripts 
(DUX4-fl) alternatively spliced in the 3’UTR that encode the complete DUX4 protein; and 
a short splice variant (DUX4-s) that utilises a splice donor site from the exon 1 of the 
coding sequence (Figure 1.3). The translated DUX4-s would produce a protein that                                                                                                                                                                                                                                       
contains the homeodomain (i.e., DNA binding domanin), but lacks the transactivation 
domain of the C-terminal (Figure 1.3)(Dixit et al. 2007; Snider et al. 2009).  
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The process of transcriptional silencing via siRNA has been well understood over the 
years (Holoch and Moazed 2015), and has been also found to be relevant in the context 
of DUX4 expression (Lim et al. 2015). A number of small RNAs have been mapped 
upstream of DUX4 coding sequences and were suggested to mediate silencing of D4Z4 
repeat array (Lim et al. 2015; Snider et al. 2009). Targeting of this distal D4Z4 region with 
exogenous siRNA resulted in augmented H3K9me2 methylation and consequent 
downregulation of DUX4 through Argonaut (AGO)-dependent pathway in FSHD cells 
(Lim et al. 2015). Non-FSHD muscle cells that possess 13 permissive repeat units and 
were subjected to DICER or AGO2 knockdown become positive for DUX4. However, 
when the same approach of DICER or AGO2 downregulation was performed in the cells 
that carried 4 D4Z4 units on a permissive haplotype, there was no apparent induction of 
DUX4 expression, further highlighting the importance of D4Z4 endogenous silencing 
(Lim et al. 2015). This also aligns with the findings showing that SMCHD1 
haploinsufficiency results in limited repression of shorter repeat arrays (Lemmers et al. 
2012). Since AGO proteins regulate elongation rate of RNA polymerase II that influences 
alternative splicing (Ameyar-Zazoua et al. 2012), it would be interesting to determine if 
it also plays a role in splicing regulation of DUX4-fl and -s isoforms. Indeed, finding these 
novel silencing processes of D4Z4 provides a platform for development of new siRNA-
mediated oligonucleotide therapeutic strategies (Lim et al. 2015).  
 DUX4 protein 
DUX4 protein is around 55kDa in size and was first detected in human testis via 
immunodetection on a western blot (Snider et al. 2010). After the first specific 
monoclonal antibody for DUX4 has been developed, studies by Dixit et al., 2007 have 
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managed to detect the protein in FSHD myoblast but not in control samples. The same 
antibody was subsequently used to stain nuclear DUX4 using immunofluorescence and 
the protein has been found to be expressed in approximately 1 in 1000 myoblast, which 
corresponds to the previous RNA data (Snider et al. 2010). However, since DUX4 protein 
levels appear to be extremely low, a number of groups have failed to reproduce the 
above experiments in muscle tissue (personal communication with Dr J. Dumonceaux). 
Another factor considered to be related to low abundance of DUX4 is its poor stability, 
as it has been reported that proteasome inhibition greatly facilitated detection of DUX4 
(Dixit et al. 2007). Also DUX4-induced cell death seems to be much more pronounced in 
myoblast rather than in myotubes, leaving virtually no DUX4-positive myoblasts that can 
be utilised for the protein detection, and few DUX4 expressing nuclei found in 
differentiated myotubes (Bosnakovski et al. 2008). Finally, there are currently no 
positive outcomes from the immunohistochemical experiments that have attempted to 
detect the DUX4 in muscle sections, which makes it difficult to establish whether the 
expression of DUX4 is specific to regenerating fibres or satellite cells (Richards et al. 
2012).  
A lot of scientific effort has recently gone into trying to better understand the biological 
role of DUX4 transcript, its encoded protein and how these potentially lead to FSHD 
pathology. Since DUX4 has been identified as a TF, it was believed that it is most likely 
involved in deregulation of an array of downstream genes. An example of a gene that 
becomes upregulated in FSHD patients by binding of DUX4 to its promoter was PITX1 
(paired-like homeodomain transcription factor 1) (Dixit et al. 2007). PITX1 TF has been 
found to play an important role in limb development and establishment of left/right 
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symmetry, and is frequently found disturbed in FSHD patients (Figure 1.4 B) (see section 
1.1). Furthermore, DUX4 expression in muscle cell culture leads to increased toxicity 
thought to be mediated by the caspase-3 upregulation that subsequently leads to cell 
death (Kowaljow et al. 2007). MyoD levels are also downregulated in DUX4-transfected 
C2C12 cells, which results in impaired differentiation of these cells (Bosnakovski et al. 
2008). PAX3 and PAX7 genes that have been found to regulate muscle regeneration and 
myogenesis have a highly homologous DNA-binding homeodomain to the DUX4 DNA-
binding domain, and it was suggested that these TFs can act as mutual competitors 
(Figure 1.3.1) (Bosnakovski et al. 2008; Buckingham and Relaix 2007). DUX4 could 
therefore interfere with PAX3/7 downstream genes such as MyoD and MYF5 that are 
responsible for normal myogenic signalling (Bosnakovski et al. 2008). A recent RNA-seq 
study show that 118 genes are dysregulated in FSHD muscle biopsies, of which 68% are 
directly regulated by DUX4 expression (Yao et al. 2014), providing a partial explanation 
how a protein expressed in such an extremely low abundance can have such a dramatic 
impact on the muscle cell function. Another mechanism explaining DUX4 potency was 
provided by the study that found the ability of DUX4 TF to diffuse from a single nucleus 
into a larger portion of the myotube affecting gene expression in neighbouring nuclei 
(Figure 1.4 A)(Tassin et al. 2013). 
Development of FSHD transgenic mouse models that use human equivalent genetic 
and/or epigenetic mechanism to drive DUX4 expression has proven to be extremely 
challenging. However, studies that used vector-induced DUX4 expression in mice and 
fish do report myopathic changes in these animals (Snider et al. 2009; Wallace et al. 
2011). Interestingly, knock-out mice for Tp53 shows reduced DUX4-related myotoxicity 
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(Wallace et al. 2011). This data aligns with the previous findings showing p53 pathway 
activation in FSHD muscle tissue (Figure 1.4 B) (Sandri et al. 2001). The p53 as well as 
being implicated in apoptosis and cell cycle regulation, has also been involved in 
regulation of muscle atrophy and metabolic homeostasis (Maddocks and Vousden 2011; 
Schwarzkopf et al. 2006). Recent development of a muscle-specific, doxyciline-induced 
DUX4 expression mouse model shows a new promise in better understanding of DUX4 
role in postnatal muscle (Bosnakovski et al. 2017). In this model, it is possible to induce 
a very low-level expression of the toxic gene, thereby recapitulating more the 
pathophysiological conditions that appear in FSHD patient muscle. Similarly to FSHD 
patients, these animals shows slow progressive degenerative myopathy and high 
frequency hearing loss (Bosnakovski et al. 2017).  
The C-terminal (transactivating) domain of DUX4 protein is believed to play a major role 
in mediating cytotoxic effects, as transfected cells with the DUX4c protein that lack the 
C terminal region do not exhibit myotoxic effects to the same extent as with the full 
length DUX4 protein (Ansseau et al. 2009). The C-terminal region is also absent in DUX4-
s isoform, which was previously found in healthy control muscle samples (Snider et al. 
2010).  
The DUX4 promoter sequence binding elements such as Sp1, YY1 and E box are 
characteristic for genes expressed in terminal differentiation (Dixit et al. 2007). 
However, the fact that half of the Caucasian population lacks the permissive FSHD allele 
suggests that the DUX4 has a limited or no function in the postnatal stages and might be 
more relevant during the development (Lemmers et al. 2002).  
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Figure 1.4 DUX4 transcription factor: process of transcription initiation and propagation cascade 
(A.) Myotubes are multinucleated cells sharing common cytoplasm. Each nucleus can express genes independently. In FSHD, DUX4 is expressed in 
a given nucleus (1.) and becomes transcribed from a distal D4Z4 arrays that contains permissive polyA signal which stabilises its mRNA. Multiple 
copies of DUX4 mRNA are transcribed and transported to the cytoplasm where they become translated into proteins (2.). DUX4 is able to diffuse 
to several adjacent nuclei (3.). (B.) Each imported DUX4 proteins affects expression of a range of genes. DUX4 can amplify its toxic potency by 
abnormally upregulating other transcription factors (e.g., PITX1) that can also diffuse into neighbouring nuclei and activate its target genes such 
as p53. DUX4 expression also leads to downregulation of muscle differentiation master regulator- MyoD transcription fact and upregulate caspase 
3 expression -a key regulator of apoptosis. DUX4 cascade in muscle cells leads to atrophy, reduced differentiation potential, and oxidative stress. 
Figure based on publications by Tassin et al., (2013) and Vanderplank et al., (2011). 
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 Path to understanding DUX4 biological role  
Evidence that DUX4 might be involved in human development comes from the studies 
that found DUX4 expression in human testis (Snider et al. 2010). DUX4 is particularly 
robustly expressed in germline cells under normal conditions (Figure 1.3)(Snider et al. 
2010). However, the transcriptional mechanisms are substantially different to those 
found in FSHD. Germ line cells express DUX4 from both 4qA and 4qB arrays as well as 
the D4Z4 array in the chromosome 10 locus (10q), and instead of the pLAM, the 
polyadenylation signal located within exon 7 is utilised, which extends the DUX4 
transcript over 4 additional untranslated exons (Figure 1.3). The fact that the DUX4 
transcript was also found to be expressed in induced pluripotent stem cells (iPS) cells 
derived from control individuals, further indicates that DUX4 most likely plays a role in 
human development (Snider et al. 2010). This idea was also supported by the study that 
found over 74 genes aberrantly expressed in DUX4-induced cultures that are directly 
involved in stem and germ cell function (Geng et al. 2012).  
Since the DUX4 retrogene is conserved exclusively in primates, it has been challenging 
to study a normal physiological role in development of the gene in standard animal 
models (Clapp et al. 2007). Current approaches focused on induced expression of DUX4 
globally, which resulted in significant defects in zebrafish or was fatal in mouse 
(Mitsuhashi et al. 2013; Bosnakovski et al. 2017). Understanding the complex spatio-
temporal expression of DUX4 during development, and recapitulation of these 
mechanism in an animal model, could lead to better understanding of DUX4 function in 
the future.  
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1.4. Therapeutic strategies to tackle FSHD 
The definitive cure for FSHD has not been found yet. Current therapies focus on 
symptom management and slow down or halting of disease progression. The non-
pharmacological interventions include; orthopaedic intervention, surgical scapular 
fixation; physical therapy; respiratory insufficiency management and aerobic exercise 
(Tawil 2008). Current pharmacological intervention focus on use of corticosteroids that 
reduce inflammation apparent in dystrophic patients (Munsat et al. 1972). Furthermore, 
compounds that could protect muscle mass and function like albuterol and creatine 
monohydrate and are also frequently recommended to FSHD patients (Benson et al. 
1991; Kemp et al. 1993; Tawil 2008). Since impaired methylation of the permissive D4Z4 
array repeat and synthesis of the toxic DUX4 TF are the molecular hallmarks of the FSHD, 
substantial pharmacological research has focused on controlling methylation of the 
D4Z4 and inhibition of DUX4 expression. 
 Attempts to increase methylation of D4Z4 repeats  
Since it has been well established that the hypomethylation of the D4Z4 repeat array is 
one of the main features of FSHD1 and FSHD2 needed for the expression of DUX4 from 
the permissive 4q chromosome (section 1.2), one rational approach to reverse the FSHD 
pathogenesis would be to promote methylation of the D4Z4 region. Indeed, a pilot study 
by Van der Kooi et al., 2006, used folic acid and methionine treatment on FSHD patients 
to test this hypothesis. Both folic acid and vitamin B12 are required for production of 
methionine, which is essential for maintenance of DNA methylation (E. L. van der Kooi 
et al. 2006). Although concentration of serum folate optimal for DNA methylation 
augmentation was achieved, no such an effect was demonstrated in the FSHD or control 
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patients following 12-week treatments. It has been proposed that a dose increase of 
folic acid combined with B12 treatment could be more beneficial (E. L. van der Kooi et 
al. 2006).  
More promising experimental results in epigenetic repression of the D4Z4 region was 
achieved using CRISPR/Cas9 method (Himeda et al. 2016). Authors have modified the 
nuclease-deficient component of the genome engineering tool (dCas9) by fusing it to 
the transcriptional effector domain known as Kruppel associated box (KRAB) that can 
suppress up to 99% of the target gene in human cells (Gilbert et al. 2013). When the 
dCas9-KRAB system was recruited to the promoter of DUX4, it has led to a significant 
downregulation of the toxic TF in the FSHD myocytes (Himeda et al. 2016). In addition, 
the ChIP analysis showed that the KRAB domain has increased recruitment of the HP1α 
HP1β that had a repressive effect on the chromatin of the D4Z4 region (Himeda et al. 
2016).  
 Silencing of DUX4 expression 
There are a number of tools are available that can be utilised to aid gene silencing, 
including: small hairpin RNA (shRNA), micro RNA (miRNA), small interfering RNA (siRNA) 
and antisense oligonucleotide chemistries (Wallace et al. 2011; Marsollier et al. 2016).  
shRNA, miRNA and siRNA are essentially double stranded, negatively charged RNA that 
can lead to target gene silencing through independent pathways (Meister and Tuschl 
2004). siRNA species was successfully used to downregulated DUX4 expression by 
targeting the 3’ untranslated region of the gene (Vanderplanck et al. 2011). Since shRNA 
and miRNA show to be activated and stable in the nucleus, it is believed that these RNA 
species can have a longer lasting effect and require lower doses to mediate gene 
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silencing (Bao et al. 2016). In the study by Wallace et al., DUX4-targeting miRNA was 
delivered via adeno-associated viral (AAV) vector into a mouse model expressing AAV-
induced DUX4, demonstrated a considerable reduction of 90% in DUX4 protein and 64% 
in DUX4 transcript levels (Wallace et al. 2011).  
 Muscle stem cell therapy  
Intramuscular transplantation of cultured myoblasts has been considered as a 
therapeutic strategy for several muscular dystrophies (Tawil 2008). An interesting 
finding comes from the Vilquin et al. study (2005), where it has been found that 
myoblasts derived from FSHD biopsies showing healthy histology have unaffected 
processes of division and differentiation (Vilquin et al. 2005). Therefore, it was proposed 
that these myoblasts could prove useful for autologous cell therapy in FSHD.  
Mesoangioblasts, another type of myogenic mesodermal stem cell, occurring within 
perivascular tissue of skeletal muscle, have been demonstrated to improve muscle 
function and morphology as shown in dystrophic animal models injected with these cells 
(Morosetti et al. 2007). Mesoangioblasts derived from FSHD patient muscle tissue, show 
to have abnormal morphology and impaired differentiation (Morosetti et al. 2007). 
Interestingly, it was possible to obtain biopsies from FSHD mosaic patients that 
produced mesoangioblast populations that were morphologically normal, and 
functioning virtually as control cells (Morosetti et al. 2007). This raises an opportunity 
to use mesoangioblasts for autologous cell therapy. An advantage of using 
mesoangioblasts over myoblasts is the fact that these cells can be delivered 
systematically, whereas the intramuscular injection of myoblasts have a less practical 
use clinically (Berry 2015).  
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1.5. G-quadruplexes: structure, function and roles as therapeutic target. 
 G-quadruplex nucleic acid motifs 
All known living organisms contain genetic information in the form of long linear chains 
of copolymers composed of many nucleotide units (Koonin and Novozhilov, 2009). 
These molecules, known as DNA and RNA, are typically formed from five different types 
of nucleotide bases: the pyrimidines - cytosine (C), thymine (T) and uracil (U); and 
purines - adenine (A) and guanine (G) (Nordhoff et al. 1996). While the T is specific to 
DNA, the U is characteristic for the RNA polymers. The most commonly occurring 
complimentary base pairing of nucleotides in the biological systems occurs via hydrogen 
bonding of A to T or U, and G to C. The A-T (-U) and G-C base pairs are held together by 
two and three hydrogen bonds, respectively (Nordhoff et al. 1996). In the contexts of 
DNA, this classical complementary base paring of nucleotides results in the formation of 
two anti-parallel strands that form the well-known, right handed canonical double helix 
(B-form) secondary structure, which was first proposed by James Watson and Francis 
Crick in 1953 (Watson and Crick, 1953). While the ability of the DNA to form secondary 
structure has been well characterised in the recent past, the discovery that in addition 
to storing and passing on information, the DNA is also capable of G-quadruplex (GQ) 
structure formation, has suggested a novel role of DNA in biology (Yang and Okamoto 
2010).  
Before the B-form DNA structure was discovered, it has been found that at high 
concentrations, G nucleotides form gels that were not characteristic for any other 
nucleobases (Bang 1910). Over 50 years later, it appeared that the gelatinous substance 
was composed of G-tetrad structures (Gellert et al. 1962). In the G-tetrad, four G 
26 
 
residues hydrogen bonded together are held in a square planar array via Hoogsteen 
pairings as opposed to the classical Watson-Crick hydrogen bonding found in the B-form 
duplex (Huppert 2010). Further stabilisation of the G-tetrad is mediated by the presence 
of monovalent cations, usually K+ and Na+ (Sen and Gilbert 1990). Since the intracellular 
concentration of K+ (140 mM) is considerably higher than of Na+ (10 mM), it is 
considered physiologically more relevant in the context of GQ formation and 
stabilisation (Sen and Gilbert 1990). The centrally positioned monovalent cation within 
the G-tetrad coordinates to O6 atom of each guanine via strong negative electrostatic 
interaction (Figure 1.5 A). The linear array assembly running through the centre of the 
core G-tetrad is promoted by the polarizable aromatic surface of guanine, this creates 
large π surfaces with a high propensity to stack (Huppert 2008). A core of two or more 
π-π G-tetrads are considered to be sufficient to form a GQ structure. 
 GQ topology 
In both DNA and RNA, the G-tetrads are held together by intervening sequences that are 
variable in length and nucleotide composition. These stretches form loops and run on 
the exterior edges of the core. Similarly to the amino acid side-chains in proteins, the 
loops are the key element that define the structural variability in GQs. The diversity in 
loop sequences results in highly variable (and sometimes flexible) cavities on the 
exterior of GQs that can form part of ligand binding sites (Balasubramanian et al.2011).  
In addition, the presence of different cations can promote formation of diverse GQ 
conformations of the same G-rich sequence (Yang and Okamoto 2010). For example, the 
conserved human telomeric DNA sequence consists of tandem repeats, and thus lacks 
this sequence variability. This elegantly evolved telomeric sequence is able to form 
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various GQ structures with low energy differences and therefore convey intrinsic 
structure polymorphism. 
Another factor that influences the GQ formation is the number of strands used to form 
the structure. In theory, the GQ can be formed from four separate DNA/RNA strands 
(tetramolecular), two distinct DNA/RNA strands (bimolecular) or a single, continuous 
strand (unimolecular or intramolecular) (Figure 1.5 B). The unimolecular GQ has been 
considered to be the most biologically relevant and its structure extensively studied, 
especially in gene promoters and telomere regions (Balasubramanian et al. 2011). A 
unimolecular GQ consist of four G-tracts (continuous or discontinuous), three or more 
loops and two flanking segments. Two types of G-tract can be distinguished based on 
their direction: parallel and anti-parallel (Figure 1.5 B). The parallel and anti-parallel 
strand directionality is associated with specific sugar glycosidic conformation. The 
possible glycosidic conformations that form between the guanine base and its sugar 
backbone are syn and anti (Figure 1.5 C). The guanines from the parallel G-tract have 
the same glycosidic conformation, whereas the antiparallel G-tract will adopt the 
opposite glycosidic conformation. Loops form three conformations: strand reversal 
(joining adjacent parallel strands), lateral (connecting adjacent antiparallel strands) and 
diagonal (coupling together diagonal antiparallel strands on opposite sides of the tetrad) 
(Figure 1.5 B).  
The first biologically relevant GQs were found in eukaryotic chromosomal telomeric DNA 
(E. Henderson et al. 1987). Human telomeres consist of 5-10 kb d(TTAGGG)¬n tandem 
sequences with a 50-600 nt single stranded 3’ overhang at chromosome ends that are 
capable of forming DNA GQs (de Lange 2005). The presence of the DNA GQs in the 
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human telomere has been demonstrated to diminish activity of telomerase, which is 
over activated in 80 to 85% of cancer, making it an attractive drug target (Kim et al. 
1994). Structure of the telomeric GQ has been found to be rather complex. It has been 
shown that in the presence of K+, it forms two coexisting hybrid structures that possess 
mixed parallel and anti-parallel G-tracts making the GQ structure (Ambrus et al. 2006a). 
Since the composition of the G-tracts is the same, it is the position of the strands that 
allows distinction of the two hybrid structures (Figure 1.5 B). Flanking sequences and 
loop content is the main contributor for the formation of these hybrid forms. Presence 
of these two hybrid structures helps explain the multimeric formation at the human 
telomere 3’ overhang. It was also suggested that the structural polymorphism, caused 
by the asymmetry of the telomeric sequence forming GQs, could provide a platform for 
protein recognition, and hence control of telomere biology (Dai, Carver, and Yang 2008).  
In recent years there was a lot of effort to try and describe structure of GQs, especially 
those present in a number of oncogene promoters (Balasubramanian et al. 2011). 
Compared to the invariable human telomeric sequence, the GQs present within the 
gene promoter regions are more diverse in sequence, possessing different length G-
tracts and flanking sequences. Several GQ structures have been described in oncogene 
promoters. These include genes encoding c-MYC, B cell lymphoma 2 (BCL-2), hypoxia-
inducible factor 1 α (HIF1α), vascular endothelial growth factor (VEGF), retinoblastoma 
protein 1 (RB1), the transcription factor MYB, human telomerase reverse transcriptase 
and platelet-derived growth factor α polypeptide (PDGFA) (Huppert 2010). Out of all of 
the above listed genes, the c-MYC was the first and most thoroughly investigated system 
for the promoter GQ formation (Seenisamy et al. 2004). Within the promoter, the GQ 
motif maps to the nuclease hypersensitivity element III (NHE III) that consist of 33 
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nucleotides and contains six G-tracts of unequal lengths. The predominant GQ formed 
within the c-MYC promoter is a parallel-stranded structure. The G-tetrads are connected 
by two single nucleotide loops and one two nucleotide loop. Interestingly, these parallel-
stranded structures appear to be the most common type of GQ structure in promoter 
regions (Agrawal et al. 2014). 
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Figure 1.5 GQ structure topology 
(A.) Four guanines (G) can self-assemble into stable square planar arrays known as the G-quartet (left panel). Guanines are held together by four 
hydrogen bonds on each guanine (shown by the dashed red lines) and may be further stabilized by the presence of monovalent cations (orange 
ball). Stacking of G-quartets generates a GQ (right panel). (B.) A basic classification of GQ structures by the number of oligonucleotide strands 
used to form a quadruplex structure. Tetramolecular structures are generated from four separate strands; bimolecular structures are generated 
from two separate strands while unimolecular structures are folded structures derived from a single guanine-rich strand. Looping sequences are 
highlighted in red and strand polarity is indicated by arrow directions. (C.) The glycosidic bond angle of G-quartets will change depending of the 
polarity of strands in a GQ. 
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 Detection, visualization and mapping of GQs in cells 
1.5.3.1. Antibody and small molecule based approach to localize GQs in cells 
Computational analysis is a useful tool to predict putative GQ motifs across genomes. 
The potential and application of these algorithms are discussed in more detail in section 
3.2.1. However, since the computational methods predict consensus GQ sequences 
only, potential structures that are formed from non-canonical sequences could be 
potentially omitted (Schiavone et al. 2014). Furthermore, long repeated DNA sequences 
are not available in current sequence databases, which could lead to underestimation 
of potential genomic GQ (Rhodes and Lipps 2015). Importantly, current algorithms 
predict the GQ motifs to be particularly enriched in non-random, functional locations of 
the genome such as telomeres, promoters and first introns (Konig et al 2010). Indeed, it 
is important that the potential role(s) of GQs are studied in a biologically relevant 
context.  
One of the current methods that aids visualisation of DNA structures in cells, utilises 
structure-specific molecular probes. Antibodies are an extremely powerful tool in 
detecting molecular structures of a particular protein with an astonishing specificity 
(Hansel-Hertsch et al. 2017). These can be also synthesised by either immunization or 
by affinity in vitro selection to recognize particular DNA or RNA structures. For example, 
a GQ-specific single chain variable fragment (scFV) of an antibody, has allowed first 
visualisation of a biologically relevant GQ formation in the telomeres of the Stylonychia 
lemnae ciliate (Schaffitzel et al. 2001). Two additional GQ-selective antibodies, 1H6 and 
BG4, have been produced and used to visualize these motifs using immunofluorescence 
microscopy in human cells (A. Henderson et al. 2014; Biffi et al. 2013). Each antibody 
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was tested by separate groups in a number of fixed human cell lines, showing cell cycle 
dynamic GQ formation with the maximum number of the structures being formed in the 
S-phase (Biffi et al. 2013). Interestingly, the number of GQ nuclear foci increased when 
the live cells were treated with the structure specific ligands, including TMPyP4, Phen-
DC3 and pyridostatin (PDS), suggesting that these compounds have the potential to 
stabilise the motifs (Henderson et al. 2014; Biffi et al. 2013). Furthermore, depletion of 
GQ-specific helicase Fanconi anaemia group J protein (FANCJ) resulted in an increase of 
GQ foci in chicken DT40 cells treated with the stabilising ligand (A. Henderson et al. 
2014).  
Modified small molecules that can bind GQ also have been used to detect these 
structures. A fluorophore fused PDS (PDSα) molecule staining has shown a significant 
accumulation of its signal with the GQ-helicase integration frequency peptide 1 (PIF1) in 
osteosarcoma cells (U20S), further supporting the role of PIF1 in regulation of GQ 
structures in human cells (Rodriguez et al. 2012). When other intrinsically fluorescent 
ligands, DAOTA-M2 and BMVC, were used to visualise GQs, it was found that the motifs 
are significantly enriched in some cancer cell lines compared to the control cells (Huang 
et al. 2015; Shivalingam et al. 2015).  
Both GQ-specific small molecules and antibodies can potentially influence stability of 
the motifs through simple binding interactions. Therefore, it is important to supplement 
the probe-based studies with observation of normal biological processes (e.g., cell cycle) 
or perform functional analysis by perturbation of key enzymes that regulate GQ stability, 
to ensure that probe binding would act independent of these processes.   
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1.5.3.2. Mapping of genomic GQs in cells  
One approach to map GQs in a purified single stranded human DNA, used next 
generation sequencing and GQ-induced DNA polymerase stalling (Chambers et al. 
2015a). In this method the isolated DNA is first sequenced under conditions that do not 
favour folding of GQ, following by sequencing of the same DNA that is sequenced in the 
presence of ions (e.g., K+) or ligands (e.g., PDS) that promote quadruplex formation. The 
GQ dependent DNA polymerase stalling events are compared between the two 
sequencing procedures. As a result, over 700,000 GQ were identified. This number 
exceeds that predicted by the bioinformatic estimations, which can be partially 
explained by false positive results caused by the non-guanine sequences forming bulges 
or formation of considerably longer loop sequences that are not accounted for in the 
standard algorithms (Huppert and Balasubramanian 2005). This data suggest that the 
human genome sequence has the potential to form GQs in numbers vastly exceeding 
previous estimations (Bedrat et al. 2016). It also confirms that the GQs were particularly 
enriched within the promoters, 5’ untranslated regions and splice sites as well as cancer 
related genes (Chambers et al. 2015a). 
The main pitfall of analysing GQs using bioinformatics and the high throughput 
sequencing methods is the fact that the DNA is predominately double-stranded (except 
for telomeric overhangs and transcripts) and condensed in the form of chromatin. In 
recent reports, detection of GQ utilising GQ-specific antibodies to probe the motif 
structures using ChIP-seq method, has been explored (Rodriguez et al. 2012; Hansel-
Hertsch et al. 2016). They have compared fixed chromatin derived from primary human 
epidermal keratinocyte (NHEK) cells to the immortalised pre-cancerous keratinocytes 
(HaCaT) (Hansel-Hertsch et al. 2016). It has been found that only around 10,000 and 
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1,000 GQ structures could be detected in the chromatin of HaCaT and NHEK cells, 
respectively. This constitutes around 1% of the GQs found by the sequencing 
experiments or bioinformatic analysis, indicating that the GQs are supressed in the 
chromatin state. Proteins might play a vital role in regulating GQ formation, as it has 
been found that GQs are particularly enriched within regions of chromatin that are 
deprived from nucleosomes- a highly transcribed sites (Hansel-Hertsch et al. 2016). In 
addition, the histone deacetylase inhibitor treatment that leads to chromatin 
condensation also resulted in decreased GQ detection by Chip-seq, consistent with the 
idea that GQ formation is correlated with transcriptionally active genomic sequences. 
Interestingly, this study also has showed that the identified sequences significantly 
overlap with binding sequences of transcription helicases, including xeroderma 
pigmentosum group B- complementing protein (XPB) and XPD (Gray et al. 2014). In 
addition, the ChIP-seq-based analysis has demonstrated that various proteins map to 
the regions that have been predicted to be significantly enriched in GQ forming 
sequences, including: α-thalasemia/ mental retardation syndrome X-linked human 
helicases; the Pif1 helicase from yeast and the RAP1-interacting factor 1 telomere 
protein (Whitehouse and Hughes 2010; Kanoh et al. 2015). Despite the fact that the 
helicases are able to bind to a range of genomic sequence, increasing evidence suggests 
that these might also play an important role in GQ regulation. 
 Formation and regulation of GQs in cells 
Since GQs formed from short artificial stretches of nucleotides are shown to be 
extremely stable and with their thermal stability significantly exceeding physiological 
range, it is important to understand how folding and unfolding kinetics of these motifs 
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are regulated in real cellular situations. This is especially important, considering that 
cellular ionic composition, consisting typically of 5-15 nM Na+, 140 nM K+ and 0.5-2 mM 
Mg2+ (pH 7.2), is particularly favourable for GQ formation (Davis 2004). The assumption 
that there are cellular proteins regulating GQ structures becomes increasingly 
supported by the accumulating number of reports suggesting that chaperone and 
helicase proteins are responsible for GQ folding and unfolding, respectively (Rhodes and 
Lipps, 2015).  
Predominant evidence showing that chaperones control GQ folding comes from the 
studies of telomeres. It has been demonstrated two decades ago that the double 
stranded DNA binding protein, Rap1, induces telomeric GQ formation in S. cerevisiae 
(Rhodes and Giraldo 1995). Yeast telomerase regulatory subunit Est1 has also been 
shown to bind and stabilise GQ, as well as the human telomeric binding protein TRF2 
(Biffi et al. 2012). A convincing in vivo experiment has demonstrated that the ciliate 
telomere ending protein (TEBPβ), regulates GQ folding in a cell cycle dependent fashion 
(Fang and Cech 1993). In addition, TEBPβ has been shown to increase GQ formation by 
105  - 106 fold in vitro. Another example of a human protein that binds to GQs is MutSα, 
which was previously implicated in recognising DNA mismatches (Larson et al. 2005). 
Nucleophosmin (NPM1), a frequently mutated gene in acute myeloid leukaemia that 
normally is involved in ribosome maturation processes, has also been found to bind 
ribosomal DNA that forms GQs both in vitro and in vivo (Chiarella et al. 2013). A well-
established GQ binding protein, nucleolin, has been recently shown to be sequestered 
by the presence of an aborted RNA transcript sequence which are carrying expanded 
hexanucleotide repeat (GGGGCC)n that forms GQs (Dempsey et al. 1999).  
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As mentioned above, helicases are very likely to play a major role in GQ unwinding. 
Helicase enzymes are part of a larger ATP-dependent family of proteins that are involved 
in unwinding of nuclei acids and are also implicated in genome stability regulation 
(Singleton et al. 2007). An important insight into the role of helicases in GQ structure 
regulation and genome stability came from studies of genetic diseases that are caused 
by mutations of these enzymes (Rhodes and Lipps 2015). The conserved domain of RQC 
present in human WRN and BLM helicases show high affinity binding to GQs, and when 
mutated it results in Werner and Blooms syndrome, respectively (Lipps and Rhodes 
2009). Interestingly, the DOG-1 helicase found in C.elegans seems to be essential to 
maintain the genomic G-rich sequences, especially the ones that have been predicted 
to form GQs (Cheung et al. 2002). The human orthologue of DOG-1, FANCJ helicase, 
when mutated has been found to result in the heritable cancer susceptibility disorder, 
Fanconi anaemia (London et al. 2008). The patient cell lines have large stretches of DNA 
deleted that are mapped to GQ forming regions. The in vitro experiments showing 
preferential unwinding of GQs over the double stranded DNA by the FANCJ, suggest that 
just like the DOG-1, these helicases are involved in resolving of transcriptional barriers 
formed by the DNA GQs (London et al. 2008). Also, RETL1, a DNA helicase regulating 
telomeres length, when mutated, it increases susceptibility to certain cancers and was 
also implicated in GQ unwinding, given its high homology to FANCJ and DOG-1 (Vannier 
et al. 2012). However, due to lack of the biochemical evidence of the RETL1 on GQ 
unwinding, more work is required to support this idea. PIF1 DNA helicase is another 
protein that is highly conserved and shows GQ unwinding ability (Paeschke et al. 2013). 
As previously mentioned, Pif1 of S.cerevisiae not only binds GQ sequences as shown by 
ChIP-seq analysis, but also when deprived from cells, it induces DNA double strand 
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breaks (Ribeyre et al. 2009; Lopes et al. 2011; Paeschke et al. 2013). It appears that when 
a GQ unwinding helicase is absent or dysfunctional, a number of nucleases can become 
involved in deletion of G-tracts that could be potentially involved in the quadruplex 
formation. Example of such nucleases, include: the yeast Kem1 and human DNA2, FEN1 
and EXO1 (Vallur and Maizels 2008; Liu and Gilbert 1994). All of these have been found 
to cleave GQs in vitro. Normally, FEN1 and EXO1 are involved DNA replication and 
telomere maintenance. In addition, when these nucleases are absent, the telomeres are 
not maintained correctly and become dysfunctional (Saharia et al. 2008). Another 
protein that has an important role in telomere maintenance, RPA, has been 
demonstrated to drive the kinetic equilibrium from the folded to unfolded state of 
quadruplex structures in vitro (Safa et al. 2014). 
On the level of translation, an DEAH-box human RNA helicase RHAU has been identified 
to bind and resolve RNA GQs into linear forms (Lattmann et al. 2011). Over 100 RNAs 
have been identified to be bound by the helicase at sites that potentially form GQs in 
vivo. Furthermore, it has been found in vitro and in vivo that binding of RHAU to one of 
its targets which is the human telomerase RNA TER, depends on the presence of a stable 
GQ structure within the 5’-region of the TER’s transcript. Additionally, disruption of the 
RHAU helicase lead to incorrect telomerase assembly and telomer extension (Booy et 
al. 2012). Together, these findings strongly indicate the there is a vast array of proteins 
mediating GQ unfolding that are involved in preventing DNA breaks, and interruption of 
replication and translational processes.  
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 Role of GQs in transcription and translation. 
Considering that over 50% of human gene promoters were found to potentially form 
GQs within their sequence, it is tempting to speculate that these motifs might play an 
important role in gene expression regulation (Huppert and Balasubramanian 2005). 
Interestingly, it has been predicted that the promoters of oncogenes and regulatory 
genes, for instance transcription factors, are particularly likely to contain GQs compared 
to other gene types, such as promoter tumour suppressor and housekeeping genes 
(Huppert and Balasubramanian 2005; Nakken et al. 2009). This pattern of GQs presence 
seems to be conserved in other organisms, for example bacteria, yeast and plants (Capra 
et al. 2010; Hershman et al. 2008; Todd et al. 2005). Furthermore, the GQs in humans 
are predominately found in the non-template strand and also to congregate at 5’ of the 
5’UTR (Huppert 2008). In bacteria transformed with GQ encoding plasmid on the non-
template strand, a loop structure formation was detected on the complementary 
strand, indicating formation of the GQs in cells during transcription (Duquette et al. 
2004). GQ formation in this case could release the template strand from the double 
stranded conformation in order to allow uninterrupted, high level transcription 
(Duquette et al. 2004). Therefore, since it is generally believed that the GQ formation 
on the non-template strand has an enhancing effect on transcription, it has been also 
suggested that the GQ present on the template strand could inhibit transcription by 
potentially blocking the transcription machinery  (Qin and Hurley 2008) (Figure 1.6).  
One of the first and best studied examples of GQ role in transcription regulation comes 
from the study of the c-MYC oncogene promoter (Huppert 2010). MYC is a cell 
proliferation-associated transcription factor that has been found upregulated in 80% of 
the human cancer cells (Pelengaris et al. 2002). The c-MYC promoter region contains GQ 
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forming sequence that has been shown to control over 80% of the gene’s expression 
(Simonsson et al. 1998). The reporter studies comparing gene expression driven by the 
wild-type c-MYC  promoter to the one carrying sequence mutation disrupting 
quadruplex formation, have demonstrated that presence of the GQ within the promoter 
sequence supresses gene expression (Siddiqui-Jain et al. 2002). In addition, treatment 
with a GQ stabilising ligand, TMPyP4, has also shown decrease in c-MYC transcription in 
lymphoma cell lines as well as antitumor effects in mice (Grand et al. 2002). However, 
since the TMPyP4 is not GQ specific and it shows binding affinity also to double stranded 
DNA in multiple regions of the genome, more work needs to be done in order to 
establish the exact mode of action of this chemistry. Interestingly, a highly selective 
compound for the c-MYC promoter-related GQ known as GQC-05 has been found. Its 
treatment of Burkit’s lymphoma cell line has led to significant reduction of c-MYC mRNA 
expression, further highlighting the potential of rational drug design for the 
development of highly specific GQ chemistries (Brown et al. 2011).  
Previously mentioned GQ-binding protein, nucleolin, is one of the most abundant 
cellular proteins and has been found to bind to the promoter sequence of c-MYC. What 
is more, over-expression of nucleolin leads to dose-dependent reduction of MYC 
transcription (González and Hurley 2010). It has been suggested that the nucleolin-
mediated oncogene suppression is mediated by binding and stabilising of the c-MYC-
related GQ, which prevents binding of the transcription activating factors (e.g., SP1 and 
CNBP) (González et al. 2009).  
GQs have been found vastly overrepresented within 5’UTRs of a large number of genes, 
suggesting their important role in translation regulation (Bugaut and Balasubramanian 
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2008). It was initially speculated that presence of the extremely thermodynamically 
stable GQs within the 5’UTR would result in an inhibition of translation, and indeed this 
has been found to be the case for number of genes, including: Bcl-2, ESR1, FMR1, NRas, 
TRF2, Zic-1 and Mt3-MMP (Bugaut and Balasubramanian, 2008). However, cases where 
translation becomes enhanced by the presence of the 5’ UTR GQs have also been 
demonstrated for fibroblast growth factor 2 and vascular endothelial growth factor 
transcripts (Bonnal et al. 2003; Morris et al. 2010). Another example demonstrating that 
mRNA GQs can regulate translation, comes from the studies of fragile X mental 
retardation, where the transcript expansion of the (CGG)n repeat causes the mental 
retardation protein (FMRP) to bind to its own transcript. It has been demonstrated that 
the expanded transcript variant forms GQ stable structures that promote binding to the 
FMRP (Brown et al. 2011). This FMRP binding to the GQ-forming transcript lead to 
abnormal mRNA processing and consequently result in the disease pathology (Darnell 
et al. 2001). Furthermore, GQs have also been found present within the 3’UTR of 
transcripts where they mediate alternative polyadenylation and transcript shortening 
(Beaudoin et al. 2014).  
Identification of RNA helicases such as RHAU that bind GQs with high affinity, also 
indicates that GQs could be instrumental in regulation of translation (Lattmann et al. 
2011). 
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Figure 1.6 Potential roles of GQs in regulating transcription 
(A.) GQs were suggested to act as physical barrier on the template strand that stalls or 
inhibits polymerase (orange) that consequently prevents transcription. (B.) Formation 
of the GQ on the coding strand may facilitate transcription by keeping the template 
strand in the open conformation. (C.) GQs could recruit transcriptional activator proteins 
(green) that promote transcription. (D.) Alternatively, GQs can recruit transcriptional 
suppressor proteins (grey, yellow) that inhibit transcription. 
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 DNA and RNA GQs as a target for small-molecules compounds. 
Design and development of effective GQ-binding small molecules still presents many 
challenges. These limitations particularly concern specificity of binding to GQs over 
duplex DNA structures, selectivity of various GQ types distributed across the genomic 
loci (e.g., telomeric vs. promoter DNA), and binding selectivity to different nucleic acid 
chemistries, e.g., DNA vs. RNA. Although GQs show a vast diversity in their structures, 
there are many common characteristics in their conformation that can be utilised for 
development of small molecule chemistries. These strategies were particularly explored 
in the targeting of telomere, promoter and 5’UTR related GQs.  
1.5.6.1. GQ targeting: telomeric DNA 
The first investigation looking at the effects of small-molecule binding to GQs was 
performed in the context of telomerase activity, which can become inhibited upon 
treatment that stabilises telomeric GQ structures (Sun et al. 1997). Consequently, a 
number of novel compounds have been developed that show binding to the telomeric 
DNA GQs. However, despite development of a large library of these compounds (listed 
in online ‘G-quadruplex Ligands Database’), only a handful of these molecules have been 
tested in cell-based systems, of which very few have reached clinical trials (De Cian et 
al. 2007). When designing small molecules to bind GQs with high affinity and specificity, 
three main chemical properties typically are maintained: 
a)  A large aromatic core that ensure maximal π stacking interaction of the G-
tetrad. 
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b) Presence of a positive charge that uses the negative charges of the negatively 
charged phosphate backbone to enhance interactions. 
c) Introduction of sidechain groups that increase specific interactions with specific 
loops/grooves or individual bases of a particular GQ structure.  
Existing methods that help accelerated rational design of small molecules with optimal 
binding properties to a given GQ structures combine high-resolution NMR and X-ray 
crystallography with computational molecular modelling methods (Li et al. 2013). The 
candidate molecules are subsequently assessed for quadruplex-ligand binding using a 
range of biophysical techniques, including circular dichroism-UV, fluorescent resonance 
energy transfer or electrospray ionisation mass spectrometry. Many small molecule 
chemistries have been developed using the above approach with many showing 
preferential binding to GQ over duplex DNA structures, and specificity for telomeric 
quadruplexes over other types of the motif structure found for example in the promoter 
sequences (De Cian et al. 2007).  
When screening test compounds, it is important to choose appropriate cell lines in order 
to assess their toxicity and ensure it is relatively low. Recently, the most comprehensive 
testing of telomeric DNA quadruplex binding in cell-based and in vivo systems has been 
performed for BRACO19, RHSP4 and telomestatin (Burger et al. 2005; Phatak et al. 2007; 
Tauchi et al. 2006). Despite a range of the compounds being synthesised and tested for 
their efficacy and safety, only one candidate has reached clinical trials, namely 
Quarfloxin. The ineffectiveness of these compounds is often attributed to their ability to 
bind off-target protein, RNA and DNA species. It has to be noted that the d(TTAGGG) 
quadruplex-forming telomeric sequence, apart from the telomeric ends, can also be 
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found in a number of regions within the genome (Todd and Neidle 2011). Therefore, any 
future quadruplex-drug design has to consider any potential off-target sites that the 
potential chemistry might bind inside the cells.  
1.5.6.2. GQ targeting: promoter DNA 
During the transcriptional process, the double-stranded DNA structure becomes 
transiently opened, which allows for the formation of a quadruplex within the G-rich 
stand and an i-motif on the complimentary C-rich strand (Brooks et al. 2010). This event 
presents an opportunity to develop small molecules that target and stabilise either of 
these structures to regulate transcription. The main limitation behind the quadruplex/i-
motif formation within the promoter sequences, is the stability of the double stranded 
DNA. However, presence of the hypersensitive elements (e.g., found in c-MYC promoter) 
and susceptibility of promoter sequences to transcription-induced supercoiling, can 
dramatically facilitate formation of these secondary structures over the duplex form 
(Sun and Hurley 2009). 
When performing bioinformatic identification of promoter GQs, it has to be noted that 
that the general algorithms that identify typical GQs of 3-5 G-runs linked by 1-7 
nucleotides, might omit promoter quadruplexes that can contain linking sequences of 
up to 26 nucleotides and extended G-runs as reported in the PDGF-A promoter (Todd et 
al. 2005). Therefore, selection of a correct sequence that will result in biologically 
relevant quadruplex forming structure is critical for rational drug design and 
development.  The first example of gene expression at the transcription comes from a 
study of TMPyP4 ligand on the expression of c-MYC oncogene (Siddiqui-Jain et al. 2002). 
The TMPyP4-mediated effects leads to gene expression inhibition, and combined with 
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mutagenesis studies of the quadruplex sequence, it has been confirmed that the 
presence the stable motif within the promoter is responsible for inhibition of the c-MYC 
expression (Siddiqui-Jain et al. 2002). Additional examples of promoter forming GQs 
were found within promoters of BCL2, c-KIT, VEGF and HIF1-α, where their presence has 
been found to be generally inhibitory, except for the VEGF promoter in which the 
presence of the quadruplex has been shown to have an enhancing effect on the rate of 
transcription (Figure 1.7 B)(Dash et al. 2008; De Armond et al. 2005; Nambiar et al. 2011; 
Sun et al. 2008). As for the telomeric quadruplexes, the same limitations exist when it 
comes to designing small molecules targeting these structures. Despite the promising 
specificity for quadruplex over duplex that can be achieved with current chemistries, 
targeting of quadruplex structures for specific promoters still remains a major challenge.  
1.5.6.3. GQ targeting: mRNA 5’UTR 
As previously mentioned, bioinformatic analysis has found a significant enrichment of 
GQs present within 5’UTR of mRNAs, indicating that these motifs might play a role in 
gene expression regulation (Huppert and Balasubramanian 2005). The first 
demonstration of function of 5’UTR GQs comes from the study of NRAS proto-oncogene, 
where it has been found that the formation of the stable motif structure within the 
5’UTR leads to the gene downregulation (Figure 1.7 C) (Kumari et al. 2007). It has been 
suggested that the gene expression downregulation is caused by the quadruplex-
induced steric blocking of the ribosome complex and inhibition of translation initiation 
(Kumari et al. 2007). One advantage of targeting 5’UTR quadruplexes is the fact that the 
mRNA is single-stranded, and there is no complimentary strand that competes with the 
motif for the duplex formation.  
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Another example of RNA GQ structure involvement in disease pathogenesis comes from 
the study of Fragile X mental retardation syndrome, where the disease-causing proteins, 
FMRP1 and FMRP2, have been demonstrated to bind and stabilise GQs of 5’UTR of a 
variety of gene transcripts (e.g., PP2 and MAPB1)(Castets et al. 2005; Darnell et al. 2001). 
In addition, the FMRP1 has been found to also bind directly to quadruplexes within its 
own coding sequence and within the mRNA of AAP gene (Westmark and Malter 2007). 
The FMRP1 quadruplex forming sequence within the coding region of the gene has been 
suggested to be a potential exon splice enhancer, since the FMRP1 and 2 have been 
demonstrated to bind to these motifs and affect splicing patters of the affected mRNA 
(Didiot et al. 2008). Interestingly, the FMRP1 has been also shown to bind RNA GQ 
targets within 3’UTR of a number of genes, however the potential role of these motifs is 
yet to be determined (Darnell et al. 2001). 
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Figure 1.7 Potential roles of GQs in gene expression regulation 
Genome wide bioinformatic analysis have demonstrated the presence of non-randomly 
distributed GQs in functional genomic loci such as telomeres, promoters and 5’UTRs of 
mRNAs. These combined with protein- and ligand-GQ interaction studies provide an 
insight into possible roles of these motifs in gene expression. (A.) GQs forming at the 
telomeric 3’ overhangs, especially when stabilised with ligands, can prevent telomerase 
from regulating length of telomeres. (B.) Before the transcription initiation process, the 
double stranded helix becomes unwound and allows stable GQ formation. This masks 
transcription factors from binding sites, leading to transcription downregulation. (C.) 
Stabilisation of GQ at the 5’UTR of pre-mRNA prevents progress of the ribosome 
complex, resulting in downregulation of translation. 
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 Berberine  
Traditional medicines, often derived from plants, have been used as remedies to 
effectively treat physical and mental disorders long before modern medicine has been 
established (Guamán Ortiz and Scovassi 2013). As modern science starts to understand 
the biological and chemical properties of these traditional treatments, they have 
become increasingly recognised and recommended by the scientific communities 
(including World Health Organization) as an alternative treatment for a number of 
different diseases (Kohler and Baghdadi-Sabeti 2011).  
Secondary metabolites from plants, such as flavonoids, tannins saponins, steroids and 
alkaloids have been shown to regulate many biological effects, including: anti-
inflammatory, anti-bacterial, immunomodulating, antioxidant and even anticancer 
(Teiten et al. 2013; Wang and Chen 2013). One example of a plant alkaloid widely 
studied for its range of pharmacological properties is berberine.  
Berberine belongs to a group of protoberberine compounds known as 
benzylisoquinoline alkaloids (C20H18NO4+) and is found in a number of plants, including: 
Coptis chinensis- Chinese goldthread, Mahonia aquifolium – Oregon grape, Berbis 
aristata- tree turmeric, Hydrastis canadensis- goldenseal, Berbis vulgaris-barberry, 
Xanthorhiza simplicissima-yellowroot,  Argemone Mexicana-prickly poppy and 
Phellodendron amurense- Amur cork tree (Tillhon et al. 2012). The use of berberine 
containing plants for medical use dates to 200 A.D where in the work of “The Herbal 
Classic of the Divine Plowman” by Shen Nong Ben Cao Jing, it was used to treat 
gastrointestinal infections (Lian 1986). Later, in 500 A.D. it was first realised that the 
berberine containing plant, Rhizoma Coptidis, shows anti-diabetic properties as 
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reported by Hongjing Tao in his “Note of Elite Physicians”(S. Li 1996). Other medical 
applications of berberine include treatment of coronary artery disease, hyperlipidemia, 
hypertension, obesity, polycystic ovary disease, diabetes and Alzheimer’s (Heidarian et 
al. 2014; Tang et al. 2013; Zhang et al. 2013). Interestingly, berberine has been recently 
demonstrated to inhibit proliferation and migration as well as promote apoptosis in a 
number of cancer cell lines, suggesting its potential as a novel anti-cancer treatment (Li 
et al. 2013; Liu et al. 2013; Zhang et al. 2010). Since berberine shows therapeutic 
benefits in a range of distinct diseases, it is clear that the compound has a complex 
mechanism of action that involves targeting of multiple pathways. Some of the 
berberine protein targets discovered to date, include p53, NF-kB, MMP, telomerase and 
estrogenic receptors (Li et al. 2013; Liu et al. 2013; Tillhon et al. 2012). Importantly, 
berberine has been shown to strongly bind DNA and RNA (Bhadra and Kumar 2011b), 
resulting in double-strand breaks and DNA topoisomerase binding inhibition (Li et al. 
2013; Qin et al. 2007). Berberine was also found to prevent transcription by binding 
TATA box sequence in gene promoters, which leads to displacement of enhancer 
proteins (Jiao Wang and Jiang 2012).  
Berberine’s particularly strong binding to secondary DNA structure such as GQ over 
duplex DNA also has been previously demonstrated (Bhadra and Kumar 2011b). Human 
telomeric sequences are bound by berberine with high affinity, and was suggested to 
block the abnormal telomerase-mediated chromosome elongation that leads to cellular 
tumorigenesis and immortalization. (Bazzicalupi et al. 2013; Bernardes de Jesus and 
Blasco 2013). This GQ binding ligand has also been shown to have antifibrotic properties 
in cardiac fibroblast and rats with induced myocardial fibrosis (Gu et al. 2012). Berberine 
upregulates relaxin-1, a protein that can prevent and reverse cardiac fibrosis, in a dose 
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depend manner in vivo and in vitro. The antifibrotic mode of action of berberine was 
suggested to be a result of the ligand binding to GQ forming structures within the 
promoter of relaxin-1 (Gu et al. 2012). 
Despite the issue of berberine having a range of non-specific binding to various protein 
and nucleic acid targets, its structural properties, in particular the aminoalkyl side 
chains,  allows for chemical modifications that can address the issue of poor specificity. 
For example, a 9-0-substituted berberine with extended side chains and terminal amino 
groups shows a significant increase in specificity for GQs over any other DNA structures 
(Ma et al. 2008; Zhang et al. 2007). In addition, linking of two berberine moieties with a 
polyether linker has demonstrated a 76-508 fold increase of binding to GQ structures 
compared to native berberine structure (Z.-Q. Li et al. 2017).  
Proven safety of berberine and its therapeutic potential in a range of diseases models 
as well as its capacity for chemical modification to increase its GQ specificity, makes it 
an attractive molecular candidate for initial proof-of-concept testing to: (i) determine 
any positive improvement of molecular disease signature, and (ii) determination of 
potential target pathways of berberine action that mediate these changes at either 
protein or nucleic acid level.  
1.6. GQs and DUX4 genomic locus.  
The D4Z4 repeat array contains a high CG content (73%) and in unaffected individuals it 
provides a large CpG island platform for the formation of methylated, DUX4 repressive 
closed chromatin state (Tsumagari et al. 2008). A lot of effort has gone into 
understanding how the impairment of the methylation process leads to the FSHD 
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pathology (Section 1.5.1).  However, virtually no attention has been paid into the 
potential presence of GQ-mediated DUX4 expression regulation. The single mention of 
potential GQ-forming sequences in D4Z4 locus has been published by Tsumagari et al., 
2008. These have been mapped to the region of putative DUX4 promoter sequences and 
proximal site of the D4Z4 repeat (Tsumagari et al. 2008). In this work the GQ-predicting 
algorithm that was used discriminates any potential motif-forming sequences with loops 
of >7 nucleotides. The idea that the GQs do not form stable genomic structures has been 
challenged with recent findings of hTERT and BCL-2 gene promoter GQs that contain 26-
nuleotide and 13-nucleotides loops, respectively (Agrawal et al. 2014; Palumbo et al 
2009). In addition, at the time of the study the DUX4 myogenic enhancer 1 and 2 had 
not been established (Himeda et al. 2014). Therefore, these elements as well the DUX4 
transcript, should be analysed using bioinformatic tools that allow for extensive GQ 
loops and allow prediction of RNA GQ sequences.
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1.7. Aims  
We aimed to advance our understanding of molecular mechanisms controlling 
expression of DUX4 by identifying, and assessing the role of, novel GQ regulatory motifs 
within enhancer, promoter and transcript elements of the gene. This was achieved 
through the following objectives: 
I. Prediction of GQ formation within the analysed sequences with bioinformatic tools, 
and assessment of the candidate sequences for the formation of GQ structures 
using biophysical techniques.  
II. Testing of the biophysical interaction between berberine and the selected 
sequences in solution, and in vitro effects of the ligand on the DUX4 expression to 
evaluate the GQ motifs as potential therapeutic targets.  
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2. Materials & Methods 
2.1. General laboratory reagents 
All general chemical reagents were purchased from Sigma, Invitrogen, BDH or VWR 
(unless stated otherwise) with standard chemical purity graded as AnalaR (Analytical 
Reagents for analysis applications). More commonly used chemicals are listed below, 
whereas the regents required for only more specialised assays are described in the 
relevant materials section.  All of the reagents were dissolved in double de-ionized H20 
(ddH20), unless stated otherwise. The majority of the solutions required for tissue 
culture use were autoclaved at 121°C for 15 min, except for the solutions containing 
protein, detergents or glucose which required passing through a 0.22 µm filter (Falcon). 
All solutions were stored at room temperature unless indicated otherwise. 
Table 2.1 List of common reagents 
Reagents  Manufacturer: 
Agar Sigma 
Agarose Invitrogen 
Berberine chloride Sigma 
Calcium chloride (CaCl2) Sigma 
Dimethyl sulphoxide (DMSO) Sigma 
EDTA Sigma 
Ethanol (EtOH) Sigma 
Glacial acetic acid WVR 
Glucose Sigma 
Goat serum Sigma 
Hydrochloric acid (HCl)  Sigma 
Lysogeny broth (LB) BDH 
Magnesium chloride (MgCl2) Sigma 
NaOH BDH 
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Na2HPO4 Sigma 
Paraformaldehyde (PFA) Sigma 
Potassium chloride (KCl) Sigma 
Phosphate buffered saline (PBS) pH 
7.3  
Sigma 
Sodium chloride (NaCl) Oxoid Ltd 
Triton X-100 Sigma 
Tween-20 Sigma 
Trizma Base Sigma 
Trizma hydrochloride (HCl) Sigma 
2.2. Bacterial culture and storage 
 Materials 
• Ampicillin (Sigma): prepared as 1000x stock in ddH2O at 20 mg/ml 
concentration, filtered through 0.22 µm filter (Falcon) and stored at -20°C.   
• Kanamycin (Sigma): prepared as 200x stock in ddH2O at 10 mg/ml concentration, 
filtered through 0.22 µm filter (Falcon) and stored at -20°C.   
• Agar (Sigma) 
• Glycerol (Sigma) 
• Lysogeny Broth (LB) (Sigma). 
• LB (1.5%) agar: 1.5% w/v agar was added to LB solution and autoclaved. The LB-
agar solution was cooled to 45°C before addition of desired antibiotic. ~25ml of LB-agar 
was added into 100 mm petri dish in proximity to the Bunsen burner. Once solidified the 
plates were sealed in cling film and stored at 4°C 
• SOC medium: 100 µl of 1 M MgSO4 and 20 µl of 1 M glucose were added to 10 
ml LB medium.  
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• TOP 10 (E. coli) competent cells (Invitrogen) 
• CaCl2 (Sigma): prepared as 100 mM stock by adding 5.5 g of CaCl2 into 500 µl of 
ddH2O. The solution was filtered through 0.22 µm filter (Falcon) and stored at -20°C. 
• 100 mM CaCl2 in (15%) glycerol: 5.6 g CaCl2 and 75 ml glycerol were made up to 
500 ml with ddH2O, filtered through 0.22 µm filter (Falcon) and stored at -20°C.   
 Preparation of TOP10 bacteria 
The bacterial cells (TOP 10, Invitrogen) were streaked on LB-agar plate without antibiotic 
and incubated overnight at 37°C. The following day, a single colony was selected and 
added to 5 ml of LB media (no antibiotic). The LB media containing the colony was then 
incubated at 37°C overnight with shaking (200 rpm). 5 ml of the overnight culture was 
added to 500 ml of LB media (no antibiotic) and incubated at 37°C with shaking (200 
rpm) until the OD260/280 was between 0.2 and 0.5. The cells were pelleted at 3000 rpm 
for 5 min at 4°C. The supernatant was removed and the pellet was resuspended in 50 ml 
of 100 mM CaCl2.  The resuspended cells were left on ice for 20 min. Cells were pelleted 
again at 4000 rpm for 5 min at 4°C. The supernatant was removed and cells resuspended 
in 5 ml (1/10 original vol) ice-cold 100 mM CaCl2/15% glycerol. Resulting cells suspension 
was divided into 50 or 250 ul aliquots on dry ice submerged in methanol and stored at -
80°C. 
 Bacterial culture and storage 
A single bacterial clone was selected from the LB selective plate and incubated overnight 
at 37°C with shaking (200 rpm) in 5 ml of antibiotic containing LB medium. 700 µl of the 
overnight culture was resuspended in 300 µl of 80% glycerol and stored at -80°C. 
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2.3. Expansion and purification of DNA plasmid 
 Materials 
• QIAprep spin Miniprep kit (Qiagen). 
• SOC medium: 100 µl of 1 M MgSO4 and 20 µl 1 M glucose were added to 10 ml 
LB medium. 
• TE: 10 mM Tris pH 8.0 and 1 mM EDTA pH 8.0 
• Ampicillin: prepared as 1000x stock in ddH2O at 20 mg/ml concentration, filtered 
through 0.22 µm filter (Falcon) and stored at -20°C.   
• DNA plasmids (for cloning procedures see section 2.4): stored in TE or ddH20 at 
-20°C. 
 DNA plasmid transformation of bacteria 
10 ng of plasmid DNA in a volume of 1 µl of ddH2O was added to 25 µl of thawed 
chemically competent cells. The cells were heat-shocked at 45°C for 30 seconds and 250 
µl of SOC media was added. The culture was incubated for at least 1 hour at 37°C with 
shaking (200 rpm) and plated on agar plates containing appropriate antibiotic. Next day 
at least one single colony was screened for the presence of the plasmid DNA by placing 
it in 5 ml LB media (with appropriate antibiotic) and incubating overnight with shaking 
(200 rpm). The following day, miniprep DNA extraction and purification was performed 
(Section 2.3.3). 
 Qiagen plasmid extraction and purification 
For DNA plasmid extraction using QIAprep spin Miniprep kit, the 5 ml starter culture 
(Section 2.3.2) was centrifuged at 6000g for 3 minutes at room temperature. The 
supernatant was aspirated and the pellet was resuspended in 250 µl of P1 buffer. The 
resuspended cells were transferred into a microcentrifuge tube and 250 µl of P2 buffer 
was added. The solutions were mixed by inverting the tube several times. 350 µl of N3 
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buffer was added and mixed by inverting the tubes several times. The tubes were 
centrifuged for 10 minutes at 1300 rpm. The resulting supernatant was transferred (up 
to 800 µl) into a QIAprep spin column that was placed in a 2 ml collection tube. The 
column was centrifuged for 30 seconds at 13000 rpm. The flow through was discarded 
and 500 µl of buffer PB was added to the spin column. The column was centrifuged for 
30 seconds at 1300 rpm and the flow through discarded. 750 µl of PE buffer was added 
and the column was centrifuged for 30 seconds at 13000 rpm. The flow through was 
discarded and the column centrifuged for 1 minute at 1300 to remove any residual 
buffer. The column was placed in a new DNase-free microcentrifuge tube and 30 µl of 
DNase-free water was added to the centre of the column. After 1 min incubation time 
the DNA was eluted from the column by 1 minute centrifugation at 13000 rpm. The 
purity and concentration of the extracted DNA was assessed using NanoDrop 
spectrophotometry (Thermo Fisher). 
 Preparing plasmids for sequencing  
Components required for sequencing, included: 600 ng of plasmid DNA and 4 µM of the 
M13 forward and reverse primers (Invitrogen). The total volume of the plasmid and 
primer solution was adjusted with water to a total of 15 µl. 
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2.4. Molecular cloning 
 Materials 
2.4.1.1. Reagents 
• 50x TAE: 242 g Tris Base, 57.1 ml glacial acetic acid, 100 ml of 0.5 M EDTA pH 8.0 
were brought to a total volume of 1 L with ddH2O. 
• 5x Loading buffer (Bioline). 
• DNA molecular weight markers (Bioline): Hyperladder I. 
• Restriction enzymes and buffers (New England Biolabs). 
• Antarctic Phosphatase (New England Biolabs). 
• T4 DNA ligase (New England Biolabs). 
• Qiaquick gel extraction kit (Qiagen). 
• 1000x SYBR Safe DNA gel stain (Invitrogen). 
• UltraPure Agarose (Invitrogen) 
• QIAquick Gel Extraction Kit (Qiagen) 
2.4.1.2. Plasmids 
pUC57.Promoter_DUX4 
The pUC57 plasmid is a commercial vector (GenScript) that carried the synthesised full 
promoter sequence of the DUX4 promoter and 5’UTR sequence. The synthesised 
promoter sequence included flanking restriction enzyme sites for directional cloning of 
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the sequence into donor plasmids, i.e.: pC1.Promoter_DUX4.GFP.3’UTR_DUX4 and 
pAAV.Promoter_DUX4.DUX4 plasmid. 
pC1.CMV.GFP. 
The pC1.CMV.GFP.3’UTR_DUX4 plasmid was kindly donated by Dr Julie Dumonceaux, 
UCL, U.K.  
pC1.Promoter_DUX4.GFP. 
The pC1.Promoter_DUX4.GFP. was created by replacing the CMV promoter sequence 
from the pC1.CMV.GFP. vector backbone with the DUX4 promoter sequence derived 
from the pUC57.Promoter_DUX4. 
pAAV.CMV.DUX4. 
The pAAV.CMV.DUX4 was a kind donation from Dr Scott Harper, The Ohio State 
University College of Medicine, U.S. 
pAAV.Promoter_DUX4.DUX4. 
The pAAV.Promoter_DUX4.DUX4 was created by replacing the CMV promoter sequence 
from the pC1.CMV.GFP. vector backbone with the DUX4 promoter sequence derived 
from the pUC57.Promoter_DUX4. 
 Restriction enzyme digest and gel electrophoresis 
For the diagnostic digest 1 µg of DNA product was subjected to a restriction enzyme 
reaction under conditions recommended by the manufacturer. 5x loading buffer was 
used to load the digested products onto an agarose gel. The 0.5-2% agarose gel was 
made with 1x TAE and 1x SYBR Safe to allow visualisation of the DNA bands with UV 
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light. The appropriate maker was chosen depending on the expected bands size. The 
loaded gel was electrophoresed at 60-100 V submerged in 1x TAE buffer. 
 Antarctic phosphatase dephsphorylation 
Antarctic phosphatase (AnP) was used to catalyse the removal of phosphates from DNA 
5’;3’ and blunt-ends extensions. Dephosphorylation was performed directly after the 
restriction digest reaction was completed by adding 5 U of AnP per 1 µg of the digested 
DNA. The reaction was incubated for 15 minutes at 37°C for blunt-ends and 5’ strand 
extensions. Inactivation was performed for 5 minutes at 70°C. The resulting product was 
verified on 1x SYBR Safe-stained, 1% agarose gel and run at 60-100 V in 1x TAE buffer. 
The expected band was excised from the gel and purified Qiaquick gel extraction kit 
according to manufacturer’s instructions. 
 DNA ligation 
To catalyse the formation of a phosphodiester bond between juxtaposed 5’ phosphate 
and 3’ hydroxyl in duplex DNA, the T4 DNA ligase was used. Typically, 1:3 or 1:5 vector 
to insert molar ration was used for the ligation reaction. The reaction was incubated at 
16°C overnight, following heat inactivation at 65°C for 10 minutes, and stored at 4°C 
ready for transfection. 
 Cloning of GFP gene into the plasmid backbone (i.e., pC1.Promoter_DUX4) 
The DUX4 promoter sequence was excised form the donor pUC57 vector with the PciI 
and NheI restriction enzymes under reaction conditions suggested by the enzyme 
manufacturer (NEB). To create compatible restriction enzyme sites for directional 
cloning between the DUX4 promoter insert and the acceptor plasmid, the pC1.CMV.GFP 
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plasmid was subjected to the same digestion reaction as the pUC57 vector, so the CMV 
promoter sequence could be removed from the pC1.CMV.GFP vector backbone (Figure 
2.1). Both reaction products were run on 1% agarose gel to separate the plasmid 
backbones from their corresponding promoter constructs. The bands corresponding to 
pC1.GFP. vector and DUX4 promoter sequences were excised from the gel and purified 
using gel purification kit (Qiagen).  
The purity and concentration of the excised DNA fragments were assessed using 
nanodrop spectrophotometer (Thermo Fisher). The vector and insert were ligated using 
the T4 DNA ligase (NEB) using 1:3 and 1:5 vector to insert ratio. The ligated product was 
transformed into chemically competent TOP10 E.coli cells. The cells were streaked onto 
the ampicillin-containing LB agar selection plates. Following day, 4 positive colonies 
were selected and grown overnight in 1X ampicillin LB media shaking at 200 rpm. The 
plasmid DNA was purified from the suspended cell culture using miniprep kit according 
to the manufacturer’s instructions (Qiagen). The quality and concentration of the 
purified plasmid was assessed with the nanodrop (Thermo Fisher). Diagnostic restriction 
enzyme digest was performed to ensure presence of the correct backbone and insert. 
The presence of the promoter insert was verified by sequencing (MWG) using primers 
listed in table 2.2. The sequencing reaction was prepared in barcoded tubes provided 
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by MWG. The reagent submitted for sequencing, included: 15 μl of 10 ng/ μl DNA 
plasmid and 2 μl primer of 10 μM concentration.  
Figure 2.1 Simplified schematic showing cloning of the DUX4 promoter construct into 
the pC1.CMV.GFP. reporter plasmid 
The DUX4 promoter sequence was excised from the donor pUC57 vector using PciI and 
Nhe-I restriction enzymes cleaving at the 5’- and 3’-end of the promoter construct. The 
CMV promoter sequence was removed from the acceptor pC1.GFP. plasmid using the 
same PciI and NheI- restriction enzymes that also cleaved the CMV sequence at the 5’- 
and 3’-end, respectively. This produced compatible sticky ends between the DUX4 
promoter insert and pC1.GFP., which were utilised for directional cloning process. 
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 Cloning of the DUX4 promoter sequence into the plasmid backbone (i.e., 
pAAV.Promoter_DUX4.DUX4) 
The restriction enzymes used to digest the donor and acceptor plasmids were SpeI and 
Nhe-I (Figure 2.2). The cloning process for the pAAV.Promoter_DUX4.DUX4 plasmid was 
the same as for the pC1.Promoter_DUX4.GFP. (Section 2.4.5). 
.
Figure 2.2 Simplified schematic showing cloning of the DUX4 promoter construct into the 
DUX4-expressing pAAV.CMV.DUX4 vector 
The DUX4 promoter sequence was excised from the donor pUC57 vector using SpeI and Nhe-
I restriction enzymes cleaving at the 5’- and 3’-end of the promoter construct. The CMV 
promoter sequence was removed from the acceptor pAAV.DUX4. plasmid using the same 
SpeI and NheI restriction enzymes that also cleaved the CMV sequence at the 5’- and 3’-end, 
respectively. This produced compatible sticky ends between the DUX4 promoter insert and 
pAAV.DUX4. plasmid, which were utilised for directional cloning process. 
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Table 2.2 Primer used in sequencing DUX4 promoter sequence from pC1 and pAAV 
plasmid backbones 
Target sequence Primer sequence Tm GC% 
DUX4 promoter in 
pC1 plasmid 
5’-GCCTATGGAAAAACGCCAGC-3’ 60 55 
DUX4 promoter in 
pAAV plasmid 
5’-GTGAATTCCCTTCCGGGGTG-3’ 61 60 
2.5. Plasmid DNA transfection 
 Materials 
• Lipofectamine 3000 (Invitrogen). 
 Protocol 
2.5x105 Rhabdomyosarcoma cells (RD) (ATCC® CCL-136™) were seeded in 2 mL of RD 
DMEM growth media per well on 6-well plates. The cells were at least 80% confluent 
before transfection. An hour prior to transfection the overnight growth media was 
replaced with fresh RD DMEM growth media. Optimal DNA to Lipofectamine 
transfection ratio was 1 μg DNA to 3.75 μl Lipofectamine per well in total volume of 250 
μl of serum and antibiotic free DMEM media. The DNA/Lipofectamine mixture was 
added dropwise to each well to make up the final volume of 2000 μl of RD DMEM growth 
media per well. 24 hours post-transfections, the cells were analysed under fluorescent 
microscope (Zeiss) and harvested for RNA extraction or flow cytometry (FACScan II) 
analysis. 
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2.6. Tissue culture techniques 
 Materials 
• Dulbecco’s Modified Eagle’s Medium (DMEM): high glucose (4.5 g/l), 
GlutaMAXTM-I (862 mg/l), pyruvate (110 mg/l) and phenol red (15 mg/l) 
(ThermoFisher). Stored at 4°C. 
• Medium 199. Stored at 4°C. 
• Foetal bovine serum Serum (FBS), certified heat inactivated (Invitrogen). Stored 
at -20°C in 50 ml aliquots.  
• Gentamicin (50 mg/ml) (Thermo Fisher).  
• FSHD skeletal muscle growth medium: 4 vols of DMEM, 1 vol 199 medium, 20% 
FBS, 50 μg/ml gentamicin, 5 μg/ml insulin, 0.2 μg/ml dexamethasone, β-FGF , 5 ng/ml 
hEGF, 25 μg/ml fetuine. Stored at 4°C. 
• FSHD skeletal muscle differentiation medium (PromoCell GmbH): 10 µg/ml 
insulin. Stored at 4°C. 
• RD growth medium: DMEM supplemented with 10% FBS. Stored at 4°C. 
• Methylthiazolyldiphenyl-tetrazolium bromide (MTT, 5mg/ml): 250 mg of MTT 
was dissolved in 50 ml of filtered using 0.22 μl filter (Falcon), stored at -20°C in the dark.   
• Trypsin-EDTA (10x)- 0.5% trypsin, 0.2% EDTA in PBS. Stored at -20°C 
• Zeiss Vert.A1 microscope with Axiocam 503 monocamera (Zeiss) 
• Basic cell culturing equipment: 37°C, 5% CO2 incubator; Class 2 microbiology 
safety cabinet; 37°C water bath, low speed centrifuge and haemocytometer. 
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 Cell lines 
• Rhabdomyosarcoma (RD) cells (ATCC® CCL-136™): Stored in vapour phase of 
liquid nitrogen at 500,000 cells/vial in growth media plus 10% DMSO. 
• DUX4 expressing FSHD patient immortalised myoblasts (kindly made available 
by Dr Vincent Mouly, Institute of Myology, Paris). Stored in vapour phase or liquid 
nitrogen at 500,000 cells/vial in growth media plus 10% DMSO. 
 Culture of human RD CCL-136 and FSHD immortalized myoblasts 
All work was performed using sterile plastic inside grade 2 laminar flow hood. Cells were 
incubated at 37°C with 5% CO2.  
 1x106 RD and 0.5x106 FSHD immortalised myoblast cells were seeded in 25 ml of their 
corresponding growth media per T175 flask. When 80% confluent, the media was 
aspirated and the cells were washed with sterile 5 ml of 1x PBS. PBS was replaced with 
5 ml of 1x Trypsin/EDTA solution and incubated at 37°C for 2-3 minutes to detach the 
cells from the flask. 10 ml of growth media was added to neutralise the trypsin and the 
cell suspension was transferred into a 50 ml Falcon tube (Corning) and spun at 3000 rpm 
for 5 minutes. The resulting supernatant was aspirated and the pelleted cells were 
resuspended in their growth media to reach concentration of 1x106 cells/ml. The 
resuspended cells were placed in a fresh T175 flask containing 25 ml of their 
corresponding media and incubated for a 3-4 days until 80% confluency was reached 
again. 
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 Freezing and thawing process of cells. 
To freeze the cells, 0.5x106 cells suspended in their corresponding growth media were 
transferred into a 1 ml sterile cryovial. DMSO was added to a final concentration of 10% 
to make up freezing media. The cell-containing cryovials were placed into cryo-freezing 
container and placed in the -80°C freezer overnight. The cryovials were transferred into 
the vapour phase of a liquid nitrogen storage facility.  
The cells were swiftly defrosted by placing cell-containing cryovial into 37°C water bath. 
As soon as they became defrosted, the cells were suspended in 9 ml of growth media 
and spun at 3000 rpm for 5 minutes. The supernatant was aspirated and the resulting 
pellet was resuspended in 1 ml of growth media. The cells were seeded in T75 flask 
containing 15 ml of growth media. When 80% confluency was reached, the cells were 
transferred into T175 flasks containing 25 ml of growth media. 
 Differentiation of FSHD immortalized myoblast cells. 
1x105 of FSHD immortalized myoblast cells were seeded in 2 ml of their corresponding 
growth media per well on 6 well plates. When >95% confluency was reached, the growth 
media was replaced with the differentiation media. The cells were fully differentiated 4 
days after the media was changed. 
 Cell viability assessment 
For assessment of the cell viability MTT assay was used. To each well containing cells 
MTT was added evenly in 1:10 ratio (MTT:media). The treated cells were incubated for 
4 hours at 37°C with 5% CO2. Media was gently aspirated and plates were air dried at 
room temperature. 1 ml of DMSO was added per well and the plates were placed on a 
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shaker (200 rpm) to dissolve the crystals. 75 μl from each well was transferred into 96 
well plate. The OD at 570 nm was recorded with the GloMax-Microplate Multidote 
Reader (Promega). The absorbance was normalised to blank containing DMSO (no MTT) 
and compared to untreated cells. 
 Berberine treatment in cell culture 
Berberine chloride was dissolved in ddH2O to produce stock solution of 1 mM. To 
increase solubility of berberine chloride, the solution was placed in the 37°C water bath 
and vortexed several times until fully dissolved.  
The seeding process of the RD cells on 6-well plates was described in section 2.5. RD 
cells were treated with berberine chloride at the time of transfection (Section 2.5). The 
berberine concentration dose range used was between 0 and 100 μM in the final volume 
of 2000 μl of the fresh growth medium per well. The treated and untreated controls 
were harvested and analysed 24 hours after the exposure to the compound.  
FSHD immortalizes myoblast cells were treated with berberine chloride on the second 
day of differentiation (Section 2.6.5). The concentration rage of berberine chloride used 
to tread the cells was 0-25 μM in the total volume of 2000 μl of the fresh differentiation 
medium per well. The cells were harvested for analysis 48 hours after treatment.  
2.7. RNA extraction 
 Materials 
• QIAshredder kit (Qiagen Ltd.): Stored at room temperature. 
• RNeasy Mini Kit (Qiagen Ltd.): Stored at room temperature. 
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• RNase-free DNase-I (Qiagen Ltd.): Stored at 4°C. Once reconstituted, stored in 50 
µl aliquots at -20°C. 
• ND-1000 NanoDrop spectrophotometer (Thermo Fisher). 
 RNA extraction protocol 
The RNA extraction was performed from cells seeded on 6 well plates using RNeasy mini 
kit and QiaShredder columns. The cell culture medium was carefully aspirated. 350 μl of 
RLT lysis buffer was added into each well. The buffer was carefully pipetted several times 
across the well to ensure complete lysis. The cell lysate was transferred into Qiashredder 
column and placed into a 2 ml collection tube. The lysate containing column was 
centrifuged for 2 minutes at full speed. The flow through could be stored at -80°C at this 
point,and defrosted at 37°C for 10 minutes when needed . 350 μl (1 volume) of 70% 
ethanol was added to the flow through and pipetted up and down several times to mix. 
700 μl of the mixture was transferred to an RNeasy mini column placed in 2 ml collection 
tube. Closed tube was centrifuged for 30 seconds at ≥8,000xg. The flow through was 
discarded and 350 μl of buffer RW1 was added to the RNeasy column. The column was 
centrifuged for 30 seconds at ≥8,000xg and the flow through was discarded. 10 μl of 
reconstituted RNase-free DNase and 70 μl of RPE buffer were mixed together and 
carefully pipette the 80 μl on to the Rease column. The column was incubated at room 
temperature for 15 minutes. After incubation was completed, 350 μl of RW1 buffer was 
added to the column and centrifuged for 30 seconds at ≥8,000xg. The flow through was 
discarded and 500 μl of RLP buffer (with ethanol added as indicated on the label of the 
bottle) the column. The column was centrifuged for 30 seconds at ≥8,000xg. The flow 
though was discarded and another 500 μl of RLP buffer was added to the column. The 
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column was spun for 2 minutes at ≥8,000xg. The column was then placed into an RNase-
free; DNase-free 1.5 ml Eppendorf tube and 30 μl of RNase-free; DNase-free water was 
added directly into the membrane of the column. The column was then spun for 1 
minute at ≥8,000xg. Quality and concentration of the extracted RNA was assessed using 
ND-1000 NanoDrop spectrometer. Samples were stored in a -80°C freezer. 
2.8. cDNA synthesis 
 Materials 
• GoScript reverse transcription system kit (Promega): Stored at -20°C. 
• Random primers (Invitrogen) 
• Oligo(dT) primers (Promega) 
• Thermal cycler (VWR) 
 Protocol 
Fort the first strand cDNA synthesis, the GoScript kit (Promega) was used. Before setting 
up the reaction, all the components were thawed on ice except for the reverse 
transcriptase that was kept in the Labtop cooler to maintain temperature close to -20°C. 
600 ng of RNA and 500 ng of both random primers and oligo(dT) were added to a RNase-
free PCR tube. Total volume of RNA/primer mixture was adjusted to 10 μl with RNase-
free water. To ensure resolution of any potential secondary structures formed by the 
RNA and effective primer annealing to the RNA, the reaction was placed in a PCR 
machine and a single cycle was run for 5 minutes at 70°C followed by at least 5 minutes 
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at 4°C. The resulting samples were stored on ice until the reverse transcription master 
mix was ready. 
Reverse transcription reaction master mix was prepared on ice in the order listed in 
table 2.3 
 Table 2.3 Composition of the reverse transcription reaction master mix 
 
The 10 μl RNA/primer mix was combined with 15 μl reverse transcription mix and placed 
in the PCR heat block. The PCR program, included: annealing for 5 minutes at 25°C, 
extension at for 1 hour at 42°C and heat inactivation for 15 minutes at 70°C. Samples 
were kept at -20°C for long term storage. 
2.9. Reverse transcriptase polymerase chain reaction (RT-PCR) 
 Materials 
• cDNA generated using Method 3.13. 
• Platinum Green Hot Start PCR Master Mix (Invitrogen). Stored at -20°C. 
Components Volume 
GoScript 5x Reaction Buffer 4 μl 
MgCl2 (25 mM) 2 μl 
dNTP (5 mM) 2 μl 
GoScript Reverrse Transcriptase 1 μl 
Nuclease-Free water 6 μl 
Final volume 15 μl 
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• Gene-specific primers and housekeeping primers designed using PrimerQuest 
Tool at https://eu.idtdna.com/PrimerQuest/Home/Index (IDT). 
• Thermal cycler (WVR) 
 RT-PCR amplification protocol 
To amplify GC-rich sequences such as DUX4 mRNA, Platinium Green Hot Start PCR 
Master Mix (2x) kit was used. Primers used are listed in table 2.4.  
Table 2.4 Primers used in RT-PCR 
Target 
gene 
Primer 
Accession 
no. 
Sequence 
(5’-3’) 
Location 
Product 
size 
DUX4 
Forward: HQ266760 AGGCGCAACCTCTCCTAGAAAC Exon1 
368/504 
bp 
Reverse HQ266761 TCCAGGAGATGTAACTCTAATCCA Exon3 
B2M 
Forward: 
NM_0040
48.2 
CTCTCTTTCTGGC-CTGGAGG Exon1 
67 bp 
Reverse 
NM_0040
48.2 
TGCTGGATGACGTGAGTAAACC Exon2 
 
All the components of the PCR mix and primers were thawed and then combined on ice in 
order listed in table 2.5 
Table 2.5 RT-PCR reaction set up 
Component Volume 
Platinum Green Hot Start PCR 2x Master Mix 12.5 μl 
Forward and reverse DUX4-all primers (10 μM each) 0.5 μl 
Forward and reverse B2M primers (5 μM each) 0.5 μl 
Platinum GC Enhancer (optional) 5 μl 
Nuclease-Free water  2.5 μl 
Final volume 21 μl 
74 
 
21 μl of the master mix reaction was added to each PCR tube. 4 μl of cDNA template 
was added to the reaction mix. At least one negative control was set up that lacked the 
cDNA, which was replaced with nuclease-free water. The PCR tubes were sealed, 
placed in the PCR machine and programmed to run the single denaturation step for 2 
minutes at 92°C followed by 30 cycles of PCR amplification (i.e., denaturation for 1 
minute at 94°C, annealing for 1 minute at 55°C and extension for 45 seconds at 72°C), 
and one final cycle of extension for 5 minutes at 72°C. The PCR program was ended by 
putting the reaction on hold at 4°C until ready for analysis on agarose gel 
electrophoresis. Otherwise, samples were stored at -20°C. 
2.10. Semi-quantitative densitometric analysis of gene expression 
 Materials 
• Agarose. Stored at room temperature. 
• 10x TAE buffer: diluted to a 1X solution. containing 40 mM Tris, 40 mM acetate, 
and 1 mM EDTA, pH ~8.3. Store at room temperature. 
• SYBR Safe (x10,000) DNA gel stain (Invitrogen). Store at room temperature. 
• DNA Hyperladder V (Bioline UK Ltd.). Stored at 4°C. 
• Horizontal electrophoresis system (Bio-Rad). 
• E-BOX VX2 gel documentation system (PeqLab). 
• Access to GeneTools software (Syngene) for densitometric analysis. 
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 Protocol 
To examine expression of target and housekeeping genes, the specific PCR products 
were separated by agarose gel electrophoresis. For the detection of the DUX4 mRNA 
detection, the PCR products were run on a horizontal 3% agarose. The gel was prepared 
by dissolving 3 g of agarose in 100 ml of 1x TAE buffer and heating until transparent, 
crystal-free solution was formed. When the gel was cooled to 60°C, 15 μl of 1000x SYBR 
safe was added and mixed into the gel solution. The gel was poured into a casting tray 
and an appropriate comb was inserted. The gel was allowed to set for 20 minutes at 
room temperature. The comb was removed and the gel in the tray was placed in the gel 
tank. The gel was submerged with 1x TAE to around 1 cm in depth. Since the PCR 
reaction mix contains the loading dye, each sample was directly loaded into each well at 
consistent volume. 7 μl of Hyperladder V was used as a verification marker of PCR 
product size and loaded at each side of the gel. The loaded gel was run at 90 volts for 45 
minutes and visualised under UV light using Ebox VX2 imaging system. The semi-
quantitative analysis of the DUX4 mRNA expression levels was done by normalising its 
expression to the levels of the house keeping gene (i.e., B2M) expression. The analysis 
was performed using GeneTools software. The formula below was used to calculate 
expression of DUX4 relative to B2M: 
𝐷𝑈𝑋4 expression =
(𝐷𝑈𝑋4−background)
(𝐵2𝑀−background)
      (Eq.1) 
2.11. Quantitative RT-PCR (RT-qPCR) 
 Materials 
• cDNA generated using Method 3.13. 
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• Housekeeping realtime primers and gene-specific primers (Primetime qPCR 
primers from IDT) or designed using PrimerQuest software (IDT). 
• 3LightCycler 488 SYBR Green I Master (Roche). Stored at -20°C. 
• LightCycler 480 (Roche) for quantitative PCR 
 Protocol 
Very low levels in human muscle and extremely GC-rich sequence of DUX4 (Snider et al., 
2010), made the direct detection of the DUX4 with qPCR extremely challenging. C2C12 
mouse myoblast cells transfected with DUX4 show to deregulate a range of the 
downstream genes (Krom et al. 2013). Expression profile of the genes downstream of 
DUX4 provided a bench standard allowing for indirect measurement of the DUX4 
expression.  
The described protocol has been optimised for use with the ROCHE SyBr Green master-
mix and the ROCHE LightCycler480 machine using a 386 well plate. Sequences of primers 
used for RT-qPCR are listed in table 2.6. All the procedures were carried out in a UV-
treated, nucleic acid-free safety cabinet. 
Table 2.6 Primers used in RT-qPCR 
Target 
gene 
Accession no Primer Sequence (5’-3’) Location 
Product 
size 
B2M NM_004048.2 
Forward 
Reverse 
CTCTCTTTCTGGCCTGGAGG Exon1 
67 bp 
TGCTGGATGACGTGAGTAAACC Exon2 
MBD3L2 NM_144614.3 
Forward 
Reverse 
CGTTCACCTCTTTTCCAAGC Exon1 
142 bp 
AGTCTCATGGGGAGAGCAGA Exon2 
TRIM43 NM_138800.1 
Forward 
Reverse 
ACCCATCACTGGACTGGTGT Exon6 
100 bp 
CACATCCTCAAAGAGCCTGA Exon7 
ZSCAN4 NM_152677.2 
Forward 
Reverse 
CTGGAGCAGTTTATGATTGG Exon3 
162 bp 
AGCTTCCTGTCCCTGCATGT Exon4 
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The synthesised cDNA (Section 2.8) was diluted in nuclease free water. The cDNA from 
untreated samples were used to set up standard serial dilutions (i.e., 1:50, 1:500, 
1:5,000 and 1:50,000) for calculation of primer binding efficiency. The final volume of 
each dilution was at least 50 μl. A qPCR plate set up by including the four standard 
serial dilution standards and one negative control that had nuclease-free water instead 
of cDNA. In each qPCR run at least three biological replicates of treated and untreated 
samples were included. Each of the biological replicates had 3 technical replicates to 
ensure consistent reading. 
The master mix for each of the DUX4 downstream genes and corresponding 
housekeeping gene was set up as outlined in table 2.7, excluding the cDNA. 6 μl of the 
master mix was added to its corresponding wells, followed by addition of 4 μl of cDNA. 
Table 2.7 Composition of RT-qPCR reaction 
Components Initial concentration Volume Final cincetration 
SYBR Green 2x 5 μl 1x 
Primer 
concentration 
10 μM 0.5 μl 0.5 μM/primer 
cDNA n.a. 4 μl n.a. 
Nuclease-free water n.a. 0.5 μl n.a. 
Fianl volume/well n.a. 10 μl n.a. 
 
The plate was sealed using the provided cover and spun briefly to ensure all the 
reagent have reached the bottom. The plate was placed into the machine and the 
programme outlined in table 2.8 was initiated. The melting curve programme was 
enabled to asses any off target primer binding (Figure 2.3). When there was no off 
target primer binding or contamination present in the sample, a single peak was 
present for each primer set (Figure 2.3). 
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Table 2.8 RT-qPCR cycling parameters 
PCR 
programme 
No. of cycles Temp. (°C) Time 
Preincubation 1 94 5 minutes 
Amplification 45 
94 10 seconds 
60 10 seconds 
72 10 seconds 
 
2.12. Immunohistochemistry  
 Materials 
 Extracellular matrix (ECM) gel from Engelbreth-Holm-Swarm murine sarcoma 
(SigmaAldrich). Diluted with DMED to 1 mg/ml and stored in aliquots at -80°C. 
 Triton X (SigmaAldrich). Stored at room temperature. 
Figure 2.3 Example of melting peaks acquired from the Roche LightCycler480 
Two distinct peaks specific for ZSCAN4 (green) and B2M (red) housekeeping gene indicate that 
the primers are amplifying a single product and no off-target amplification or sample 
contamination is present. 
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 Goat serum (SigmaAldrich). Stored in aliquots at -20°C. 
 4% paraformaldehyde (SigmaAldrich) in 1xPBS pH 7.0. Stored in aliquots at-20°C. 
 Tween-20 (SigmaAldrich). Stored at -20°C. 
 DAPI (SigmaAldrich) in ddH2O at 20 mg/ml. Stored at -20°C. 
 Odyssey CLx Imaging System (Licor) 
 Primary antibodies:  
 Mouse anti MF20 (DSHB, MF20). Stored in aliquots at -20°C 
 Rabbit anti-DUX4 (Abcam, E5.5). Stored in aliquots at -20°C 
 Secondary antibodies: 
 Goat anti-mouse (Licor, IRDye 680RD). Stored in aliquots at -20°C 
 Goat anti-rabbit (Licor, IRDye 680RD). Stored in aliquots at -20°C 
 Goat anti-rabbit (ThermoFisher, AlexaFluor488). Stored in aliquots at 
-20°C 
 In-cell Western of FSHD cell culture 
6-well plates were coated with 500 μl of ECM (1 mg/ml) to ensure cell adhesion. The 
seeding of the FSHD patient myoblast, differentiation and berberine treatment were 
described in sections 2.6.5 and 2.6.7, respectively. At the end of incubation period, the 
culture medium was removed and cells rinsed with 1xPBS, followed by fixing in ice cold 
4%PFA for 15 minutes at room temperature. Cells were washed three times with 1xPBS 
for 5 minutes. Permeabilization of cell was performed in 0.5% Triton X-100 in 1xPBS for 
10 minutes at room temperature. 10% goat serum in 1xPBS was used to perform 1 hour 
blocking. The primary antibodies were diluted 1:100 in 5% goat serum, 1xPBS and added 
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to each well for overnight incubation at 4°C. Each well was washed three times for 5 
minutes with 1xPBST (0.1% Tween-20). Secondary antibody was diluted 1:800 in 5% goat 
serum, 1xPBS, Cells were incubated for 1 hour with the diluted secondary antibodies. 
1xPBST washes were preformed three times for 5 minutes. After the final wash, any 
remaining solution was removed from the wells completely. The plates were used for 
the analysis using Odyssey CLx Imaging System. Plates can be stored if 1xPBS was added 
to each well and kept at 4°C.  
 Fusion index of FSHD patient cells 
6-well plates were coated with 500 μl of ECM (1 mg/ml) to ensure cell adhesion. The 
seeding of the FSHD patient myoblast, differentiation and berberine treatment were 
described in sections 2.6.5 and 2.6.7, respectively. The cell culture medium was 
removed and cells were washed with 1xPBS once. The cells were fixed with ice cold 4% 
PFA for 10 min at room temperature. The fixative was washed away by rising once in 
1xPBS. The cells were permeabilised in 0.5% Triton X-100, 1xPBS for 10 minutes at 
room temperature. Blocking was performed with 10% goat serum in 1xPBS for 1 hour 
at room temperature. The mouse anti-MF30 primary antibody was diluted 1:1000 in 
5% goat serum, 1xPBS. The primary antibody incubation was performed overnight at 
4°C. Next day cells were washed in 1xPBS three times for 5 minutes. The goat anti-
mouse , AlexaFluor488 secondary antibody was diluted 1:200 in 5% goat serum, 1xPBS. 
The secondary antibody incubation was performed for 1 hour at room temperature. 
The cells were washed three times for 5 minutes with 1xPBS. DAPI stock was diluted 
1:100 in 1xPBS, added to each well and incubated at room temperature for 10 
minutes. The cells were rinsed twice in 1xPBS and kept in 1xPBS at 4°C protected from 
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light. Fluorescent microscope at 10x magnification was used to acquire images for 
analysis. The fusion index was calculated by counting the number if nuclei in MF20 -
positive myotubes containing 3 or more nuclei, and expressed as a percentage of total 
number of nuclei present in the captured field.  
2.13. Flow cytometry  
 Materials 
• Paraformaldehyde (PFA). 4% PFA in 1x PBS. Stored at -20°C. 
• 5 ml snap cap round bottom tubes (Falcon) 
• FACSCantoII flow cytometer (BD Bioscience) 
• FACSDiva Software (BD Bioscience) 
 Analysis of GFP expression in transfected RD CCL-136 cells by flow cytometry 
RD cells were trypsinised 24 hours post-transfection/berberine treatment (Section 2.5 
describing transfection; Section 2.6.7 describing the berberine treatment), transferred 
into 5 ml snap cap round bottom tubes and pelleted by centrifugation at 3000 rpm for 
3 minutes. The supernatant was aspirated and the cells were resuspended in 300 μl of 
4% PFA. A mock transduced (i.e., no plasmid) control population was also included in 
every experiment analysing GFP expression.  
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To discriminate debris from the viable cell population FSC-A/SSC plot was selected and 
the P1 gate was drawn over the cells (Figure 2.4.A). Single viable cell population were 
selected from doublets by selecting them using polygonal on the FSC-H/FSH-A plot 
(Figure 2.4.B). The GPF positive cell population was displayed in a histogram using FITC 
channel. The mock population was analysed first to set the gate of false GFP positive to 
<1%. At least 10 000 cells were analysed for each condition. 
. 
2.14. Spectroscopic analysis of nucleic acid secondary structures and 
ligand binding  
 Materials  
• KP buffer: 100 mM KCl, 10 mM K2HPO4/KH2PO4, pH 7.0, ddH2O, filtered using 
0.22 μm filter (Flacon). 
Figure 2.4 Example of gating to select viable (A.) and single (B.) in flow cytometric analysis 
(A.) Forward scatter-area vs. side scatter-area plots allowed for selection of viable RD cells 
as shown by the polygonal gate. Cells outside the gate were consider debris. (B.) Forward 
scatter- area vs. forwards scatter-height was subsequently selected in order to select single 
viable cells for the analysis. Cells outside the polygonal gate are considered to be doublets. 
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• Tris buffer: 10 mM Tris-HCl, 100 mM KCl, pH 7.0, ddH20, filtered using 0.22 μm 
filter (Flacon). 
• Chirascan qCD, circular dichroism spectrometer (Applied Photophysics Ltd). 
• Nuclear magnetic resonance spectrometer (800 MHz; Bruker Avance III). 
• Fluorescent spectrometer (Perkin Elmer). 
• UV/Vis spectrophotometer (Jenway 7305). 
• 1 mM Berberine chloride stock: berberine was dissolved in either KP or Tris 
buffer and heated at 37°C until fully dissolved. Stored at room temperature.  
• DNA and RNA oligonucleotides (IDT) (Table 2.9). 
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Table 2.9 List of oligonucleotides used in spectroscopic analysis 
Oligonucleotides synthesised at 0.2 μm and HPLC purified by IDT. Underlined guanine 
residues are predicted to form putative GQs. Adenosine residues in bold indicate 
guanine substitution to disrupt GQ and hairpin structures in M1-3M2DGCb_GQ, 
oligonucleotides. Abbreviations: DMEM_GQ, DUX4 myogenic enhancer 1 G-quadruplex; 
DGCb_GQ, DUX4 GC box; M1DGCb_GQ, mutant 1 DUX4 GC box; CSS, cryptic splice site; 
E1, enhancer 1; SS1, splice site 1; H.telomere, Human telomere. 
 
 
Construct 
name: 
Construct sequence: 
Amount 
(µmol) 
Purification 
method 
DME1_GQ CAGGGGATGGTGGGGCTGGGGTTGAGTGATGGGC  0.2 HPLC 
D4P_ GQ CGGGGTGGGGCGGGCTGTCCCAGGGGGGCT  0.2 HPLC 
M1DGCb_GQ 
(NO GQ) 
CGAAAATGGGGCGGGCTGTCCCAAAAAACT 0.2 HPLC 
M1DGCb_GQ 
(NO GQ) 
CGAAAATGGGGCGGGCTGTCCCGGGGGGCT   
M3DGCbQ 
(no Hairpin) 
CGGGGTGGGGCGGGCTGTAAAAGGGGGGCT 0.2 HPLC 
CSS_GQ AGGGCCAGGCACCCGGGACAGGGUGGCAGGGC 0.2 HPLC 
E1_GQ AGGGGAGUCCGUGGUGGGGCUGGGGCCGGGGU 0.2 HPLC 
SS1_GQ CGGGGUUGGGACGGGGUCGGGU 0.2 HPLC 
H. 
telomere_GQ 
AGGGTTAGGGTTAGGGTTAGGG 0.2 HPLC 
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 Circular dichroism and nuclear magnetic resonance spectroscopy  
DNA and RNA oligonucleotides for circular dichroism (CD) and nuclear magnetic 
resonance (NMR) were prepared from the HPLC purified samples by resuspending them 
in KCl buffer to a final concentration of 2–4 µM.  
CD spectra were acquired using a Chirascan qCD spectrophotometer (Applied 
Photophysics Ltd), equipped with a LTD6G circulating water bath (Grant Instruments, 
UK) and thermoelectric temperature controller (Melcor, USA). Samples were heated in 
the cell to 95oC for a total period of 15 minutes, samples were then annealed by allowing 
to cool to room temperature for a minimum period of 4 hours. CD spectra were recorded 
over a wavelength range of 215– 340 nm using a 1 cm path length strain-free quartz 
cuvette and at the temperatures indicated. Data points recorded at 1 nm intervals. A 
bandwidth of 3 nm was used and 5000 counts acquired at each point with adaptive 
sampling enabled. Each trace is shown as the mean of three scans (±SD). CD temperature 
ramps were acquired at 265 nm corresponding to the band maxima of the folded 
quadruplex species. Ranges between 5 and 99oC were used, with points acquired at 
0.5oC intervals with a 120–180 s timestep between 0.5oC increments. Points were 
acquired with 10 000 counts and adaptive sampling enabled.  
CD was recorded in units of absorbance known as ellipticity [θ]. Data was normalised to 
molar concentration of the repeating unit, where the repeating unit represents number 
of bases in each of the DNA/RNA oligonucleotide. The mean residue weight (MRW) was 
calculated from the molecular weight (MW) of each oligonucleotide divided by the 
number of bases (N) minus 1 (i.e., [MRW=MW/N-1]). To calculate the molar residual 
ellipticity (M.R.E) the following equation was applied: 
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𝑀. 𝑅. 𝐸 =
θ∗𝑀𝑅𝑊
10∗𝑑∗𝑐
  [𝑑𝑒𝑔. 𝑐𝑚2. 𝑑𝑚𝑜𝑙−1]   (Eq. 2) 
 
Where: 
θ= observed molar ellipticity 
d= path length in cm 
c= concentration in g/L  
 
The molar residue ellipticity equation (Eq. 2) was used to normalise the molar ellipticity 
spectrum in order for the measured value to be independent of the nucleic acid polymer 
length (Ishtikhar et al. 2014). 
NMR spectra (1H) were collected at 800 MHz using a Bruker Avance III spectrometer with 
a triple resonance cryoprobe. Standard Bruker acquisition parameters were used. Data 
were collected using Topspin (v. 3.0) and processed in CCPN Analysis (v. 2.1). 
 UV/Vis and fluorescence spectroscopy binding and analytic techniques 
DNA and RNA oligonucleotides for UV/Vis spectrophotometric and fluorescent 
spectrometric analysis stock solutions were prepared from the HPLC purified samples 
by resuspending them in Tris buffer to a final concentration of 500 µM. To anneal the 
oligonucleotides, the samples were placed on a heat block at 950 for 10 minutes and 
annealed by allowing to cool overnight to room temperature.  
Annealed oligonucleotides were titrated in 0-10 μM range in both UV/Vis and florescent 
spectrometry readouts. The berberine concertation was kept constant at 10 and 5 μM 
in UV/Vis and fluorescent spectroscopic analysis, respectively. Tris buffer was used as a 
blank. The UV/Vis spectrophotometer was set to record spectra from 300-550nm. Both 
types of spectra were recorded at room temperature. Fluorescent spectra were 
measured at λex/λem=355/530 nm. To measure the binding constant (Ka) data was 
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plotted into hyperbolic function using KaleidaGraph software following the equation 
below: 
𝛥𝐹 = (
𝛥𝐹𝑚𝑎𝑥
2[𝐿]0
) {([𝐿]0 + [𝑄] +
1
𝐾𝑎
) − √([𝐿]0 + [Q] +
1
𝐾𝑎
)
2
− 4[𝐿]0[𝑄]}              (Eq. 3) 
Where: 
ΔF=F-F0 and ΔFmax= Fmax-F0.  
F0 and F- initial and subsequent fluorescent intensities  
[L]0-berberine concertation 
[Q]- oligonucleotide concertation.  
Ka-binding constant 
The Eq. 3 is a quadratic velocity equation for tight-biding substrates to determine the 
affinity binding between berberine and quadruplex. The Eq. 3 was previously used to 
determine the binding affinity of berberine to the human telomeric DNA quadruplex 
structure by utilising the fluorescent spectroscopic analysis (Arora et al. 2008).   
2.15. Bioinformatics  
 Online resources 
 NCBI GenBank (www.ncbi.nlm.nih.gov/genbank/) 
o Genomic sequences 
  Ensembl (www.ensemble.org) 
o Transcript sequences 
 DUX4 secondary structure was predicted with mFold software:  
o Duplex DNA and RNA formation prediction 
 QGRS Mapper (http://bioinformatics.ramapo.edu/QGRS/index.php) 
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o DNA and RNA GQ formation prediction 
  DNA and RNA sequences 
The DUX4 sequences enhance and promoter sequences were acquired from the 
GenBank database (gene ID: AF117653). The DUX4 transcript isoform sequence were 
taken from the Ensembl database with their ID outlined in table 2.10. Sequences were 
exported in FASTA format form both databases and used to be directly inputted into a 
web server of software of interest. 
Table 2.10 Details of GenBank and Ensemble entries used 
  MFold 
The RNA folding form was set to default conditions. Folding temperature was at 37°C, in 
1 M NaCl. Maximum loop sizes were set to 30 bases and there was no limit on the 
distance between base pairs. The inputted sequences were no longer that 40 bases. The 
output structures were saved as pdf for later analysis. 
 QGRS Mapper 
The data could be submitted in the input box as raw FASTA nucleotide sequence, by 
providing the NCBI gene ID or Ensemble transcript ID. The GQ max length was set to 30 
DUX4 gene feature Database ID 
Enhancer and promoter GenBank AF117653 
Transcript 1 Ensembl ENST00000565211.1 
Transcript 2 Ensembl ENST00000569241.5 
Transcript 3 Ensembl ENST00000616166.1 
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base and loop size to 36 bases. The output view was provided as a FASTA sequence view 
with highlighted potential GQ-forming tetrads. The JavaScript enable internet browser 
(e.g., Internet Explorer) allowed for graphical view of putative GQs formation. GQ 
predicted sequences with a G-score of above 30 were considered for further analysis. 
2.16. Statistical analysis 
All statistical analysis was performed using GraphPad Prism 6 software.  
The data from the RT-PCR, RT-qPCR flow cytometry and spectrophotometry was 
analysed using one-way Anova unless stated otherwise.  
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3. Analysis and determination of GQ formation within 
DUX4 enhancer, promoter and transcript sequences 
3.1. Introduction  
 Computational prediction of GQs 
Computational analysis investigating GQs permits a thorough genome wide analysis of 
mammalian genes. These methods already allowed detailed surveillance of the GQ 
structures in the human genome (Huppert and Balasubramanian, 2006). However, a 
user friendly software that is available to a wider public has not existed until the release 
of QGRS mapper (Kikin et al. 2006). Particular focus of this software was to analyse 
alternatively processed mammalian pre-mRNA sequence of human and mouse genes 
(Kostadinov et al. 2006). As a result it has been found that GQ motifs are particularly 
enriched at or near alternative splice sites and poly(A) regions (Kostadinov et al. 2006). 
Furthermore, the QGRS Mapper provides comprehensive information on the 
configuration and distribution of potential GQ forming sequences that can be either 
manually submitted or retrieved from the NCBI databases through options provided in 
the software (Kikin et al. 2006). One of the core strengths of the software is the fact that 
it is able to analyse mammalian pre-mRNA sequences that have been alternatively 
processed i.e., have different splice isoforms or have been alternatively polyadenylated. 
The software provides flexibility in allowing the user to define the parameters of a 
number of tetrads, length of the quadruplex structure and content as well as size of the 
loops (Kikin et al. 2006). Selected genomic sequences such as enhancers, promoters, 
91 
 
telomeric regions as well as RNA sequences can be submitted in FASTA format for 
mapping unimolecular GQ motifs. In addition, QGRS Mapper is a very useful tool in 
predicting oligonucleotide structures. To retrieve desired genomic or transcript 
structures for the analysis, the software provides direct access to the NCBI Gene Entrez, 
GenBank and RefSeq databases. The output is represented in the form of an interactive 
graphic that can be also viewed in the form of a raw sequences and visualised 
distribution of the quadruplex motifs across all alternative RNA transcripts of a gene. 
Therefore, the QGRS Mapper allows functional analysis of the GQ motifs that might be 
involved in the alternative processing of a gene. The basic motif that QGRS uses to 
predict putative GQs is the following: 
GxNy1GxNy2GxNy3Gx 
Where x= number of guanine tetrads in the GQ and y1, y2, y3,= length of the loops 
connecting the guanine tetrads (Kikin et al. 2006).  
 Circular dichroism and nuclear magnetic resonance as 
experimental methods to study GQ structures and ligands 
Phenomenon of circular dichroism (CD) arises when chiral molecules interact with 
circularly polarized electromagnetic rays (Woody, 1995). In biological research, the CD 
has proven to be particularly useful in determining secondary structures of DNA and/or 
RNA due to their asymmetric sugar backbone and the helical structure resulting from a 
specific arrangement of its constituent nucleobases. Typical CD analysis uses UV light 
within 200-320 nm range of the spectrum that detects electronic transition of DNA (or 
RNA) bases (Gray et al. 1995). Although the resulting CD spectra of the nucleic acid 
chemistries can be calculated using complex quantum mechanical methods, in practice 
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the spectra patterns are interpreted empirically (Vorlickova et al. 2012). CD 
spectroscopy is a convenient method to analyse conformational changes in DNA 
structure that might be affected by environmental cues, such as pH, temperature, 
counter ions concentration or presence of crowding agents.  
Since the discovery of GQ motifs in the human genome and the fact that these structures 
might play an important biological role in processes related to aging and cancer 
development, extensive effort has gone into understanding of the biological role of 
these guanine-rich nucleic acids and potential molecules that regulate their stability. 
One of the most widely used techniques to interrogate the conformational changes and 
ligand interactions within GQs is CD. Three major DNA GQ conformations have been 
described using CD, such as parallel, antiparallel or mixed (Gray et al. 2008). Since RNA 
molecules lack the anti and possess only the syn glycosidic bond geometry, they form 
only parallel quadruplexes. Different types of quadruplex folding can be distinguished 
by characteristic pattern of CD spectra. The parallel GQs can be distinguished by the 
pronounced positive 260 nm band, while a positive band at 295 nm and a negative band 
at 260 confirm presence of an antiparallel quadruplex topology (Karsisiotis et al. 2011). 
Currently CD spectral patterns cannot be used to unambiguously determine the exact 
topology of the GQ structure. Since the CD analysis limits the number of possible 
structures that can be distinguished, defining exact GQ topology should also be 
supported by nuclear magnetic resonance (NMR) or X-ray crystallography data and 
techniques. 
NMR spectroscopy is a powerful tool that allows atomic resolution of GQ structures 
(Campbell and Parkinson, 2007). In addition, NMR is the only technique providing such 
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a high resolution that also allows structural analysis and ligand interaction in solution. 
Presence of the GQ structure can be determined by detection of the hydrogen bonds 
formed between guanines (Hoogsteen base pairing) within the G-tetrad. These 
characteristic guanine imino protons (1H) show a specific chemical shift in the region of 
10-12 nm of the spectrum, whereas the typical Watson-Crick base pairing can be 
detected within the range of 13-14 nm (Webba da Silva 2007). NMR has proven to be 
extremely useful in determining kinetic and dynamics of the interaction of GQ structures 
with their specific ligands, especially in the context of telomeric and oncogene promoter 
GQs. Furthermore, NMR can be also used to characterise 3D structures of an individual 
GQ as well as GQ-ligand complexes (Haider et al. 2002). The fact that the structure is 
investigated in solution serves as an advantage over the static crystallography approach.  
CD and NMR are currently considered be state-of-the-art scientific techniques that 
tremendously increased our understanding of GQ structure topologies as well as 
allowing us to test an extensive array of GQ interacting ligands that might serve as a 
potential treatment for many devastating diseases, including cancer (Balasubramanian 
et al. 2011). 
 Berberine binding affinity for RNA and DNA secondary structures measured with 
UV-Vis and fluorescent spectroscopy 
Photochemical properties of berberine were widely utilised to study its binding affinity 
to different types of nucleic acid secondary structures, including double stranded DNA, 
tRNA, GQs and triple helical nucleic acids (Basu et al. 2013; Nandi et al. 1990; Park et al. 
2004; Zhang et al. 2007). Berberine is a planar molecule with a large aromatic surface 
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that contains an extensive π-delocalised system and partial positive charge on N7 (Figure 
3.1) (Grycová et al. 2007).  
 
Figure 3.1 Chemical structure of berberine 
 
These chemical characteristic properties of berberine result in a specific absorbance 
pattern of the molecule. The absorption maximum of berberine has two characteristic 
peaks at 340 and 420 nm that change when the compound is bound to nucleic acid 
sequences (Arora et al. 2008; Li et al. 2017). Generally, the red shift in absorption peak 
indicates end stacking for GQs or intercalative properties for duplex DNA or RNA. The 
hypochromic shifts indicate reduction of the berberine absorption due to its binding to 
DNA/RNA. Furthermore, when the hypochromicity occurs without any red shift, it 
indicates groove binding rather the above-mentioned end stacking or intercalating 
interactions of berberine to the nuclei acid. 
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In addition, berberine shows significant fluorescent emission enhancement at 525 nm 
when bound to DNA/RNA and excited at 355 nm wavelength, while being essentially 
non-fluorescent while unbound. By utilising the UV-Vis and fluorescence spectroscopy 
techniques berberine binding affinity and recognition of nucleic acid secondary 
structures can be studied. 
 Objectives of the chapter 
The study of DUX4-related GQs was initiated by in silico analysis of the DUX4 myogenic 
enhancer 1 and 2, promoter and transcript elements to determine presence of the 
putative motifs within the analysed sequences. The candidate quadruplex-forming 
sequences were then subjected to the CD and NMR spectroscopy to determine their 
secondary structure topology in solution. Finally, the binding properties of berberine to 
the selected DNA and RNA oligonucleotide was assessed by the UV-Vis and fluorescence 
spectroscopy methods.
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3.2. Results 
 Bioinformatic analysis of GQ formation within the enhancer, promoter and 
transcript of DUX4 
The full promoter and enhancer sequences were manually selected and submitted into 
the QGRS Mapper software in FASTA format (Figure 3.2 and 3.3). The output result for 
the DUX4 myogenic enhancer 1 and 2 (DME1 and 2) has predicted 11 and 1 GQ motifs, 
respectively. Out of those predicted motifs only 1 has scored the value of ≥30 G-Score 
in the DME1 sequence, which is considered to likely form GQs in vitro (Prof M. Searle 
personal communication). The QGRS Mapper analysis of the DUX4 promoter (D4P) 
sequence has found 4 putative GQ motifs, from which only 1 has a G-Score of ≥30.  
The whole DUX4 transcript sequence (ENST00000569241.5) contains 30 putative GQ 
motifs according to the GQRS Mapper analysis (Figure 3.2.3). However, only 4 sequences 
have been predicted to have a G-Score of ≥30.  
All of the predicted sequences with the score of ≥30 were mapped to their 
corresponding positions within enhancer, promoter or transcript sequence regions as 
shown in Figure 3.4. From the schematic, it can be deduced that GQs with the G-Score 
≥30 cluster particularly with the coding sequence (CDS) and exon/intron boundaries of 
the transcript, indicating their possible biologically relevant role. The overlap of the GQ 
at the cryptic splice site (CSS), suggest a role in alternative splicing. There were no GQ 
forming sequences predicted within the exon 3 where the polyadenylation signal 
resides.  
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A particularly strongly scoring GQ (G-score: 36) motif has been also identified in the 5’ 
end of the DUX4 promoter (Figure 3.4). The motif spans through the conserved GGGGCG 
sequence known as GC box that has been previously found to be an important cis-
element recognised by common transcription factors such as Sp1 (Rettion et al. 2009).
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 Figure 3.2 QGRS Mapper-based prediction of G-quadruplexes within DUX4 enhancer sequences 
Top and bottom graphic show predictions of GQs within the sequence of DUX4 myogenic enhancer 1 and 2 (DM 
E1 and 2), respectively. (A.) The summary table showing the total number of GQs predicted and a number of motifs with a G-score ≥ 30 (i.e., 
highly likely to form GQs in vitro) present within the analysed sequence. (B.) Full FASTA sequence for each analysed genomic element with 
potential GQ sequences highlighted in yellow. (C.) A graphical output form QGRS Mapper showing all the potential GQ motifs forming within 
the analysed sequences and their relative position. 
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Figure 3.3 QGRS Mapper-based prediction of GQs within DUX4 promoter sequence 
(A.) The summary table showing the total number of GQ predicted and a number of 
motifs with the G-score ≥ 30 (i.e., highly likely to form GQs in vitro) present within the 
analysed sequence. (B.) Full FASTA sequence for each analysed genomic element with 
potential GQ sequences highlighted in yellow. (C.) A graphical output from QGRS 
Mapper showing all the potential GQ motifs forming within the analysed sequences and 
their relative position. The sequences were acquired from the study by Himeda et al., 
(2014) that first identified DUX4 myogenic enhancers. Promoter sequence was acquired 
from GenBank (Accession number: AF117653). 
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Figure 3.4 QGRS Mapper-based prediction of GQs within DUX4 transcript sequence 
(A.) The summary table showing the total number of GQ predicted and a number of 
motifs with the G-score ≥ 30 (i.e., highly likely to form GQs in vitro) present within the 
analysed sequence. (B.) Full FASTA sequence for each analysed genomic element with 
potential GQ sequences highlighted in yellow. (C.) A graphical output from QGRS 
Mapper showing all the potential GQ motifs forming within the analysed sequences and 
their relative position. Coding and 3’UTR sequence was acquired from Ensembl 
(ENSG00000260596), whereas the 5’UTR was derived from GenBank (Accession 
number: AF117653). 
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Figure 3.5 Schematics of GQ motifs prediction scores (B.) aligned with the biologically relevant genetic signal elements of DUX4 genomic locus 
(A) and transcript (C) 
Score prediction of the putative GQ structures was preformed using QGRS Mapper software. Location of the genomic elements relative to the 
start codon (ATG) was mapped based on the data acquired form GenBank (Accession number: AF117653) and publications by Himeda et al., 
(2014) and Dixit et al., (2007). The transcript sequences were derived from Ensembl (ENSG00000260596). Abbreviations: DME1 and 2, DUX4 
myogenic enhancer 1 and 2; DUX4-fl, DUX4 full length; DUX4-s, DUX4 short; Ex, exon; In, intron; CDS, coding DNA sequence; UTR, untranslated 
region; GQ, G-quadruplex. 
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Since the GQ forming sequences often contain cytosine residues, it is important to 
determine whether these will contribute to potential hairpin formations that are more 
thermodynamically stable than the corresponding GQ (Fay et al. 2017). To assess 
potential for formation of other secondary structures by the selected GQ sequences 
from enhancer, promoter and transcript sequences, the Mfold software was used. The 
isolated oligonucleotide GQ forming sequences (as predicted by the QGRS Mapper), that 
have ΔG <-10  kcal/mol were considered to have a higher driving force for hairpin 
formation structures over the GQ motifs. The ΔG prediction for DME1 G-quadruplex 
(GQ) and D4P GQ sequence was -3.31 and 0.33 kcal/mol, indicating a very low potential 
for these oligonucleotide sequences to fold into hairpin structures (Figure 3.6). The 
sequences with highest G-Score present within exon 1 (E1 GQ), has a ΔG= -7.30 kcal/mol 
that is relatively unfavourable for the hairpin formation (Figure 3.7). The relatively high 
ΔG=-0.66 kcal/mol predicted for the GQ predicted sequence motif located in the 
proximity of the splice site 1 (SS1_GQ), indicated low probability for this sequence to 
form hairpin structure (Figure 3.7). The ΔG for the remaining GQ forming sequences 
within CSS and splice site 2 (SS2 GQ) scored -14.70 and -10.00 kcal/mol, respectively, 
indicating that these sequences have a significantly higher potential to form hairpin 
structures rather than the GQ motifs (Figure 3.7).
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Figure 3.6 Mfold analysis of GQ forming sequence derived from the DUX4 myogenic 
enhancer 1 (DME1) and promoter (D4P) regions 
(A.) QGRS mapper graphic score highlighting sequence that is highly likely to form GQ in 
vitro (dashed box; G-score ≥ 30). (B.) Mfold analysis of the GQ forming sequence. The 
free energy (ΔG) is indicated. 
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Figure 3.7 Mfold analysis of GQ forming sequence derived from the DUX4 transcript region 
(A.) QGRS mapper graphic score highlighting the sequences that are highly likely to form GQ in vitro with the G-score ≥ 30. The putative GQ sequences 
that lay within the regions of cryptic splice site (CSS; black solid box), exon 1 (E1; black dashed box), splice site 1 (SS1; red box) and splice site 2 (SS2; 
green box) of the DUX4 transcript. (B.) Mfold analysis of the detailed GQ forming sequences. The free energy (ΔG) is indicated.  
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 CD and NMR structural analysis to determine GQ formation of selected DNA and 
RNA oligonucleotides  
To confirm whether the in silico predicted GQ-forming sequences (Figure 3.5) derived 
from the enhancer, promoter and transcript elements of DUX4, form in solution, CD and 
NMR analyses were performed on corresponding synthetic oligonucleotides. In addition, 
to determination of GQ presence, the CD and NMR were used to establish secondary 
topology of the selected DNA and RNA oligonucleotides. To generate a stable GQ 
structures the oligonucleotides were annealed in KP buffer with added 100 mM KCl that 
promotes formation of the motif. Exact sequence of each oligo is outlined in (Table 2.9). 
All of the selected oligonucleotides carry 4 runs of three Gs that have potential to form 
3 tetrads within the GQ structure. The runs of Gs are interspaced by varying number of 
nucleotides that will form loops in the potential GQ structure. Each oligonucleotide 
sequence was selected so the nucleotide at the end of each sequence is different than 
G to prevent stacking of the GQ molecules. 
3.2.2.1. CD and NMR structural analysis of GQ formation by the DNA oligonucleotide sequences 
derived from DME1 and D4P of DU4 
The DME1 DNA GQ oligo (5’ CAGGGGATGG TGGGGCTGGG GTTGAGTGAT GGGC 3’) shows a 
characteristic CD spectrum pattern of an ellipticity maximum around 260 nm and 
negative ellipticity minimum at 240 nm at room temperature indicative of a parallel GQ 
structure (Figure 3.8 A). The NMR spectrum confirmed the presence of GQ formation by 
the oligo as detected by the strong signal at 10 and 12 ppm, which is specific to the 
Hoogsteen hydrogen boding. The NMR readout also shows no signal detection at the 
>12 ppm range, indicating no other secondary structure formation by the 
oligonucleotide (Figure 3.8 C). CD spectra shows weak absorbance at the 290 nm 
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ellipticity, suggesting presence of external loops formed by bimolecular parallel GQ, 
rather than the tetramolecular (four stranded) structure that has a single positive peak 
at 260 nm ellipticity (Paramasivan, Rujan, and Bolton 2007)(Figure 3.8 A). The melting 
transition appears smooth, further indicating that there is one predominant structure of 
the oligonucleotide formed (Figure 3.8 B). The relatively low melting temperature of 
~70°C is most likely caused by the presence of potential long loop-forming sequences 
within the motif. Upon thermal renaturation of the DNA oligo, the absorbance pattern 
returns to the original position suggesting no transition to other stable topologies or 
secondary structures than the parallel GQ (Figure 3.8 A).  
The CD and NMR spectral data, supplemented by the bioinformatic analysis, showing a 
low probability of hairpin formation (ΔG=0.33 kcal/mol) and relatively high score for 
quadruplex formation (≥30) strongly suggest that the DME1 DNA oligonucleotide forms 
a single species GQ of bimolecular parallel structure in solution (Figure 3.8 D).
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Figure 3.8 Biophysical characterisation of DNA secondary structure of the predicted GQs in the DUX4 myogenic enhancer 1 (DME1) sequence 
(A.) Far-UV circular dichroism spectrum at 25°C reveals ellipticity maximum at 265 nm indicative of a parallel GQ structure formation by the 
oligonucleotide. The temperature at which each absorption spectra was obtained is expressed in degrees Celsius. (B.) Sigmoidal CD melting 
curves for the oligonucleotide shows transitional mid-point at 70°C indicating modest stability of the quadruplex structure. (C.) 1H NMR spectrum 
of the oligonucleotide recorded at 800 MHz and 298K showing groups of resonances characteristic for Watson-Crick (solid line box highlighting 
non-quadruplex structure signal) and Hoogsten H-bonded bases (dash line box highlighting quadruplex structure). As highlighted, the DME1 
sequence forms a single species of quadruplex structure. (D.) Bioinformatic prediction of possible secondary structures formed by the sequence 
using mFold (solid arrow) or QGRS Mapper (dashed arrow). Abbreviations: M.R.E - molar residue ellipticity 
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The D4P DNA GQ oligonucleotide (5’ CGGGGTGGGGCGGGCTGTCCCAGGGGGGCT 3’) has 
a characteristic pattern of absorbance at the ellipticity maximum at 260 nm and 
ellipticity minimum at 240nm for a parallel GQ as shown by the CD (Figure 3.9 A). Lack 
of apparent absorbance at 290 nm indicates that the structural topology is 
tetramolecular lacking external loops (Figure 3.9 A). The NMR spectrum displays 
distinctive signals characteristic of both GQ as well as double-stranded hairpin structure 
(Figure 3.9 C). The double transition of the melting curve indicates presence of two 
structures with quite different stabilities (i.e., hairpin and quadruplex). There is no 
significant transition in the CD spectra upon thermal renaturation of the oligonucleotide, 
since both hairpin and parallel GQs have a strongly overlapping ellipticity maxima at 
260nm (Kypr et al. 2009). The negative ΔG of -3.32 kcal/mol for the oligonucleotide 
indicates that there is a possibility of a hairpin and GQ folding might exist in 
thermodynamic equilibrium, which is supported by the CD and NMR readouts (Figure 
3.9 D).
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Figure 3.9 Biophysical characterisation of DNA secondary structure of the predicted GQs in the DUX4 promoter (DP) sequence 
(A.) Far-UV circular dichroism spectrum at 25°C reveals ellipticity maximum at 265 nm indicative of a parallel GQ structure formation by the 
oligonucleotide. The temperature at which each absorption spectra was obtained is expressed in degrees Celsius. (B.) However, the melting 
curve shows a double transition, indicating that two different structures i.e., hairpin and quadruplex exist with different stabilities. Overall 
melting temperature was recorded at 78°C (C.) 1H NMR spectrum of the oligonucleotide recorded at 800 MHz and 298 K showing groups of 
resonances characteristic for Watson-Crick (solid line box highlighting non-quadruplex structure signal) and Hoogsten H-bonded bases (dash line 
box highlighting quadruplex structure). Recorded NMR signal confirms presence of hairpin (solid line box) and quadruplex structure (dashed line 
box). (D.) Bioinformatic prediction of possible secondary structures formed by the sequence using Mfold (solid arrow) or QGRS Mapper (dashed 
arrow). Abbreviations: M.R.E - molar residue ellipticity 
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The DNA oligonucleotide sequence derived from the human telomere (H. Telomer GQ) 
(5’AGGGTTAGGGTTAGGGTTAGGG 3’) was used as a positive control. The classic CD 
absorption spectra for an antiparallel GQ has the ellipticity maxima at 290 nm and 
ellipticity minima 260 nm. Although the measured H. Telomere GQ oligonucleotide 
shows maximum absorbance at 290 nm, there is a shoulder peak at around 250 nm and 
ellipticity minimum at 238 nm (Figure 3.10 A). This absorption patterns is indicative of a 
hybrid type unimolecular parallel/antiparallel GQ structure as it has been previously 
reported for this sequences (Ambrus et al. 2006b). The melting temperature of the GQ 
structure was recorded at around 60°C using the CD analysis (Figure 3.10 B). The CD data 
confirms the bioinformatic data predicting no hairpin structure and high G-Score (i.e., 
42) for quadruplex formation as shown by the Mfold and GQRS Mapper, respectively 
(Figure 3.10 C).
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Figure 3.10 Biophysical characterisation of DNA secondary structure of the human telomeric sequence  
(A.) Far-UV circular dichroism spectrum at 25°C reveals ellipticity maximum at 290 nm, shoulder peak at 250 and ellipticity minimum at 238 nm 
indicative of a hybrid parallel/antiparallel GQ structure formation by the oligonucleotide. The temperature at which each absorption spectra 
was obtained is expressed in degrees Celsius. (B.) Overall melting temperature was recorded at 60°C (C.) Bioinformatic prediction of possible 
secondary structures formed by the sequence using mFold (solid arrow) or QGRS Mapper (dashed arrow). Abbreviations: M.R.E - molar residue 
ellipticity 
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3.2.2.2. GQ formation by RNA oligonucleotides derived from DUX4 transcript analysed by CD 
and NMR 
The first RNA oligonucleotide of interest that was tested by the CD and NMR for the 
formation of GQ was the sequence derived from the region overlapping the cryptic 
splice site (CSS), since it could be involved in alternative splicing of the DUX4 transcript 
and yielded non-toxic DUX4 (short) isoform (Snider et al. 2010). As the RNA GQcan only 
form parallel structures due to the lack of the anti-glycosidic bond geometry and the 
fact the hairpin structures show overlapping ellipticity maximum absorbance at 260 nm 
with parallel quadruplexes, it is important to supplement the CD data with the NMR and 
bioinformatic analysis to discriminate between those two secondary structures.  
As predicted, the CSS GQ oligonucleotide (5’ CGGGGUUGGGACGGGGUCGGGU 3’) 
measured by the CD shows ellipticity maxima at 260 nm and ellipticity minimum at 
around 240 nm that would normally indicate that it is a parallel GQ motif (Figure 3.11 
A). However, presence of a second ellipticity minima at 210 nm suggest that the A-form 
(i.e., hairpin) structure is formed by this sequence (Figure 3.11 A). The clear signal at 
>12ppm from the NMR also shows presence for hairpin specific hydrogen bonds, 
whereas no GQ specific signal was recorded (Figure 3.11 C). The smooth melting curve 
indicates a single hairpin structure in the solution (Figure 3.11 B). The mFold predicts a 
very thermodynamically stable hairpin formation due to presence of multiple C residues 
within the analysed sequences (Figure 3.11 D). Despite the high G-Score of 41, the NMR 
and CD analysis does not confirm quadruplex formation by the analysed sequences, but 
confirms the hairpin formation as predicted by the Mfold analysis. 
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Figure 3.11 Biophysical characterisation of RNA secondary structure of the predicted GQs in the cryptic splice site (CSS) sequence 
(A.) Far-UV circular dichroism spectrum at 25°C reveals the ellipticity maximum at 265 nm and the ellipticity minimum at 240 and 210 nm 
characteristic for a hairpin structure. (B.) 1H NMR spectrum of the oligonucleotide recorded at 800 MHz and 298 K showing groups of resonances 
characteristic for Watson-Crick (solid line box highlighting non-quadruplex structure signal) and Hoogsten H-bonded bases (dash line box 
highlighting quadruplex structure). As highlighted, the CSS sequence forms a single species of hairpin structure. (C.) Bioinformatic prediction of 
possible secondary structures formed by the sequence using mFold (solid arrow) or QGRS Mapper (dashed arrow). Abbreviations: M.R.E - molar 
residue ellipticity 
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The highest scoring sequence for the formation of GQ out of all of the analysed 
sequences was present downstream of the CSS in the exon 1. The exon 1 GQ (E1 GQ) 
had a G-Score of 55 as predicted by the GQRS Mapper, which is higher than the well-
studied human telomeric quadruplex sequence that scored 44 when analysed with the 
same software (Figure 3.7; Figure 3.10 C).  
The RNA E1 GQ sequences (5’ AGGGGAGUCCGUGGUGGGGCUGGGGCCGGGGU 3’) 
analysed by the CD shows the ellipticity maximum at 260 nm and ellipticity minimum at 
240 nm, which is a characteristic pattern of absorption for a parallel GQ (Figure 3.12 A). 
The oligonucleotide shows high thermal stability as the full melting profile could not be 
achieved at the near 80°C (Figure 3.12 B). Despite the relatively large intervening loops 
between the G-tetrads, the analysed sequence shows to be particularly 
thermodynamically stable, which aligns with the QGRS Mapper output predicting the 
high G-Score of 55 for the RNA oligo. The NMR shows a strong, clear signal at the 10-12 
ppm range indicating presence of quadruplex-specific Hoogsteen hydrogen bonding 
(Figure 3.12 C). No Watson-Crick hydrogen bonding could be detected by the NMR, 
confirming that no hairpin structures are formed by this sequence in the solution (Figure 
3.12 C). The ΔG of <10 kcal/mol from the Mfold output indicates small probability of a 
stable hairpin formation by the E1 GQ sequences (Figure 3.12 D). 
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Figure 3.12 Biophysical characterisation of RNA secondary structure of the predicted GQ in the exon 1 (E1) sequence 
(A.) Far-UV circular dichroism spectrum at 25°C reveals the ellipticity maximum at 265 nm and the ellipticity minimum at 240 typical for parallel 
GQ structure. The temperature at which each absorption spectra was obtained is expressed in degrees Celsius. (B.) Sigmoidal CD melting curve 
was not fully formed in the assessed temperature range; therefore, no Tm was assessed. (C.) 1H NMR spectrum of the oligonucleotide recorded 
at 800 MHz and 298 K showing groups of resonances characteristic for Watson-Crick (solid line box highlighting non-quadruplex structure signal) 
and Hoogsten H-bonded bases (dash line box highlighting quadruplex structure). As highlighted, the E1 GQ sequence forms a single species of 
quadruplex structure. (D.) Bioinformatic prediction of possible secondary structures formed by the sequence using mFold (solid arrow) or QGRS 
Mapper (dashed arrow). Abbreviations: M.R.E - molar residue ellipticity 
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The final RNA oligonucleotide that had the G-score ≥30 lies at the exon1/intron1 
boundary, in the region of the first splice site (SS1). The RNA oligonucleotide SS1 GQ 
sequences (5’ CGGGGUUGGGACGGGGUCGGGU 3’), when subjected to the CD analysis, 
shows ellipticity maximum at 265 nm and ellipticity minimum at 240 nm, which is 
characteristic of a parallel GQ (Figure 3.13 A). The complete thermal denaturation of the 
structure could not be achieved within the available temperature limits, showing high 
stability of the analysed sequences (Figure 3.13 A). As a result, full melting curve profile 
could not be achieved for this sequence and therefore no Tm could be derived (Figure 
3.13 B). Interestingly, the peak at 265 nm becomes more pronounced after the 
renaturation process, suggesting that the process of denaturation promoted formation 
of additional GQ motifs that failed to form during the initial annealing process (Figure 
3.13 A). In the NMR analysis, the oligonucleotide sequences have been found to produce 
a signal within the 10-12 ppm rage which is GQ specific (Figure 3.13 A). No signal for 
Watson-Crick, hairpin specific signal was recorded in the NMR readout (Figure 3.13 C). 
In support of the CD and NMR analysis, the Mfold predicted a potential hairpin 
formation with a modest stability as suggested by the low ΔG of -0.60 kcal/mol (Figure 
3.13 D). 
125 
 
 
Figure 3.13 Biophysical characterisation of RNA secondary structure of the predicted GQs in the splice site 1 (SS1) sequence 
(A.) Far-UV circular dichroism spectrum at 25°C reveals the ellipticity maximum at 265 nm and the ellipticity minimum at 240 nm typical for 
parallel GQ structure. The temperature at which each absorption spectra was obtained is expressed in degrees Celsius. (B.) Sigmoidal CD melting 
curve was not fully formed in the assessed temperature range, therefore no Tm was assessed. (C.) 1H NMR spectrum of the oligonucleotide 
recorded at 800 MHz and 298 K showing groups of resonances characteristic for Watson-Crick (solid line box highlighting non-quadruplex 
structure signal) and Hoogsten H-bonded bases (dash line box highlighting quadruplex structure). As highlighted, the SS1 GQ sequence forms a 
single species of quadruplex structure. (D.) Bioinformatic prediction of possible secondary structures formed by the sequence using mFold (solid 
arrow) or QGRS Mapper (dashed arrow). Abbreviations: M.R.E - molar residue ellipticity 
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 Effect of berberine on secondary structure of selected DNA and RNA 
oligonucleotides 
Having established that all of the selected oligonucleotide sequences from the 
enhancer, promoter and transcript elements (except for the hairpin-forming CSS 
sequences) form GQs in solution, the next step was to investigate the effect of berberine 
on conformation of these secondary structures. The CD spectra was used to assess 
structural changes of the DME1 GQ, D4P GQ, CSS GQ and SS1 GQ oligonucleotides (5 
μM) in the presence of increasing concentrations of berberine (0-50 μM). Each of the 
sequences was also subjected to thermal denaturation process in the presence of the 
ligand at the maximum concentration (50 μM) in order to study berberine’s binding 
properties.  
First, the DME1 GQ DNA oligonucleotide was investigated (Figure 3.14). Upon increasing 
concentration of the compound, no apparent change of the ellipticity maximum at 265 
nm, ellipticity minimum at 240 nm and the shoulder peak at 290 nm indicative of 
bimolecular parallel GQ structure has occurred (Figure 3.14 A). This indicated that no 
further induction of the GQ structure has been promoted, and that there is no structural 
shift towards other types of GQ topologies (e.g., antiparallel) induced by the presence 
of berberine. The melting curve analysis reveals melting transition increase from ~44 to 
55°C for the oligonucleotide with the berberine added compared with the 
oligonucleotide solution that did not contain the compound, indicating potential binding 
of the compound to the GQ. The double transition in the melting curve for the 
oligonucleotide solution containing berberine, might indicate the temperature-induced 
dissociation of the compound from the GQ prior to the denaturation of the secondary 
structure (Figure 3.14 B). Furthermore, the double transition might be also indicative of 
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a weak binding of berberine, leading to equilibrium between bound and unbound state. 
However, due to the limitations of the apparatus, it was not possible to reach 
temperatures above ~80°C that would allow formation of the full melting curve profile 
for both of the analysed oligonucleotides (Figure 3.14 B). Therefore, an accurate Tm 
could not be calculated that in turn would allow for assessment of berberine’s binding 
affinity to the DME1 GQ DNA oligonucleotide.
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Figure 3.14 Effect of increasing berberine concentrations on secondary structure formation of DME1 GQ sequence 
(A.) Far-UV spectra were recorded using CD at each concentration of berberine (0-50μM) added to the fixed concentration of the oligonucleotide 
(5 μM). Each measurement was performed at room temperature. Increasing concentration of berberine has not changed the intensity or 
transition the 265 or 290nm peaks noticeably, indicating no change in the parallel GQ structure of the oligonucleotide. (B.) CD spectra recorded 
at 265 nm absorbance of the DME1 GQ oligo without and with 50μM berberine added. The absorbance was expressed as a function of 
temperature ranging from ~20 to 80°C (±2°C). Melting of the oligonucleotide structure is increased in the presence of berberine from ~45 to 
~55°C. Abbreviations: M.R.E (molar residue ellipticity); DME1 GQ (DUX4 myogenic enhancer 1 G-quadruplex). 
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When the D4P GQ DNA oligonucleotide was analysed in the presence of berberine, a 
very significant change in ellipticity was recorded (Figure 3.15 A). The ellipticity 
maximum at 265 nm has decreased as the concentration of the ligand was increased. In 
addition, the absorbance peak at 290 nm has increased as the berberine was added to 
the D4P GQ oligonucleotide solution. At the highest concentration of the ligand, the 290 
nm absorbance has reached ellipticity maximum and has become more pronounced 
than the 265 nm absorbance. This 265 to 290 nm shift of absorbance is mediated by end 
stacking of berberine to the GQ structures that leads to transition from the parallel to 
the antiparallel topology (Figure 3.15 A). The berberine-induced change in structural 
plasticity of the D4P GQ is also apparent from the melting profile (Figure 3.15 B). The 
early increase in temperature (~20-50°C) initially displaced the ligand from the GQ and 
lead to the initial return from the antiparallel to the original (i.e., ligand free) parallel 
structure conformation with the ellipticity peak shifting from 290 to 265 nm. As the 
temperature was increased to ~60°C, the secondary structure of the D4P GQ started to 
denature (Figure 3.15 B). The full melting profile of the measured GQ structure could 
not be achieved due to the limitations of the machine. Therefore, an accurate Tm value 
for binding affinity calculations could not be derived. 
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Figure 3.15 Effect of increasing berberine concentrations on secondary structure formation of D4P GQ sequence 
(A.) Far-UV spectra was recorded using circular dichroism at each concentration of berberine (0-50 μM) added to the fixed concentration 
of the oligo (5 μM). Each measurement was performed at room temperature. Increasing concentration of berberine induces a transition 
of 265 nm to 290 nm peak, indicating shift of the GQ structure from parallel to anti-parallel form. (B.) CD spectra recorded at 265 nm 
absorbance of the D4P GQ oligo without and with 50 μM berberine added. The absorbance was expressed as a function of temperature 
ranging from ~20 to 80°C (±20). In the presence of berberine the 265 nm peak increases as the temperature is raised. Melting of the 
secondary structure of the oligonucleotide initiates between 50 and 60°C. Abbreviations: M.R.E., molar residue ellipticity; D4P GQ, DUX4 
promoter G-quadruplex. 
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Introduction of berberine to the RNA CSS GQ solution has not induced any major 
changes in the ellipticity of the oligonucleotide’s secondary structure (Figure 3.16). This 
suggests that this particular hairpin conformation is a weak binder of berberine.  
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Figure 3.16 Effect of increasing berberine concentrations on 
secondary structure formation of CSS GQ sequence 
Far-UV spectra was recorded using circular dichroism at each 
concentration of berberine (0-50 μM) added to the fixed 
concentration of the oligonucleotide (5 μM). Each measurement 
was performed at room temperature. 
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No significant changes in ellipticity was reordered for the RNA E1 GQ oligonucleotide 
upon increasing concentrations of berberine in solution (Figure 3.17 A). As a result, no 
apparent effects of berberine on E1 GQ structure was reported. The melting profile for 
E1 GQ in the presence and absence of the ligand shows to be similar and has estimated 
melting transition point of ~65°C and ~70°C, respectively (Figure 3.17 B). The estimated 
melting point indicates a relatively high stability of the GQ structure. At the maximum 
temperature of ~80°C, that could be achieved by the CD spectroscopy, the secondary 
structure was not fully dissociated as the full meting curve was not formed (Figure 3.17 
B). Therefore, it was not possible to establish accurate Tm values.  
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Figure 3.17 Effect of increasing berberine concentrations on 
secondary structure formation of the E1 GQ sequence 
(A.) Far-UV spectra was recorded using circular dichroism at each 
concentration of berberine (0-50 μM) added to the fixed 
concentration of the oligonucleotide (5 μM). Each measurement 
was performed at room temperature. Increasing concentration of 
berberine has not changed the intensity or transition the ellipticity 
maximum at 265 nm and ellipticity minimum at 210 nm, indicating 
no change in parallel GQ structure of the oligonucleotide. (B.) CD 
spectra recorded at 265 nm absorbance of the E1 GQ 
oligonucleotide without and with 50 μM berberine added. The 
absorbance was expressed as a function of temperature ranging 
from ~20 to 80°C (±20). Melting curve for the oligonucleotide in 
presence and absence of the ligand is incomplete within the limits 
of temperature range used. Abbreviations: M.R.E molar residue 
ellipticity; E1 GQ, exon 1 G-quadruplex 
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Finally, the RNA SS1 GQ oligonucleotide shows no change in the CD spectra in the 
presence of increasing concentrations of berberine (Figure 3.18 A). This suggests that 
the ligand does not have a major effect on the topology of the SS1 quadruplex. 
Overlapping melting profiles of the SS1 GQ in presence and absence of berberine, 
indicates weak binding of the compound to the structure (Figure 3.18 B). The GQ 
structure shows to have a modest thermodynamic stability as its melting transition 
begins at ~65°C. The full melting profile could not be achieved due to the device 
limitations (Figure 3.18 B). Therefore, the Tm for the oligonucleotide could not be 
measured.  
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Figure 3.18 Effect of increasing berberine concentrations on secondary 
structure formation of the SS1 GQ sequence 
(A.) Far-UV spectra was recorded using circular dichroism at each 
concentration of berberine (0-50 μM) added to the fixed concentration of the 
oligonucleotide (5 μM). Each measurement was performed at room 
temperature. Increasing concentration of berberine has not changed the 
intensity or transition the ellipticity maximum at 265 nm and ellipticity 
minimum at 240 nm, indicating no change in the parallel GQ structure of the 
oligonucleotide. (B.) CD spectra recorded at 265 nm absorbance of the SS1 GQ 
oligonucleotide without and with 50 μM berberine added. The absorbance was 
expressed as a function of temperature ranging from ~20 to 80°C (±2°C). 
Melting curve for the oligonucleotide in presence and absence of the ligand is 
incomplete within the limits of temperature range used. Abbreviations: M.R.E’ 
molar residue ellipticity; DME1 GQ, DUX4 myogenic enhancer GQ. 
Abbreviations: M.R.E., molar residue ellipticity; SS1 GQ, splice site 1 G-
quadruplex. 
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 Berberine binding affinity to selected DNA and RNA oligonucleotide sequences 
measured using UV-Vis and fluorescent spectroscopy 
3.2.4.1. UV-Vis spectroscopic analysis of berberine binding to DNA and RNA oligonucleotides 
Addition of DME1 GQ and D4P GQ oligonucleotides into berberine solutions resulted in 
considerable λmax hypochromicity of ~26 and 24% at the highest concentration of the 
oligonucleotides, respectively (Figure 3.19). A red shift of ~6 nm at 320 nm and ~8 nm 
at 420 nm for the DME1 GQ oligo was recorded, whereas the D4P GQ oligonucleotide 
induced a shift of ~4 nm at 320 nm and ~8 nm at 420 nm (Figure 3.19). This absorbance 
pattern change is indicative of end-stacking of the ligand (i.e., berberine) to the G-
quadruplex structures, which further supports the data obtained from the CD and NMR 
analysis of these sequences.  
The DNA control sequences included calf thymus (CT) DNA, long sequence 
oligonucleotide (LS) (26-mer) and short sequence oligonucleotide (SS) (12-mer) were 
annealed to form a double stranded DNA conformation. For the CT, LS and SS there was 
a noticeable λmax hypochromicity recorded of 14.4; 13.7; and 7.0%, respectively. No red 
shift was recorded for any of the negative DNA controls, indicating that the berberine is 
not a good intercalator but rather a duplex groove binder (Figure 3.19).
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 Figure 3.19 UV-Vis absorbance spectra of putative G-quadruplex forming oligonucleotides 
UV-Vis absorbance spectra of 10 µM berberine in presence of DNA oligonucleotides at a range of concentrations (0-10 µM) in Tris-HCl 
(10 mM), KCl (100 mM) pH 7.0, measured at room temperature. The GQ forming DNA oligonucleotide sequences, include: DME1 GQ and 
D4P GQ. The Negative controls used are CT DNA, DNA LS and DNA SS. Abbreviations: CT, calf thymus; LS, long sequence; SS, short 
sequence; DME1, DUX4 myogenic enhancer 1; D4P, DUX4 promoter; GQ, G-quadruplex.  
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The binding mode of berberine towards CSS, E1 and SS1 GQ RNA oligonucleotides was 
also investigated. At the highest oligonucleotide concentration, the λmax hypochromicity 
for the CSS, E1 and SS1 was up to 20.4; 28.0 and 30.0%, respectively (Figure 3.20). The 
red shift at the highest concentration of each oligonucleotide was ~6 nm at 340 nm and 
~12 nm at 420 nm for the CSS GQ; ~6 at 340 nm and 0 nm at 420 for the E1 GQ; ~4 nm 
at 340 nm and ~12 nm at 420 nm for the SS1 GQ (Figure 3.20). The recorded absorbance 
signal at 420 nm measured in the presence of the E1 GQ was particularly noisy that most 
likely resulted in an error producing no red shift for berberine at this particular 
wavelength. 
The RNA oligonucleotides that were used as a negative control were the RNA LS (26-
mer) and SS (12-mer) that were annealed to form a duplex structure. The RNA LS and SS 
show a negligible λmax hypochromicity of 7.8 and 8.9%, respectively (Figure 3.20). The 
red shift of berberine absorbance was not induced by presence of neither of the 
negative control oligonucleotide. This suggests that berberine is a weak groove binder 
of the annealed negative control RNA sequences.
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Figure 3.20 UV-Vis absorbance spectra of RNA oligonucleotides 
UV-Vis of 10 µ M berberine in presence of RNA oligonucleotides at a range of concentrations (0-10 µM) in Tris-HCl (10 mM), KCl (100 mM) pH 
7.0, measured at room temperature. The GQ forming DNA oligonucleotide sequences, include: CSS GQ, E1 GQ and SS1 GQ. The Negative controls 
used are RNA LS and RNA SS. Abbreviations: LS, long sequence; SS, short sequence; CSS, cryptic splice site; SS1, splice site 1; E1, exon 1; GQ, G-
quadruplex.
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3.2.4.2. Fluorescence spectroscopic titration to assess binding kinetics of berberine to secondary 
structures of selected DNA and RNA 
The berberine alone in Tris-HCL buffer was essentially non-fluorescent. The change in 
fluorescent emission intensity at 525 nm was recorded as each of the oligonucleotides 
was titrated gradually at increasing concentrations. The gradual addition of the DME1 
and D4P GQ DNA oligonucleotides resulted in up to ~7 and ~2.5-fold fluorescent increase 
of berberine fluorescent emission, respectively (Figure 3.21). The negative control DNA 
duplexes such as CT, LS and SS DNAs show minimal fluorescent emission of 0.5; 0.4 and 
0.2, respectively (Figure 3.21). The results collected for the DME1 and D4P GQ sequences 
were plotted as a hyperbolic function using the equation listed in section 2.14.3, to 
calculate the binding constant (Ka). When plotted, the data points from the DME1 and 
D4P GQ titration forms a clear hyperbolic curves indicative of binding of berberine to 
these conformations (Figure 3.22 A). The calculated Ka for DME1 and D4P GQ are 1.9 ± 
0.2 x 106 M-1 and 4.0 ± 0.3 x 105 M-1, respectively (Figure 3.22 B). All of the titrated 
duplex DNA negative control tested (i.e., CT, LS and SS DNA) form a straight-line function 
indicative of low or no binding activity of berberine to these conformations (Figure 3.22 
A). The calculated Ka values of ~1 ± 0.2 x 105 M-1  for the CT and LS DNA oligonucleotides 
indicate that these duplexes are weak berberine binders (Figure 3.22 B). The DNA SS has 
considerably lower binding affinity with a large error, suggesting that it does not bind 
berberine effectively (Figure 3.22 A).
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 Figure 3.21 Fluorescent spectra of DNA oligonucleotides 
Fluorescent emission spectra of (0.5 µM) berberine in the presence of increasing concentrations (0-10 µM) of DME1 GQ, D4P GQ, CT 
DNA, DNA LS and DNA SS oligos in Tris-HCl (10 mM), KCl (100 mM), measured at pH 7.0 and room temperature. Arrow indicates increase 
of fluorescent emission at 525 nm as the increasing amount of the oligo was titrated. Abbreviations: CT, calf thymus; LS, long sequence; 
SS, short sequence; DME1, DUX4 myogenic enhancer 1; D4P, DUX4 promoter; GQ, G-quadruplex 
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Figure 3.22 Binding affinity of berberine to DNA oligonucleotides 
(A.) Plot of ΔF emission at 522 nm of (0.5 μM) berberine versus DNA oligo concentrations (0-10 
μM). The DNA oligonucleotide measured include DME1 GQ, D4P GQ, CT DNA, DNA LS and DNA SS 
sequence. (B.) To calculate the binding affinity for the plotted data, the equation from section 
2.3.13 was used. Abbreviations: CT, calf thymus; LS, long sequence; SS, short sequence; DME1, 
DUX4 myogenic enhancer 1; D4P, DUX4 promoter; GQ, G-quadruplex. 
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The CSS, E1 and SS1 GQ RNA oligonucleotides were gradually titrated at increasing 
concentrations, resulting in an increase in fluorescent emission of 2, 3 and 4-fold, 
respectively (Figure 3.23). The fluorescent emission data was plotted as a hyperbolic 
function using the same method as the above-mentioned DNA counterparts using the 
equation described in section 2.143. These RNA sequences show to have a comparable 
Ka of 4.3-3.3 x 105 M-1 and a relatively low error of ±0.2-0.3 x 105 M-1 (Figure 3.24 B). 
Furthermore, the RNA secondary structure motifs show to have a comparable berberine 
binding affinity to the DNA D4P GQ conformation (Figure 3.22 B and 3.24 B). The highest 
berberine binding affinity was calculated for the DME1 DNA GQ, which was ~5-fold 
higher than for second highest GQ-forming sequence (i.e., D4P GQ). The relatively low 
Ka value calculated for the CSS GQ, could be dictated by the fact that the sequence forms 
a hairpin rather than the GQ structure.  
The RNA SS negative control was plotted as a flat straight line and its Ka was calculated 
to be particularly low and with high error, indicating that this RNA duplex has a very low 
binding potential to berberine (Figure 3.24 B).
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Figure 3.23 Fluorescent spectra of RNA oligonucleotides 
Fluorescent emission spectra of (0.5 µM) berberine in the presence of increasing concentrations of (0-10 µM) CSS GQ, E1 GQ, SS1 GQ, RNA LS and RNA 
SS oligonucleotides in Tris-HCl (10 mM), KCl (100 mM) pH 7.0, measured at room temperature. Arrow indicates increase of fluorescent emission at 525 
nm as the increasing amount of the oligo was titrated. Abbreviations: LS, long sequence; SS, short sequence; CSS, cryptic splice site; SS1, splice site 1; E1, 
exon 1; GQ, G-quadruplex. 
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Figure 3.24 Binding affinity of berberine to DNA oligonucleotides 
(A.) Plot of ΔF emission at 522 nm of (0.5 μM) berberine versus RNA oligonucleotide 
concentrations (0-10 μM). The RNA oligonucleotide measured include CSS GQ, E1 GQ, 
SS1 GQ and RNA SS sequence. (B.) To calculate the binding affinity for the plotted data, 
the equation from section 2.3.13 was used. Abbreviations: SS, short sequence; CSS, 
cryptic splice site; SS1, splice site 1; E1, exon 1; GQ, G-quadruplex. 
. 
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3.3. Discussion 
QGRS Mapper proved to be a very intuitive, easy to use software that allowed prediction 
with high confidence of six novel GQ: two of these were found in DME1 and D4P, 
respectively and 4 in the transcript coding sequence of DUX4. Interestingly, the D4P GQ 
and three of the transcript predicted GQ motifs (i.e., the CSS the E1 and SS2 GQ) contain 
a loop that is >7 nucleotide long.  
The biophysical analyses confirm GQ formation in solution within the selected putative 
GQ sequences except for the CSS sequence that was found to form a hairpin. Therefore, 
the original GQ predicting algorithm assuming that any potential GQ forming sequences 
with loops longer than 7 are redundant should be re-evaluated, especially since there is 
a body of accumulating experimental evidence showing that extensive loops sizes do 
not prevent formation of stable GQs. For example, a nine-nucleotide propeller loop was 
found within the stable GQ structure of the human CEB25 mini-satellite locus as 
determined by NMR studies (Amrane et al. 2012). Furthermore, a very long 26-
nucleotide loop, stabilised with a GC-based hairpin has been found to form within a 
promoter sequence of hTERT gene (Palumbo et al. 2009). Finally, the human BCL-2 gene 
contains GQ-forming sequences containing a 13-nuclotide central loop (Agrawal et al. 
2014). Since these restrictive algorithm were originally used to predict total number of 
350000 putative GQ within the human genome, it highly likely that this number could 
be much greater and potentially needs to be revised (Huppert and Balasubramanian 
2005). The development of a whole genome GQ screening assay that utilises 
combination of next-generation sequencing and the polymerase stop assay, identifies 
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~720000 potential GQ motifs, which further demonstrates the redundancy issue of GQ 
prediction by the early bioinformatic software (Chambers et al. 2015b).  Indeed, the 
recent updates of the QGRS mapper software allows for more extensive loop analysis of 
up to 36 nucleotides.  This could also explain why the previous study could not predict 
presence of the putative GQ motifs that we present in this work (Tsumagari et al. 2008).  
Another limitation of the GQRS mapper is the fact that it does not account for the 
formation of competing secondary structures other than the GQ motifs. For instance, 
we have found a run of CCC within a central loop of the putative CSS GQ oligonucleotide. 
Although there are reports demonstrating that the secondary structures forming within 
the loops of GQs present within hTERt and c-KIT promoter sequences, the cytosine 
present in the CSS GQ sequences have been found to thermodynamically favour hairpin 
formation rather than a GQ (Palumbo et al. 2009; Phan et al. 2007). The addition of 
berberine to the CSS GQ solution did not influence the topology in favour of GQ 
formation, suggesting that the sequence in fact forms a highly thermodynamically stable 
hairpin structure. This study also demonstrates the importance of the secondary 
structures of loops and flanking sequences that could potential affect formation of the 
GQ structures. The study by Beauodin et al., has demonstrated that GQ structures are 
strongly inhibited by the presence of flanking or loop-related runs of CCC, particularly 
when present within RNA sequences. As a result, the group derived a new scoring 
system taking into account the neighbouring sequences containing C-tracks that can 
form hairpin structures and inhibit GQ formation (Beaudoin et al. 2014).  
Particularly interesting was the fact that both the DUX4 DME1 enhancer and promoter 
show presence of GQs within their sequence. It has been previously suggested that 
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hybrid GQs can be actually formed between enhancer and promoter sequences, where 
each of the cis-elements contributes half of the GQ structure bringing these two 
regulatory elements together (Hegyi, 2015). Since the DUX4 enhancer elements are 
separated a considerable distance of up to 20 kb from the target promoter sequences, 
it can be hypothesised that both of these elements come into proximity by the looping 
out of the intervening DNA sequences between them (Dean 2011). While the looping 
out theory has previously been supported experimentally, it is not clear if the looping 
out process happens first and is followed by binding of transcription factors or vice versa. 
It has been demonstrated that in the immunoglobulin heavy-chain locus, the looping-
out and nuclear migration to the site of transcription occurs first and is then followed by 
transcription (Guo et al. 2011). As it is not clear what are the molecular mechanisms that 
regulate enhancer-promoter interactions to drive DUX4 expression, it would be 
interesting to investigate a potential role GQs in mediating this process.   
Stabilisation and folding pathways for the DNA and RNA sequences into GQ structures 
depend upon among other things, length and composition of the loops as well as 
concentration of stabilising ions present (eg., K+ and/or Na+), and number of G-tetrads 
(Mullen et al. 2012; Pandey et al. 2013). Although we could not achieve a full melting 
curve profiles for the majority of the analysed sequences using CD, the difference in the 
melting transition points was apparent. Therefore, the hypothetical speculation on the 
thermal stability of the analysed secondary structures was made. 
Initial reports investigating the GQ structure stability in the motifs containing loops 
ranging from 1-4 nucleotide in size, have found that the longer the loop size the less 
stable is the GQ structure (Guédin et al. 2010). However, in our analysed DNA GQ-
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forming sequences the shorter loops did not correlate with a higher thermal stability of 
the analysed secondary structures. For example, the human telomeric quadruplex-
forming sequences containing of 3-nucleotide loops shows the main melting transition 
point at ~50°C, whereas the D4P GQ sequences that contains 8-nucleotide loops has a 
melting transition point of ~65°C. In addition, the DME1 GQ with the 9-nucleotide loops 
appears to start melting at ~60°C, indicating higher thermal stability compared to the 
human telomer GQ structure. Indeed, the recent findings looking at the loop length 
stability could not determine an upper limit of GQ loop sizes (Guédin et al. 2010). In their 
study, the analysed GQ structures containing loops of up to 30-nucleotides still show to 
be thermodynamically stable and the size of the loops and Tm trends were found to be 
an independent variable (Guédin et al. 2010). In addition, the C-track present in the D4P 
GQ nucleotide could potential form a C:G stabilised secondary structure, which would 
contribute to the overall stability of the GQ. The hairpin forming, C:G stabilised loops 
have been previously reported in the context of GQ structure found in the promoter of  
the hTERT (Palumbo et al. 2009).  
When comparing the thermal stability of the DNA and RNA GQs, it was found that the 
RNA GQ structures appear to be more stable in general. The melting transition for all of 
the analysed RNA GQs appears to begin at ~70°C, which is a considerably higher 
temperature compared to the DNA counterparts which show melting transition at ~50-
65°C. In addition, the melting profile is more complete at the maximum melting 
temperature (~82°C) for the DNA GQs, when compared to the melting curves of the RNA 
GQs. These findings confirm the previous studies showing that RNA GQs are typically 
more stable than analogous DNA sequences (Zhang et al. 2010). For instance, the ΔG 
and Tm for the RNA GQs composed of 3 G-tetrads and loops of a single nucleotide, in 15 
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mM of cationic solution are 9 kcal/mol and 86°C, respectively, compared to 5 kcal/mol 
and 77°C for the DNA analogue (Lane 2012). It was suggested that the difference in the 
stability seen between the DNA and RNA quadruplexes is dictated by the differences in 
the chemistry of the two nucleic acids, rather than their folding topology (Joachimi, et 
al. 2009; Zhang et al. 2010).  The presence of 2’-OH-group in the RNA sugar plays crucial 
roles in water molecules binding to the groves of the quadruplex structure, formation 
of H-bonds, and conformation of the sugar residue (Zhang et al. 2010). In addition, 
molecular modelling studies demonstrate that the 2’OH-groups provide additional 
intramolecular contacts with different hydrogen bond acceptors, for example, within 
the phosphate and backbone oxygens, 04’ atoms of the ribose as well as the polar 
exocyclic groups of the bases (i.e, the NH2-group), which leads to the increased stability 
of the parallel RNA GQ structures (Collie et al. 2010). 
Although the loop size can play a role in stability of RNA and DNA GQ structures, we 
suggest that the composition of intervening sequences is also an important factor and 
that runs of cytosine residues within the RNA GQ sequence especially influence stability 
of the motif. The size of the largest loop within both DME1 and SS1 GQ oligonucleotides 
consists of 10-nucleotides. However, the DME1 GQ forms a very thermodynamically 
stable GQ structure, whereas the CSS1 GQ appears to form a hairpin conformation as 
shown by the CD and NMR analyses. It seems that the presence of the C-track within the 
loop sequence is a major factor contributing to the inhibition of GQ formation and that 
the relatively long loop did not interfere with the DME1 GQ formation significantly. C-
tracks within the RNA sequences have indeed been shown previously to strongly inhibit 
GQ formation (Beaudoin et al 2014). Interestingly, In the D4P GQ oligonucleotide a run 
of cytosine residues has not interfered with the formation of the GQ structure, indicating 
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that perhaps the RNA-forming GQ sequences are more prone to C-track mediated 
inhibition of quadruplex formation.  
In the absence of the GQ-binding ligand, all of the tested oligonucleotides showed to 
form parallel GQ structures as demonstrated by the CD and NMR analyses, expect for 
the CSS GQ and h. telomere GQ that formed a hairpin and an anti-parallel GQ motif, 
respectively. As expected, both RNA GQ forming sequences (i.e., E1 and SS1 GQ) form a 
parallel GQ topology due to presence of the restrictive 2’OH-group that allows for only 
the anti- conformation in guanosines. The addition of berberine did not influence 
changes in the topology and thermal stability of the RNA GQ and the analysed hairpin 
motif (i.e., CSS GQ). Previous attempts also failed to modulate topology of the parallel 
RNA GQ structures by introducing: small-molecule ligands; changes in loop configuration 
and composition of monovalent ions (K+ and Na+), further confirm that the highly stable 
parallel topology of the RNA GQs is mainly due to the chemical properties of the 
ribonucleotide residues (Collie et al. 2011). On the other hand, the DNA GQ structures 
show much greater flexibility in their topology due to their ability to adapt syn- and anti- 
glycosidic bond conformation, which allows for formation of both parallel and 
antiparallel GQ motifs.   
The flexibility of the DNA GQ motifs was particularly apparent in the context of the D4P 
GQ structure when the berberine was introduced. Using the CD analysis, we have 
demonstrated that berberine can recognise and stabilise the antiparallel D4P GQ 
conformation over the parallel topology. Since the loop sequences are the key elements 
in dictating the preferred GQ topology, it can be suggested that connecting loops of the 
GQ structure play an important role in small-molecule binding. Indeed, it has been 
153 
 
previously demonstrated that the RHPS4 ligand has affinity for lateral and diagonal 
loops, which promotes formation of an antiparallel conformation of the human telomer 
GQ structure (Garner et al. 2009). Although it should be noted that the GQ groove-
specific recognition also have been exploited as a target for drug design, the loop-
mediated targeting of the GQ structures serves as an attractive alternative strategy for 
drug discovery (White et al. 2007).  
In order to study the ligand-GQ binding interaction in terms of affinity and sequence 
specific recognition, it is important to support the high-resolution CD and NMR studies 
with thermodynamic analysis. Especially, since the melting curves from the CD data for 
each of the analysed oligonucleotides in the presence or absence of berberine were 
unable to form and therefore their thermal stability and interaction could not be 
thoroughly analysed. By utilising UV-Vis and fluorescent spectroscopy techniques, we 
could assess the thermodynamic binding profiles of berberine to the secondary 
structures of the selected sequences.  
The UV-Vis absorption titration has demonstrated a clear red shift for all sequences that 
have tested positively for  GQ formation (i.e., DME1, D4P, E1 and SS1 GQs) in CD and 
NMR analysis. Previous studies indicate that this characteristic change in absorbance is  
specific for GQ-ligand end stacking interaction (Arora et al. 2008; Li et al. 2017). In 
addition, the red absorbance shift is also associated with intercalating properties, 
explaining why the titration of the hairpin-forming CSS GQ also shows similar pattern of 
absorbance to the GQ forming sequences. The λmax hypochromicity for these samples 
was in the 20-30% range, which is comparable to that of berberine binding to the human 
telomeric GQ, reported to be ~35% (Arora et al. 2008). The Arora et al., 2008 study has 
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estimated 1:1 berberine to GQ motif binding ratio through the end stacking interactions, 
suggesting that the partial binding mode and stoichiometry of berberine to the GQ-
forming sequences analysed by us is also similar. The 2:1 stoichiometry of ligand (i.e., 
porphyrin) binding to parallel GQ structure had been previously demonstrated to have 
λmax hypochromicity of 56-60% (Wei et al. 2006). Therefore, it can be speculated that the 
hypochromicity of berberine (roughly half that seen for the porphyrin-GQ binding) 
would be indicative of 1:1 binding ratio through end stacking interaction.  The significant 
λmax hypochormicity (~14%) combined with the lack of any red shift as recorded for the 
CT DNA titration, indicates groove binding interaction as it has been previously 
suggested by the work of Li et al., 2017.  
However, the accuracy of the UV-Vis read out could be questioned by the fact the 
absorption curve is not perfectly smooth, indicating potential noise in the recorded 
signal. This could perhaps explain why the E1 GQ, despite showing a clear red shift at 
340 nm, no red shift at 420 nm was produced. One explanation for the poor resolution 
readout could be the fact that the bandwidth of the UV-Vis apparatus (Jenway 7305) 
used in our experiments was set and limited to 5 nm. Other UV-Vis spectrometry devices 
(e.g., UV-2450), where the bandwidth can be reduced to 0.1,  have up to 10 times higher 
resolution (Soares and Costa 1999). Therefore, a UV-Vis spectrophotometer with a 
higher accuracy bandwidth capability, would perhaps allow formation a smoother more 
accurate absorbance readout at lower berberine concentrations giving more reliable 
indication of berberine binding to the titrated GQ structures.  
The gradual increase in the fluorescence emission of berberine upon addition of 
increasing concentrations of GQ, suggests transfer of the ligand from the aqueous to the 
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hydrophobic environment. Therefore, the end stacking on the end terminals of GQs is 
more likely, since the outside berberine stacking would allow continuing quenching of 
the chromophore fluorescence by the solvent. (Bhadra and Kumar 2011a). Indeed, 
molecular modelling studies show that berberine stacks on the G-tetrad terminal end 
human telomeric quadruplex structure (Moraca et al. 2017). 
The relatively high binding affinity of berberine to DME1 GQ (1.9 ± 0.2 x 106 M-1) was 
found to be comparable to the one established for the human telomeric GQ (1.2 ± 0.1 x 
106 M-1), which has also been determined using the fluorescence spectroscopy (Arora 
et al. 2008). However, the berberine binding affinity to the DNA GQ (i., e D4P GQ) and 
RNA GQ (i.e., E1 and SS1 GQ) was ~5 times lower than to the DME1 GQ, suggesting a 
moderate binding but no preference between DNA and RNA GQ binding. Chemical 
modification such as polyether-tethered berberine dimers shows a remarkably high 
binding to GQ structures with Ka values >108 M-1 (Z.-Q. Li et al. 2017). In other studies, 
9-O-N-aryl/arylalkyl amino carbonyl methyl substituted berberine analogues shows 10 
times higher binding affinity towards tRNA sequences that berberine. RNA GQ-specific 
small-molecule high affinity binders such as  tetrandrine, fangchinoline and 
cepharanthine have also been recently established (Cui et al. 2012). This highlights that 
the literature on natural and synthetic small-molecule and their thermodynamic 
interaction with GQ sequences is expanding. Combined with the accumulating high-
resolution GQ-ligand structural data, the prospect of future development of potentially 
highly specific therapeutics to treat a range of diseases (including FSHD) remains 
optimistic. 
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4.  Chapter 4: Role of DUX4 promoter GQ (D4P GQ) 
4.1. Introduction 
 Evidence suggesting presence of GQs within the DUX4 promoter 
The identification of the DUX4 promoter was discovered by chance in the study by Ding 
et al., (1998), where the binding sites of helicase-like transcription factor (HLTF) was 
investigated. Surprisingly, one of the HLTF binding sites had 87% homology with a region 
derived from the D4Z4 repeat region (Ding et al. 1998). Subsequently this led to 
identification of the putative promoter mapped directly upstream of the ORF of DUX4 
gene (Gabriels et al. 1999). Functionality of the putative DUX4 promoter was initially 
doubted since its TATAA box carries sequence mutation (i.e., TACAA). Furthermore, the 
lack of the introns in the gene’s coding sequence and the presence of a canonical polyA 
signal indicated that the DUX4 might be a pseudogene. To assess the activity of the 
promoter, its 191 bp fragment was cloned upstream of the luciferase reporter gene 
(Gabriels et al. 1999). The study showed that the DUX4 promoter is up to 30 times more 
active in human rhabdomyosarcoma TE671 cells compared to non-muscle HeLa cells 
(Gabriels et al. 1999). Further studies on the functionality of the promoter has revealed 
that a 2 bp mutation in the GC box sequence can significantly reduce its activity (Gabriels 
et al 1999). It has been also discovered that the cis-elements of the promoter is 
recognised and bound to by a multiprotein complex composed of YY1, HMGB2 and 
nucleolin, which have been suggested to act as a transcriptional suppressor element 
(Gabellini et al. 2002). YY1 is a trans-factor known to activate or repress transcription 
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depending on the cell type and promoter context (Bauknecht et al. 1996). In 
undifferentiated myoblasts YY1 represses expression of a number of muscle specific 
genes, whereas in differentiated myotubes the transcription factor is subjected to 
proteolytic degradation allowing upregulation of these genes (Walowitz et al. 1998). For 
example, the DMD gene promoter has the YY1 binding site which drives low expression 
of a reporter gene in C2C12 cells, and is increased five times once the cells become 
differentiated (Galvagni et al. 1998). HMGB2 is one of the three members of high 
mobility group (HMG) proteins. These proteins show affinity to DNA as well as other 
proteins and are thought to facilitate multiprotein complexes assembly on DNA (Bianchi 
and Beltrame, 1998). Interestingly, HMGB1 (the most studied protein member) interacts 
with human telomeric GQ DNA (Pagano et al. 2015). Nucleolin is an abundant nuclear 
protein and has been associated with chromatin structure regulation, rRNA maturation, 
rRNA transcription, ribosome assembly and cytoplasmic transport (Ginisty et al. 1999). 
Most importantly, nucleolin was identified by affinity chromatography to bind to the c-
MYC promoter GQ (Gonzalez et al. 2009). Furthermore, nucleolin stabilises the 
promoter quadruplex and subsequently leads to repression of c-MYC expression in vitro 
(Gonzalez et al. 2009). The nucleolin mediated transcription repression is mediated 
through prevention of Sp1 activator protein from binding to its recognition sequence in 
the c-MYC promoter (Gonzalez et al. 2009). Since the above mentioned DUX4 promoter 
associated proteins have also been found to have affinity for the GQ structures, it 
suggests that interaction of these in-trans elements could be regulated by the formation 
of the potential GQ motifs within the promoter sequence.  
The GQ-forming sequences have been predicted, using bioinformatics, to form 
upstream of the functional promoter region of DUX4 on the antisense (non-coding) 
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strand (Tsumagari et al. 2008). However, at the time of the analysis the outdated GQ 
predicting algorithm omitted any potential GQ-forming sequences with loops longer 
than 7-nucleotide in length (Tsumagari et al. 2008)(Discussed in Section 3.3). 
Furthermore, the role of the identified GQ motifs has not been studied. 
  Study of function and targeting of promoter GQs 
The first evidence of GQ formation comes from the study of c-MYC oncogene expression 
(detailed in Section 1.5.1). The study of c-MYC promoter GQ served as a paradigm for 
subsequent research that identified a number of other GQ motifs located within the 
promoters of human oncogenes and the genes expressed in tumour cells , including: 
BCL-2, h-RAS, b-RAF, HIF, c-KIT, VEGF, HSP90, RET (Agrawal et al. 2014; Hsu et al. 2009; 
Kuryavyi, Phan, and Patel 2010; Ohnmacht et al. 2012; Sun et al. n 2011; Sun and Hurley 
2009; Tong et al. 2011; Zidanloo et al. 2016). Examples of non-cancer related genes that 
also had GQ motifs recognised within their promoters, include: HIV-1 genes and tyrosine 
hydroxylase gene that is linked with number of neurological disorders such as 
schizophrenia and Parkinson’s (Amrane et al. 2014; Farhath et al. 2015).  
The canonical approach to study promoter GQs typically involves: a) identification of the 
motifs using a bioinformatics approach; b) CD and NMR analysis of secondary structures 
of oligonucleotide sequences derived from promoter regions containing four 
consecutive G-tracts; c) plasmid reporter construct development that contain G-rich 
promoter regions or their fragments to give a better indication of the motif’s role in gene 
expression in vitro (Balasubramanian et al. 2011; Małgowska et al. 2014; Podbevšek and 
Plavec 2016). Mutagenesis of the GQ-forming sequences was also frequently performed 
to disrupt formation of the motif (Dolinnaya et al. 2016) . Finally, the early proof-of-
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concept experiments demonstrating c-MYC expression downregulation by small-
molecule (e.g, porphyrin) treatment has served as an example of a new potential 
quadruplex-targeted therapeutic strategy (Siddiqui-Jain et al. 2002). Although the 
ligand-mediated, promoter GQ targeting predominately has been shown to lead to 
target gene downregulation, several cases exist where upregulation of gene expression 
was reported. Most notably, the GQ stabilisation in the promoter of relaxin (encoding 
an antifibrotic protein in rat cardiac fibroblasts) with the berberine treatment has led to 
upregulation of the gene (Gu et al. 2012).  
Since DUX4 protein is expressed at extremely low levels and it has a high sequence 
homology with number of other double homeobox transcription factors (eg., DUX4c and 
DUX1) expressed in muscle tissue, targeting it at the protein levels might be extremely 
challenging (Ansseau et al. 2016; Snider et al. 2010). Therefore, targeting the DUX4 at 
the gene level, in principle, serves as an alternative strategy to regulate expression of 
the toxic transcription factor.  
In this work we have already demonstrated presence and formation of novel GQ-
forming sequences within the proximal region of the DUX4 promoter using CD and NMR 
analysis on the sense (coding) strand (Section 3.2.2). In order to better understand the 
potential role of the motif formation in vitro, we have introduced the isolated DUX4 
promoter sequence containing the GQ motif and inserted it upstream of the eGFP 
reporter gene. In addition, the GQ formation was either interrupted by mutagenesis of 
the GQ-forming sequence or stabilised by addition of a small-molecule ligand- (i.e., 
berberine). The effect of the mutagenesis of the GQ-forming oligonucleotide sequences 
was also assessed using CD analysis.
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4.2. Results 
 Design and bioinformatic analysis of the D4P GQ sequence variants 
In order to begin evaluation of the biological role of the D4P GQ, we assessed how the 
substitution of the oligonucleotide G-tetrad sequences would affect the formation of 
the motifs using the bioinformatic and biophysical analysis.  
First, G-A base pair substitutions at 5’ and 3’- ends (M1D4P) or 3’-end only (M2D4P) of 
the GQ forming sequence was introduced (Figure 4.1 A). The QGRS mapper analysis of 
the D4PGQ disrupted sequences shows that the G-A substitutions introduced at each 
end of the oligonucleotide eliminate formation of the putative GQ motif completely as 
the G-score for the M1D4P oligonucleotide was zero. Interestingly, the G-A substitution 
of the G-tract at the 5’ of the M2D4P oligonucleotide did not result in a significant 
disruption of the putative GQ formation as the predicted G-score was 34 (Figure 4.1 A). 
The 3’-end of the M2D4PGQ oligo consists of 6 G run that can serve as two separate G-
tracts providing a platform to rescue formation of the GQ structure. The C-A of the 
hairpin forming C-tract did not show any potential effect on the GQ formation within 
the D4PGQ sequence (Figure 4.1 A). The introduced G-A substitutions introduced in the 
M1-(ΔG=-3.91 kcal/mol) and M2D4P (ΔG=-3.80 kcal/mol) oligonucleotides was shown 
not to have a major influence on the stability of the hairpin formation compared to the 
wild-type sequences (ΔG=-3.32 kcal/mol) as shown by the mFold analysis  (Figure 4.1 C). 
In addition, a mutation variant was created where the C-tract was also disrupted to 
eliminate the potential hairpin formation (M3D4P) (Figure 4.1 A). The C-tract sequence 
disruption by the C-A substitution showed predicted elimination of a strong hairpin 
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formation by the M3D4PGQ sequence (Figure 4.1 C). However, the 2 Cs present at the 
3’ end of the M3D4P oligonucleotide interspaced by the 13 nucleotides could still serve 
as a platform for a weak hairpin formation with ΔG=0.16 kcal/mol (Figure 4.1 C).  
  
 
Figure 4.1 Mutagenesis of DP4 GQ oligonucleotide sequences required for secondary structure 
formation 
(A.) Table listing the analysed sequences. Underlined sequences indicate substituted nucleotides from 
the native D4P sequence. Three altered variants were created: M1D4P, carries G to A substitution of 
the tetrad forming sequences at the 5’ and 3’ of the sequence; M2D4P, has a G to A substitution of 
the tetrad forming sequence at the 3’ end of the oligo; M3D4P, C to G substitutions was introduced 
to disrupt hairpin formation. G-tetrad forming residues highlighted in bold. (B.) Bar chart summarising 
G-Scores of each of the oligonucleotide listed in table A). Oligonucleotides were analysed using QGRS 
Mapper. G-score is a GQ scoring system of the QGRS Mapper. Sequences with higher G-Score (≥30) 
make better GQ candidates. (C.) Mfold analysis of each sequence listed in table A). Free energy (ΔG) 
is indicated for each oligonucleotide. Sequences with lower ΔG have higher chance of forming hairpin 
structures.  
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 CD analysis of D4PGQ and its sequence variants 
The structural analysis of the D4P GQ sequences using CD revealed that it forms a stable 
parallel GQ structure in KP buffer solution containing of 100 mM KCl (Section 3.2.2). Each 
spectrum was recorded at ~20-85°C temperature range to achieve unfolding for each 
oligo. Refolding from ~85-20°C was also recorded for each oligo to assess their potential 
to form alternative secondary structures. This would show how the introduced 
sequence alternation of the oligonucleotide might interfere with the formation of the 
GQ motif.  
In the M1D4P oligo where the G-tracts were substitute with runs of As, a complete 
absence of the parallel GQ absorbance pattern was observed; instead an ellipticity 
maximum at 260 nm and ellipticity minimum at 210 nm was recorded, which is indicative 
of a hairpin conformation (Figure 4.2). As previously shown by the mFold analysis, the 
run of Cs in the middle of the M1D4P oligonucleotide sequence could bond to the 
proximal G residues and promoter hairpin structure formation (Figure 4.1). Therefore, 
the QGRS Mapper and mFold bioinformatic analysis of the M1D4P, demonstrating lack 
of GQ structure and strong hairpin-forming potential, respectively, are strongly 
supported experimentally by the CD data.   
The 5’ end A to G sequence substitution in the M2D4PGQ oligo did not result in a major 
disruption of the native GQ structure as the ellipticity maximum and minimum recorded 
by the CD was at 265 and 240 nm, respectively (Figure 4.2). This indicated that the 
parallel GQ fold could form due to the presence of the run of 6 G residues in the 3’ end 
of the oligonucleotide. Thus, the CD data aligns with the QGRS Mapper analysis of the 
M2D4PGQ predicting formation of the GQ by the oligo sequence. What is more, the 
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absorbance maxima of the M2D4PGQ was marginally reduced, compared with the 
absorption spectrum of the wild-type D4P GQ sequence (Figure 4.2). Interestingly, the 
G-score of QGRS Mapper for the M2D4P sequence was also only marginally lower (i.e., 
by 2 points) compared to the D4P GQ sequence (Figure 4.1 B), suggesting that the 
software can serve as a powerful tool for prediction of GQ formation in vitro.  
During the process of M2D4P denaturation, an additional absorbance minimum started 
to form at 210 nm, suggesting that potential structure transition from quadruplex to 
hairpin was occurring. It is possible that the introduced G to A substitutions reduced the 
thermodynamic stability of the GQ-motif and indirectly promoted formation for the 
hairpin formation upon increasing temperatures.  
The M3D4P oligonucleotide with the intact GQ-forming sequence and C-A substitution 
which disrupts the hairpin structure, had a strong ellipticity maximum and minimum at 
265 nm and 240 nm, indicating a parallel quadruplex formation by the oligonucleotide. 
The absorbance pattern of the M3D4PGQ strongly overlapped with the absorbance of 
the D4PGQ sequence at all measured temperatures, which could suggest that the 
thermal stability of the measured GQ motif was not affected by the introduced sequence 
alterations (Figure 4.2). Lack of negative ellipticity absorbance recorded at 210 nm 
further reinforces the idea that the M3D4P sequence did not form a hairpin structure
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Figure 4.2 Assessment of secondary structures of the D4P and its variant sequences using far-UV CD spectra 
20 μM of each DNA oligonucleotide dissolved in KP buffer with 100 mM KCl, pH 7.0 was analyzed using CD at ~20-85°C temperature range (solid 
lines). The refolding was assessed by reverse temperature ramp at ~85-20°C (dashed lines). The ellipticity maximum at 265 nm indicative of a 
parallel GQ structure formation was recorded for the D4P GQ oligonucleotide. The sequence substitution of G-tetrad forming sequences in the 
M1D4P variant resulted in formation of the 210 ellipticity minimum indicative of a hairpin structure, whereas the M2D4P sequence substitution 
preserved but thermodynamically weakened (dashed lines) the native GQ parallel structure. Disruption of the hairpin forming sequence (i.e., C-
tract) strengthen the thermodynamic stability of the native motif (solid and dashed lines). The number of G-tract in the native were underlined 
and numbered I-V. Abbreviations: M.R.E - molar residue ellipticity 
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The recorded CD absorbance at 265 nm (major absorbance point) for the D4P GQ 
sequence and its variants was expressed as a function of temperature ranging from ~20 
to 85°C (Figure 4.3), in order to assess the effects of the sequence substitutions on the 
stability of the M1-M3D4P oligonucleotides. The full melting curve profiles could not be 
produced due to the limited maximum heating capacity (~85°C) of the equipment. 
Therefore, accurate Tm values indicative of thermal stability could not be produced. 
However, the considerable differences in melting transitions recorded between the 
oligonucleotides, suggest the presence of distinct thermodynamic profiles characteristic 
for each of the analysed sequence.  
The native D4P GQ sequence displayed a main melting transition temperature at ~65°C 
and a double transition point indicating heterogeneous population of secondary 
structures (Figure 4.3). Supported by the bioinformatic analysis and the CD absorbance 
spectra, the proposed secondary structures responsible for the initial melting transition 
could be caused by the existence of hairpin-forming oligonucleotide species present in 
the solution alongside the quadruplex-forming sequences.  
The melting profile of the M1D4P sequence expressed as a straight line, indicates that 
the oligonucleotide forms a hairpin structure derived from a single strand of nucleic acid 
with significantly weaker stability compared to the other analysed GQ-forming 
sequences (Figure 4.3). 
The A-G substitution at the 3’-end of the M2D4P did not prevent the quadruplex motif 
formation as the double melting transition was recorded, indicative of an additional 
hairpin-forming sequences being present. Although the comparable melting profiles 
were produced for D4PGQ and M2D4PGQ sequences, the oligonucleotide carrying the 
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GQ disrupting sequence substitutions has a steeper and earlier descending melting 
curve slope, suggesting a potentially lower Tm value and therefore decreased stability 
compared to the native D4P GQ sequence.  
A to C substitution of the hairpin-forming C-tract sequence in the M3D4P 
oligonucleotide, clearly eliminated a double melting transition pattern that has been 
recorded for the D4P GQ and M2D4P oligos (Figure 4.3). This suggests that only a 
homogenous population of quadruplex structure is present in the analysed solution. 
Furthermore, the more gradual descending melting slope of the M3D4PGQ, indicates 
possibly higher Tm value indicative of higher stability of the secondary structure formed 
by the oligo compared to the D4P GQ and M2D4P sequences.  
 
Figure 4.3 Effects of D4P sequence substitution on the melting profile 
The far-UV spectra from circular dichroism at 265 nm absorbance was expressed as a 
function of temperature ranging from 20 to 85°C. Each DNA oligonucleotide was measured 
at 20 μM in KP buffer, 100 KCl, pH 7.0. Arrows indicate melting transition points. 
Abbreviations: M.R.E - molar residue ellipticity. 
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 NMR analysis of the D4PGQ oligo and its variants 
The CD spectra for the parallel quadruplexes and hairpin structures have a very similar 
pattern of absorption (Kypr et al. 2009). Since quadruplexes have a characteristic NMR 
spectrum that is separate from the resonances formed by other forms of nucleic acids, 
such as single strands, duplexes (e.g., hairpins) and other secondary structures, it can 
serve as a useful tool to assess the secondary structure differences induced by the base 
substitutions introduced to the D4P GQ sequence (Webba da Silva 2007).  
The NMR analysis of the D4P GQ oligo showed a strong resonance signal detection in 
the 10-12 ppm range, indicating formation of the quadruplex structure by the sequence 
(Figure 4.4). However, a weak resonance signal was also detected between the 12-14 
ppm, suggesting presence of a double strand nucleic acid structure existing within the 
solution. Combined with the mFold analysis, this alternative secondary structure formed 
by the D4P GQ sequence was most likely a hairpin motif (Figure 4.1).  
The 5’ and 3’ end G to A substitutions introduced to the M1D4P demonstrated a 
significant reduction in the GQ-specific resonance signal between 10-12 ppm (Figure 
4.4). Interestingly, a weak quadruplex specific resonance remained present, suggesting 
that the oligonucleotide could still perhaps form an intramolecular GQ structure 
composed of two oligonucleotide residues. The hairpin-specific imino proton signal 
appeared to be more pronounced in the M1D4P compared to the native D4P GQ 
sequence (Figure 4.4). Therefore, the dominant secondary structure formed by the 
M1D4P in solution was highly likely to be the hairpin motif.  
The NMR readout for the M2D4P sequence shows only the quadruplex specific 
resonance signal at 10-12 ppm range (Figure 4.4). Lack of the hairpin-specific NMR 
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signal, suggest that the parallel GQ structures were likely to form a heterogenous 
population of inter- and intramolecular quadruplex motifs, rather than a mixture of 
hairpin and quadruplex structures as proposed by the CD analysis (Figure 4.2).  
C-tract substitution with A residues in the M3D4P oligonucleotide eliminated formation 
of the hairpin structure as the NMR readout demonstrated presence of the imino 
pronton signal resonance characteristic for quadruplex secondary structure only (Figure 
4.4). The NMR findings combined with the CD and bioinformatic analysis strongly 
indicate that the M3D4P sequence was highly likely to form a stable parallel GQ 
structure in solution. 
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Figure 4.4 NMR analysis of the effects of D4P GQ sequence substitution on the 
secondary structure of the oligo 
The 1D 1H NMR spectra was acquired at the 9-15 ppm range to detect imino proton 
signal relating to hydrogen bonded bases. The Hoogsten hydrogen bonding 
corresponding to bonded Gs within the G-tetrad are recorded at 10-12 ppm (dashed 
box), whereas the Watson-Crick hydrogen boding within hairpin structure are present 
at >12 ppm (solid box). The DNA oligonucleotide samples were measured in 20 μM in KP 
buffer, 100 mM, pH 7.0 at 298 K 
 
 
171 
 
 In vitro function assessment of the DUX4 promoter fragment containing the 
D4PGQ sequence in the reporter plasmid system 
4.2.4.1. Sequence analysis of the DUX4 promoter fragment and 5’UTR 
Plasmid constructs with inserted G-rich promoter regions or their fragments upstream 
of a reporter gene, have been previously found to be a useful tool in assessing the in 
vivo role of the motifs on gene expression (Sun and Hurley 2009). The DNA GQ structure 
can be formed by either the sense or antisense strand of the promoter sequence, while 
the 5’UTR can only be formed in the mRNA coded by the positive strand (Agarwal et al. 
2014). Previously, the GQ-forming sequence was predicted to form ~400-500 bp 
upstream of DUX4 start codon on the antisense strand (Hewitt et al. 1994; Tsumagari et 
al. 2008). However, since the previously used algorithms to predict GQ-sequences within 
the DUX4 gene would discriminate any potential candidates with loops larger than 7 
nucleotides (Tsumagari et al. 2008), we asked the question whether the updated 
software (i.e., QGRS Mapper) would predict any GQs forming closer to the 
transcriptional start site (TSS) or within the 5’UTR of the DUX4. Therefore, we have 
analysed the 235 bp promoter region (including the 97 bp DUX4 5’UTR region) upstream 
of the DUX4 start codon (Figure 4.5). The closest GQ forming sequence predicted by the 
QGRS Mapper was located on the sense strand, upstream of the previously determined 
functional DUX4 TACAA (equivalent to TATTA box) and GC box as well as the 5’UTR 
sequence (Figure 4.5) (Gabriels et al. 1999; Dixit et al. 2007). No GQ motifs were 
predicted on the antisense strand of the DUX4 promoter fragment or the 5’UTR (Figure 
4.5). 
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Figure 4.5 Schematic primary structure and sequence of DUX4 promoter and 5’UTR 
(A.) Schematic of the DUX4 promoter and position of its key elements. 5’UTR and the 
transcriptional start site (TSS; -1;+1 position) are indicated. Nucleotide positions of each 
element are numbered relative to the TSS. (B.) The DNA primary sequence of DUX4 
promoter and 5’UTR. The most proximal GQ-forming sequence (D4P GQ; red font) to 
the TSS on the sense strand is shown. No quadruplex-forming sequences on the 
antisense strand of the analyzed sequence could be predicted. The key promoter 
elements such as GC and TACAA box are highlighted in green and purple, respectively. 
The 5’UTR sequence is underlined. Putative G-tracts of the D4P GQ sequence are 
numbered I-V. ATG denotes start codon. Nucleotide positions of each element are 
numbered relative to the TSS (-1;+1). 
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4.2.4.2. Development of expression plasmid constructs containing the 5’UTR and the DUX4 
promoter fragment containing D4PGQ sequence 
We have observed the presence of the GQ forming sequence in DUX4 promoter 
fragment but not in the 5’UTR region (Figure 4.5). In addition, the promoter GQ-forming 
oligonucleotide sequence (D4P GQ) was confirmed to form the GQ motif in solution as 
shown by the CD and NMR analysis (section 4.2.2 and 4.2.3). The substitutions in the 
D4P GQ sequence were purposely introduced to prevent or weaken the GQ formation 
(M1-M2D4P) (section 4.2.2 and 4.2.3). In another D4P GQ oligonucleotide variant (i.e., 
M3D4P), the hairpin-forming sequence substitution was preformed to assess the 
influence of other secondary structure formation within the GQ forming region.  
Once we have observed and confirmed the presence of GQ structure formation in the 
D4P GQ sequence and its variants (M1-M3D4PGQ), we then asked whether these 
structures or their lack may affect the expression of DUX4. To address this question, the 
wild-type, D4PGQ-containing 235 bp promoter fragment that also includes the 5’UTR of 
DUX4 were designed and then synthesised by GenScript (Figure 4.5). The promoter 
sequence variants (M1-3D4PGQ) containing mutations to the promoter GQ forming 
sequence (as outlined in figure 4.1 A) were also synthesised. An additional mutation 
construct (MGCbox) of the DUX4 promoter sequence was designed where the GC box 
sequence mutation was introduced (GGGGTGG to GGAATGG), since it has been 
previously shown to strongly affect the DUX4 promoter activity (Gabriels et al. 1999).  
The DUX4 promoter fragment constructs were directionally cloned from the commercial 
plasmids (pUC57, GenScript) directly upstream of the eGFP-containing plasmid (Figure 
4.6 A). The resulting plasmid constructs were subjected to restriction enzyme diagnostic 
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digest reaction to determine: (i) DUX4 promoter sequence presence using the SpeI-HF 
and NheI-HF restriction enzymes; (ii) correct orientation of the cloned fragment using 
AlwNI and NheI-HF enzymes; and (iii) presence of the eGFP reporter sequence by 
performing the XhoI digest (Figure 4.6 B). All of the plasmid constructs tested positive 
for presence and correct orientation of the inserted DUX4 promoter plasmid construct 
and eGFP in the restriction enzyme diagnostic digest analysis (Figure 4.6 B). 
Subsequently, each of the cloned DUX4 promoter fragments were sequenced to confirm 
whether the cloned inserts are present at the correct orientation within the plasmid and 
to ensure that the mutagenesis of the D4PGQ and GC box sequences has been carried 
out correctly. The sequencing results confirm the results of the diagnostic restriction 
digest reaction and show that the specific mutation of the D4PGQ and GC box sequences 
are present within their corresponding plasmid backbones (Figure 4.6 A)
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Figure 4.6 Mutagenesis of G-quadruplex sequence within DUX4 promoter driving eGFP expression construct 
(A.) Schematic plasmid map demonstrating restrictive enzyme sites used for cloning and diagnostic digest of the DUX4 promoter sequence 
upstream of the eGFP. Sizes of the digested products are indicated in base pairs (bp) (B.) Restriction enzyme digest of the 
p.C1.DUX4_promoter.eGFP plasmid. All samples were run on 1% agarose gel (w/v) in TAE, stained in with 10,000x SYBRSafe (Invitrogen). (C.) 
Partial DNA sequencing graph showing successful mutations of the GQ sequence within the DUX4 promoter (M1-M3D4PGQ). MGCbox represents 
mutation within the GC box sequence of DUX4 promoter. Native DUX4 promoter sequence corresponds to D4PGQ. Dashed box highlights the G 
to A substitutions. Abbreviations: H1, Hyperladder I (Bioline); D4PGQ, DUX4 promoter G-quadruplex; M1-3D4PGQ, mutation1-3 of D4PGQ; 
MGCbox, mutation of GC box. 
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4.2.4.3. Optimisation of DNA amount for optimal transfection for the DUX4 promoter fragment-
containing reporter plasmid in RD CCL-136 cells 
After developing reporter plasmids containing DUX4 promoter fragment and its 
variants, it was important to derive optimal DNA plasmid amounts for transient 
transfection conditions using Lipofectamine 3000 (Invitrogen) reagent to assess the 
activity of the promoter in vitro. The human rhabdomyosarcoma (RD) CCL-136 cell have 
been used for the transection experiments as it has been demonstrated that the DUX4 
promoter is activated at significantly higher rates in these cells (i.e., 10-30 fold increase) 
compared to non-muscle tissue such as HeLa cells (Gabriels et al. 1999). In the transient 
transfection reaction, the plasmid containing wild-type DUX4 promoter was used over a 
range of concentrations from 0.5 to 2.5 μg (Figure 4.7). 24 hours after transfection, cells 
were harvested for flow cytometry analysis. The eGFP protein expression detected by 
the flow cytometry has shown to be present at the highest levels in cells transfected 
with the 1 μg of the plasmid (Figure 4.7). Since the maximum transfection efficiency at 
1 μg of the transfected plasmid could only achieve 37% (± 1%) of cells positive for the 
GFP protein expression, it can be suggested that the DUX4 promoter activity in muscle 
tissue is relatively weak under the tested conditions (Figure 4.7). Other amounts of 
plasmid than the 1 μg resulted in significantly lower transfection efficiency (Figure 4.7). 
Therefore, the transfection conditions utilising 1 μg of plasmid were used in all of the 
subsequent transient transfection experiments involving DUX4 promoter plasmid and 
its variants. Since the concentration of the Lipofectamine regent was kept constant 
during the experiment, the decreasing transfection efficiency could be attributed to the 
increasing plasmid concentration. Apart from the GFP protein, the transfected plasmid 
also encodes ampicillin resistance gene driven by a strong CMV promoter. Therefore, 
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other than the GFP protein, the cells are very likely to express large amounts of other 
proteins. This alone could be inducing a protein unfolded response leading to 
endoplasmic reticulum stress-induced cell death (Egger et al. 2007) and/or depletion of 
the histidine pool (essential amino acid that is limiting in tissue culture)(Salazar et al. 
2016).  
 
 
Figure 4.7 Transcriptional activity of the DUX4 promoter 
Increasing amounts of GFP expressing plasmid, driven by DUX4 promoter was 
transfected into RD CCL-136 cells using Lipofectamine 3000 (Invitrogen). (A.) Flow 
cytometry plots showing count of GFP-expressing RD CCL-136 cells. Background 
fluorescence was set using mock samples and was below 1%. The transient GFP activity 
was measured in harvested cells 24 hours after transfection with flow cytometry using 
FITC-A channel. (B.) Statistical analysis of the flow cytometry data comparing effects of 
varying plasmid concentrations on GFP expression in RD CCL-136 cells. A one-way Anova 
test was performed (*p<0.05; **p<0.01 ***p<0.001); N=3
%
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4.2.4.4. D4PGQ motif present in DUX4 promoter weakly modulates the expression of a reporter 
gene 
Next, the presence of the sequences responsible for the formation of secondary 
structures (e.g., GQ or hairpin) within the DUX4 promoter was assessed for their role in 
the regulation of the reporter gene expression. Five of the generated reporter plasmids, 
including: the wild-type promoter fragments sequence containing the GQ motif (i.e 
,D4PGQ); mutated variants of the GQ-forming sequence (M1-M2D4PGQ) and hairpin-
forming sequence (M3D4PGQ); as well as the GC box mutated sequence of the DUX4 
promoter, were transiently transfected into the RD CCL-136 cells  
The reporter gene expression driven by the wild-type DUX4 promoter, transfected into 
the RD CCL 136 cells using the optimised transfection conditions, resulted in 36% (± 2%) 
of the cells positively expressing GFP protein as recorded by the flow cytometry (Figure 
4.8 B). The plasmid construct containing the M1D4PGQ sequences mutation that 
significantly disrupts formation of the GQ motif as shown by the CD and NMR analysis, 
demonstrated a statistically significant decrease (p<0.0001; 31% (±2%) GFP positive 
cells) in the reporter gene expression compared to the wild-type construct (Figure 4.8 
B). Although the M2D4PGQ plasmid carries the sequence mutations that perhaps 
weaken thermodynamic stability but not completely abolishes the GQ formation within 
the DUX4 promoter, there is a still statistically significant reduction (p<0.001) in the 
number of cells positively expressing the GFP (i.e. 33±2%), compared to the D4P GQ-
containing promoter construct. Interestingly, the statistical significance of the GFP 
expression was found to be lower for the M1D4PGQ construct, compared to the 
M2D4PGQ plasmid variant, suggesting that the severity of the GQ disruption potentially 
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correlates with the activity of the promoter (Figure 4.8 B). Mutation of the hairpin 
forming sequence in M3D4PGQ construct variant did not result in any significant change 
of the DUX4 promoter activity compared to the wild-type plasmid and indicates that it 
does not play a major role in regulating expression of the reporter gene (Figure 4.8 B). 
The plasmid construct carrying the mutation of the GC box sequences, downstream of 
the GQ forming region within the DUX4 promoter fragment, led to a dramatic reduction 
in GFP expression of 30-fold compared to the wild-type plasmid construct (Figure 4.8 B).  
The microscopic analysis of the GFP expression of each plasmid construct also confirms 
the weak activity of the wild-type expression construct demonstrated by the dim 
fluorescence of the protein in the transfected cells (Figure 4.8 A). The qualitative 
difference of the reporter gene expression between the D4P GQ and the M1-M3D4PGQ 
are virtually indistinguishable (Figure 4.8 A). Furthermore, the activity of the DUX4 
promoter shows to be almost completely deactivated by the mutation introduced to its 
GC box sequence as no GFP expression could be detected microscopically in the cells 
transfected with the MGCbox construct (Figure 4.8 A).
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Figure 4.8 Effect of sequence mutagenesis of DUX4 promoter in-cis elements of gene expression 
RD CCL 136 cells were transfected with the eGPF-containing plasmids driven by the native DUX4 promoter sequence and its variants containing 
GQ sequence mutations (M1-M3D4PGQ). The construct containing mutation within the GC box of the DUX4 prompter was also analyzed 
(MGCbox). Lipofectamine 3000 (Invitrogen) was used to transfect 1 µg of each plasmid. Mock sample contains non-transfected cells. (A.) 
Expression of GFP was photographed using FITC channel. Scale bar: 100 μm. (B.) Flow cytometry measuring number of GFP positive cells 
expressed as a percentage of the total cell count. The FITC-A channel was used for the GFP positive cell detection. Background fluorescence was 
set using mock samples and was below 1%. A one-way Anova test was performed (*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001;); N=6. 
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4.2.4.5. Effects of berberine on DUX4 promoter activity 
We have previously observed a strong affinity binding and stabilising effect of berberine 
on the GQ-forming D4P GQ oligonucleotide sequence in solution (section 3.2.4). 
Assuming that berberine also binds to the D4P GQ sequence in the DUX4 promoter 
fragment in vitro, we asked the question how the small-ligand binding to the DUX4 
promoter GQ structure would affect gene expression. When the D4P GQ expression 
construct was transiently transfected and the cells were treated with berberine, there 
was a dramatic dose-dependent increase in the green fluorescence recorded by flow 
cytometry (Figure 4.9). However, when the ligand was added to the cells in the absence 
of the eGFP expressing plasmid, there was a significant fluorescent emission detected 
by the FITC-A channel of the flow cytometry (Figure 4.9). At the highest ligand 
concentration, the recorded emission was comparable to the emission from the group 
cells that were treated with the same ligand-concentration in the presence of the 
reporter plasmid (Figure 4.9). This indicates that the GFP and berberine have a very 
similar excitation and emission spectra. Therefore, the signal produced by the ligand 
interferes with the GFP readout produced by the reporter system. As a result, it is very 
difficult to draw any conclusions regarding the effects of berberine treatment on the 
activity of the DUX4 promoter fragment using this reporter system.  
The microscopy images confirm the flow cytometry data as there is a clear green 
fluorescence increase, especially at higher berberine concentrations (e.g., 50 and 100 
μM), in groups of cells untransfected with the reporter plasmid (Figure 4.9). Although 
the cells transfected with the reporter plasmid do show a clear increase in the green 
fluorescence emission between the 5 and 20 μM berberine concentration range  
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compared to the cells treated with the same concentrations of the ligand in the absence 
of the plasmid, it is difficult to conclude whether the increase in the recorded emission 
is a result of the ligand-mediated upregulation of the DUX4 promoter activity or the 
combined emission of berberine and GFP has caused the qualitative increase in the 
recorded fluorescent intensity (Figure 4.10). 
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Figure 4.9 Analysis of DUX4 promoter driven eGFP expression in presence of berberine 
RD CCL 136 cells were transfected with the eGPF plasmids driven by the native DUX4 
promoter sequence (D4PGQ) in presence of increasing concentrations of berberine. 
Lipofectamine 3000 (Invitrogen) was used to transfect 1 µg of the plasmid. Mock sample 
contains non-transfected cells. Flow cytometry measuring number of eGFP positive cells 
expressed as a percentage of the total cell count. The FITC-A channel was used for the eGFP 
positive cell detection. Cells treated with berberine only were used to detect background 
noise. Background fluorescence produced by the cells was set using mock samples and was 
below 1%. A one-way Anova test was performed (*p<0.05; **p<0.01 ****p<0.0001;); N=3. 
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Figure 4.10 Analysis of eGFP expression driven by the DUX4 promoter sequence in presence of berberine 
RD CCL 136 cells were transfected with the eGPF-containing plasmids driven by the native DUX4 promoter sequence (D4PGQ) in presence of increasing 
concentrations (0-100 μM) of berberine. Lipofectamine 3000 (Invitrogen) was used to transfect 1 µg of the plasmid. Non-transfected cells treated with 
berberine were used to established background fluorescent. Expression of eGFP was photographed using FITC channel. Scale bar: 100 μm. 
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4.3. Discussion  
In this chapter, the biophysical (i.e., CD and NMR) and bioinformatic analysis in 
combination with in vitro transient transcription assay were used to explore the 
potential role of GQ structure in the DUX4 promoter. The novel GQ-forming sequence 
was predicted to form closely upstream of the TSS on the sense strand of the promoter 
sequence. Different variants of GQ-related sequence substitutions were preformed, and 
each was assessed for its ability to form the motif before it was cloned into the reporter 
plasmid. The CD and NMR of the analysed GQ-forming sequence showed to have more 
than four G-tracts (i.e.,                  ) contributing to the 
formation of more than one discrete quadruplexes depending on what combination of 
G-tracts was used. The analysed D4P GQ oligonucleotide was revealed to have 
potentially five G-tracts that could contribute to the GQ formation, since when the 5’ 
end was G-A substituted, the motif structure was still able to form as shown by the 
bioinformatic and the biophysical analysis. Therefore, various GQ conformations are 
formed by the D4P GQ sequence that could potentially exist in dynamic equilibrium with 
each other.  
This idea was previously explored in the context of the P1 promoter region of the Bcl-2 
gene, where a 39 nucleotide G-rich sequence (i.e., Pu39), containing six G-tracts of 3-5 
guanosine residues was analysed for the GQ formation as well as the effect of loops and 
flanking regions on the thermodynamic stability of the motif folding (Sun et al. 2014). A 
range of oligonucleotides with overlapping sequences that contain four G-tracts were 
selected for the analysis (Sun et al. 2014). Interestingly, it has been shown that the 
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individual short GQ-forming sequences derived from the Pu39 sequence form 
heterogeneous GQ structures. In addition, the GQ topology of the investigated 
sequences would have a mixed structure, rather than a parallel conformation , 
commonly found in promoter sequences (Dolinnaya et al. 2016). However, when the full 
39 nucleotide Pu39 sequence was analysed, the dominant structure found in vitro in the 
folded sequence was a parallel quadruplex with two single and one 13 nucleotide loops. 
Interestingly, the long nucleotide sequence was the most thermodynamically stable 
compared to its oligonucleotide variants (Sun et al. 2014). 
In addition, the ability to form a variety of GQ topologies by the same sequence regions 
could be instrumental in regulating gene expression by fine-tuning binding affinity to the 
different quadruplex structures by in-transacting factors. The Bcl-2 promoter region, 
contains another 28- nucleotide GQ-forming region, that can form two parallel GQ 
motifs under physiological conditions and exist in an equilibrium state with each other. 
Both motifs form protruding loops that assume hairpin conformation and can be 
selectively recognised by small molecules (Onel et al. 2016). Similarly, our findings 
suggest the D4P GQ structure that has the potential to form both a parallel GQ and 
hairpin structure, providing a unique conformation that distinguishes it from other 
promoter-based parallel GQ structures and could potentially provide a platform for 
recognition by specific proteins or small molecules. These unique structural 
characteristics of the D4P GQ sequence combined with the findings that its topology can 
be changed by small-molecule binding interaction (i.e., berberine), suggests an 
unexplored platform for development of novel, highly specific compounds that can 
effectively target and regulate nucleic acid secondary structure formation.  
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In addition to the idea that D4P GQ sequence can form single GQ confirmation and/or 
multiple GQ structure formed by overlapping motifs, it can be speculated that other 
models of DUX4 promoter GQ structures can exist. For example, it has been previously 
found that upstream of the DUX4 promoter region (i.e., in hhspm3 region) there is a GQ 
forming sequence (Tsumagari et al. 2008), suggesting that multiple (or at least two) GQ 
structures can be formed within the promoter region separated by a long nucleotide 
stretch. There is a well-documented example of two GQ structures forming within the 
promoter of the c-KIT gene separated by over 30-nucleotide long sequence (Hsu et al. 
2009). Although the structure topology for both of these structure have been well 
characterised and have been found to be an overall parallel structure, the exact 
combined role of these two motifs is not well understood (Hsu et al. 2009). It is therefore 
important to analyse a larger upstream portion of the DUX4 gene in the D4Z4 satellite 
region, to assess the presence of other potential GQ sequences that could play a role in 
the DUX4 promoter regulation. 
Although the understanding of DUX4 promoter interaction with regulatory proteins is 
not yet clear, there is an accumulating number of studies shedding light on the role of 
in-trans acting elements in regulating the DUX4 expression (Dixit et al. 2007; Himeda et 
al. 2014; Sharma et al. 2016). A number of well know transcription factors that regulate 
gene expression have been found to specifically bind to quadruplex structures (Brázda 
et al. 2014). One prominent example of promoter GQ binding protein is poly [ADP-
ribose] polymerase 1 (PARP1). PARP1 is an zinc-finger protein, abundantly found in 
nucleosomes and has been implicated in DNA damage repair, chromatin remodelling 
and gene expression (Benjamin and Gill 1980; Soldatenkov et al. 2002). Interestingly, it 
has been found to bind DUX4 promoter fragment and strongly activate its activity 
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leading to increased DUX4 expression in FSHD myoblasts (Sharma et al. 2016). In 
addition the same report have found that the PARP1 regulates the DUX4 promoter 
function in conjunction with a catalysing enzyme, the DNA methyltransferase 1 
(DNMT1)(Sharma et al. 2016). Both PARP1 and DNMT1 are known for their affinity for 
GQ binding (Cogoi et al. 2010; Cree et al. 2016). For example, the PARP1 has also been 
found to be an activator of the KRAS promoter that recognises parallel quadruplex DNA 
(Cogoi et al. 2010). Furthermore, the PARP-1 becomes catalytically activated upon 
binding to GQ derived from the c-KIT promoter and binds the motif with high affinity. 
Interestingly, in a separate report, the DNMT1 has also been found to play a vital role in 
genome methylation and co-localised at the sites of DNA damage (Cree Simone L. et al. 
2016). The DNMT1 also shows strong binding affinity to GQ structures in gene promoters 
in vitro, but becomes catalytically inhibited by the RNA GQs that specifically targets the 
enzyme’s active site (Cree et al. 2016; Zhang et al. 2015). 
Nucleolin is another nuclear protein found to play multiple cellular roles, including: 
ribosome biogenesis, chromatin remodelling and apoptosis (Angelov et al. 2006; Ginisty 
et al. 1999; He et al. 1998). Overexpression of nucleolin was also correlated with c-MYC 
promoter inhibition as measured by the luciferase expression construct assays in 
MCF10A cells (Cogoi et al. 2010). It has been demonstrated that the nucleolin also binds 
to the c-MYC GQ motif with high affinity and its binding to the quadruplex structure was 
also confirmed in vivo (Cogoi et al. 2010). In addition, the nucleolin protein has been 
found to bind the D4Z4 repeat unit as a multiprotein complex and mediate repression 
of the genes expresses proximal to the D4Z4 (Gabellini et al. 2002). However, the role of 
nucleolin on DUX4 expression is not clear as the mechanisms describing binding to the 
promoter of the toxic gene have not been investigated yet. 
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MyoD is a master regulator transcription factor that plays a key role in differentiation 
process of myoblast cells (Ishibashi et al. 2005). MyoD transcriptional activity is 
promoted by the formation of a heterodimer with E-proteins that recruits the complex 
to E-box motifs present in promoter sequences that regulate muscle gene expression 
(Wendt, Thomas, and Ellenberger 1998). Interestingly, the MyoD shows a high affinity 
binding to promoter GQ structures, which leads to significant gene expression 
upregulation compared to the gene expression driven by the promoter that lacks GQ-
forming sequences (Shklover et al. 2010). It has been suggested by the author that the 
GQ helps to recruit the MyoD transcription factor to the site of the promoter (near the 
E-box sequence) without activating transcription (Figure 4.11). Subsequent heterodimer 
formation between the MyoD and E-proteins, weakens the MyoD association with the 
quadruplex structure which then able to bind to the neighbouring E-boxes to activate 
the gene expression (Figure 4.11) (Shklover et al. 2010). Interestingly, the DUX4 
promoter fragment does contain the E-box motif and MyoD has been found to bind the 
promoter sequence (Dixit et al. 2007). Since the D4P GQ sequence is present closely 
upstream of the E-box of the DUX4 promoter, it could be speculated that MyoD may 
potentially also be recruited to the promoter sequence aided by the presence of the GQ 
structure. This is supported by the fact that the mutation of the GQ-forming sequence 
downregulates expression of the reporter gene, but does not completely eliminates it, 
indicating that the MyoD can still perform its role once it forms a heterodimer with the 
E-proteins and is recruited to the E-box. Conversely, the presence of the GQ structure in 
the DUX4 promoter sequence increases gene expression levels as MyoD is more 
effectively recruited to the promoter target region. Whether MyoD has a strong binding 
affinity to DUX4 promoter GQ structures is still to be established.  
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Figure 4.11 Hypothetical model of transcriptional enhancement by promoter 
quadruplex structure 
MyoD myogenic transcription factor show high binding affinity towards promoter GQs. 
The MyoD GQ-mediated binding near E-box sequence promotes dimerization between 
MyoD and E-proteins that together activate transcription upon binding to the promoter 
sequence. Since MyoD and E-box binding sites have been previously mapped in DUX4 
promoter sequences (Dixit et al. 2007), the presence of the GQ within the promoter of 
the toxic transcription factor could have an enhancing effect on gene expression. 
Red circles represent MyoD, yellow triangles represent E-protein.  
 
 
Mutation of the non-canonical GC box sequence (GGGGTG -> GGAATG) in the promoter 
of DUX4 has resulted in a potent inhibition of the reporter gene expression, confirming 
the importance of this in-cis element on gene expression (Gabriels et al. 1999). The 
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consensus GC box motif (GGGGCG) typically serves as double-stranded binding site for 
the SP1 transcription factor. Since the DUX4 promoter lacks the minimal canonical GC 
box sequence, it was not clear how the SP1 can effectively bind to the in-cis acting 
element. Interestingly, the evidence from the genome-wide SP1 ChIP analysis showed 
that around 36% of the SP1 binding sites lack the consensus GC box sequences (Raiber 
et al. 2012). Furthermore, the majority of the SP1 binding fragments were predicted to 
form putative GQ structures. The SP1 strong binding affinity to GQ motifs was confirmed 
in the promoter sequence of the c-KIT gene (Raiber et al. 2012). Collectively these 
findings show that the SP1 transcription factor can interact with promoter sequences 
through interaction with the double-stranded GC box consensus sequence and/or 
through interaction with the GQ-forming sequences within the target promoter. 
However, in the context of the DUX4 promoter, it is not clear how the potential GQ could 
form the non-canonical GC box sequence, since the G-tract of the in-cis element would 
be separated from the nearest GQ-forming sequences by a relatively long loop of 13 
nucleotides. Nevertheless, stable GQ-structure with loops longer than 13 nucleotide 
have been reported, for example in the Bcl-2 gene (Sun et al. 2014). Therefore, it would 
be an interesting prospect to determine whether the DUX4 promoter GC box sequence 
could contribute to GQ motif formation and contribute to regulation of the promoter’s 
activity by recruitment of SP1.  
Structural motifs can form in either the sense (i.e., coding) or antisense (i.e., template) 
strands of the double stranded DNA. A striking asymmetric difference of putative GQ 
structure distribution between sense/antisense DNA strands have been reported across 
the human genome in the proximity (± 500b) of the TSS (Du et al. 2008). Additionally, 
GQ motifs have been more often found in the sense strand than the antisense strand 
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(Du et al. 2008). Indeed, in the DUX4 promoter fragment only one GQ motif was 
predicted closely upstream of the TSS in the sense strand. Disruption of the GQ motif by 
the sequence mutagenesis resulted in modest downregulation of gene, suggest that the 
presence of the GQ in the sense strand of the DUX4 promoter may act as an activator in 
gene expression. This model was supported by the fact that RNA polymerase II (RNAP II) 
occupancy (an important factor directly associated with gene expression) highly 
correlates with the putative GQ-forming regions proximal to the TSS found in the sense 
strand (Du et al. 2008). In the proposed model, the presence of GQ in the sense strands 
promotes opening of double-stranded DNA structure, making RNAP II binding more 
accessible and subsequently resulting in higher rates of transcription (Figure 4.12). 
Furthermore, lack of the GQ motifs in the antisense strands eliminates a barrier that 
would potentially have an inhibitory effect on RNAP II progression during mRNA 
synthesis (Figure 4.12)(Du et al. 2008). Indeed, the inhibitory effect of GQ formation in 
the antisense strand, particularly downstream of TSS, has been demonstrated 
experimentally (Agarwal et al. 2014). This collective data further strengthens the idea 
that the presence of GQ structures in promoter regions could play an important role in 
fine tuning gene regulation.  
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Figure 4.12 Role of G-quadruplex strand asymmetry on transcription 
Quadruplex structure formed on the sense strand promotes transcription by holding the 
DNA helix in an open conformation, making RNAP II more accessible. GQ forming on the 
antisense strand creates a physical barrier for RNAP II progression leading to 
transcription inhibition. 
 
 
It is also important to note that while the GQ motif is formed on one strand, on the 
complementary C-rich strand, an i-motif may form (Kuryavyi et al. 2010). Although there 
is a strong evidence that C-rich sequences can form i-motifs, their in vivo role is still a 
matter of an ongoing scientific debate (Zeraati et al. 2018). The fact that folding of i-
motifs requires acidic conditions, resulted in major doubts of the in vivo role of the 
secondary motif (Jin et al. 2009). However, a recent discovery of antibody fragments 
that bind the i-motifs with high affinity and selectivity enabled visualisation of the motifs 
formation in nuclei of human cells (Zeraati et al. 2018). Furthermore, the small-molecule 
specific targeting of the i-motif in the upstream region of the Bcl-2 promoter, has 
resulted in significant gene expression upregulation, supporting the argument that these 
secondary structures could play a major role in the regulation of expression(Cui et al. 
2014). The Bcl-2 example also supports our model where the mutagenesis of the GQ 
sequence in the DUX4 promoter would also eliminate the C-rich sequence that could 
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potentially form an i-motif, subsequently leading to downregulation of the reporter 
gene expression. Although the idea of a potential i-motif regulating DUX4 expression is 
highly hypothetical at this stage, it is an undoubtedly and interesting prospect for the 
future studies.  
Although mutagenesis of GQ-forming promoter sequences was commonly applied as a 
tool to disrupt the motif’s secondary structure formation in order to study its function, 
its obvious limitation is that the primary sequence of the promoter becomes changed. 
Therefore, it is not always clear if the changes of the reporter gene expression are 
predominately related to changes to the secondary structure of the primary sequence 
of the promoter. For this reason the studies of promoter GQ are often complimented by 
the use of small-molecules that can target and stabilise GQ structures with relatively 
high specificity and affinity. Unfortunately, the small-molecule berberine used in this 
study has demonstrated to have an overlapping excitation and emission spectra with 
the GFP readout. This introduced a significant background signal noise that made it 
virtually impossible to measure the GQ-stabilising effects of berberine on the reporter 
gene expression. Since we are interested in investigating the role of berberine effects 
on DUX4 expression, changing the reporter system to luciferasefor example, would 
eliminate the issues of background signal noise interference with the protein readout. 
Alternatively, the DUX4 expression could be also assessed on the mRNA level using RT-
qPCR. Despite the above limitations, the finding of the novel GQ structure within the 
DUX4 promoter provides a new platform for a scientific debate about its potential role 
in gene expression regulation that contributes to the field of FSHD and GQ biology.
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5. Effects of berberine on DUX4 expression 
5.1. Introduction 
 Emerging roles of RNA GQs in health and disease 
In addition to the finding that the putative DNA GQ structures are highly prevalent in 
the human genome regions such as telomeres, gene promoter recombination hotspots 
and ribosomal DNA, the bioinformatic analysis also have found GQ enrichment in 5’end 
of the 1st introns as well as the 5’ and 3’ UTRs of pre-mRNAs, suggesting an important 
role of these motifs in mRNA synthesis, processing and function (Huppert and 
Balasubramanian 2005). This bioinformatic data is further supported by the in vitro 
experiments showing that the RNA GQs could play an important role in cellular functions 
(Agarwala et al. 2015; Simone et al. 2015), including: gene expression regulation and 
telomere homeostasis. The mRNA-associated GQs are now becoming widely recognised 
as a crucial in cis-acting elements regulating processing of pre-mRNA (e.g., 
polyadenylation and splicing), mRNA targeting and turnover as well as translation. The 
genome wide sequencing provided further evidence of GQ overrepresentation in 5’UTR 
and introns of mRNA sequences, implying important regulatory functions (Chambers et 
al. 2015b). GQs also have been linked to pre-microRNA and long non-coding RNA 
sequences, suggesting a novel role of GQ in miRNA biogenesis and in-trans post-
transcription gene expression regulation, respectively (Jayaraj et al. 2012; Arachchilage 
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et al. 2015). Interestingly, RNA GQs have been implied in immunoglobulin class switch 
regulation, indicating that the motif plays a role in the humeral immune system  pathway 
(Zheng et al. 2015).  
One of the major mechanism through which the RNA GQs mediate their function in cells, 
involves binding of protein factors such as RNA-binding proteins (RBP) that regulate 
topology of the secondary structure and/or recruit other protein regulators (review 
Brázda et al. 2014). It has been demonstrated in vivo that the predominant role of the 
RBPs is unfolding of the eukaryotic RNA GQs. Furthermore, the RNA GQ associated RBPs 
were also implicated in the DNA-related processes such as recombination (e.g., 
immunoglobulin class switch) or elongation of telomeres (Guo and Bartel 2016; 
Takahama et al. 2013; Zheng et al. 2015). RNA and DNA complementary sequences can 
also interact with each other to form hybrid GQ sequences that have been suggested to 
regulate transcription termination (Skourti-Stathaki et al. 2011). RBPs such as the 
Senataxin helicase and Xrn2 endonuclease can  interact with and unwind the hybrid 
RNA/DNA GQs, subsequently leading to 3’end RNA product cleavage and release of RNA 
polymerase II from DNA (Skourti-Stathaki et al. 2011).  
An increasing body of evidence suggests that impaired biological function of RNA GQ 
structures could lead to diseases pathogenesis as demonstrated in cancer and several 
neurological disorders (review: Maizels, 2015). Reports demonstrating that RNA GQs act 
as cis-regulatory elements involved in mRNA expression regulation in several cancer-
related genes, include: the angiogenic factor, VEGEF; the tumour suppressor TP53 and 
the oncogene NRAS (Cammas et al. 2015; Kumari et al. 2007; Marcel et al. 2011). In the 
context of neurological disorders, a non-coding expansion of the GQ-forming 
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hexanucleotide repeat (GGGGCC) in the first intron of C9orf72 gene leads to 
frontotemporal dementia and/or amyotrophic lateral sclerosis (Reddy et al. 2013; Su et 
al. 2014). In addition, RNA GQs have been found to play a role in controlling microbial 
pathogenesis (Métifiot et al. 2014). For example, Epstein-Barr virus (EBV) encodes the 
RNA GQ binding protein, EBNA1. It has been suggested that EBNA1 is involved in an 
autoregulatory feedback loop that finely tunes its expression during the viral cell cycle 
process.  
The above outlined examples along with others suggest that the RNA GQs play an 
important role in regulating cell biology. Advancing our understanding of biological 
processes regulating RNA GQ function could help to uncover mechanisms behind the 
pathogenesis of many diseases and contribute to the development of potential 
treatments. 
 DUX4 transcript GQs and study objectives 
In this chapter we have explored the role of DUX4 transcript GQs on gene expression. In 
theory, formation of the RNA GQ in vivo is a more likely possibility compared to the DNA 
GQ motifs due to their increased thermal stability in the folded state in comparison to 
the DNA counterparts (Dolinnaya et al. 2016). In addition, the fact that the RNA is single-
stranded, means it does not have to compete with the hybridising forces of the 
complementary strand. Using bioinformatic and biophysical analysis, two stable RNA GQ 
motifs have been identified within the exon 1 and intron 1 of the DUX4 transcript 
previously (section 3.2.1). Furthermore, both of the analysed sequences show a 
relatively strong binding affinity (Ka) towards a GQ-stabilising small-molecule i.e., 
200 
 
berberine. Therefore, to investigate the effect of the DUX4 transcript GQs on gene 
expression, berberine was tested in the FSHD immortalised patient cells as well as cells 
transiently transfected with DNA plasmids containing the DUX4 transcript specific 
constructs sequence. Using RT- and RT-qPCR we demonstrate for the first time that the 
stabilisation of the novel DUX4 transcript GQ motifs could have a potentially 
downregulatory effect on DUX4 expression, providing a new platform for therapeutic 
strategy to treat the FSHD.  
5.2. Results 
 Berberine downregulates expression of DUX4 mRNA in FSHD cells 
The semi-quantitative analysis of the DUX4 expression in the FSHD-A5 cell line in the 
presence of berberine, demonstrated a dose dependent downregulation of the 
transcription factor (Figure 5.1 A.). At the lowest tested dose (5 μM), the recorded DUX4 
expression was reduced by 4% and the difference was not statistically significant (Figure 
5.1 C). However, at the highest ligand concentration (25 μM), the reduction of DUX4-
specific band was clearly apparent (p<0.0001) and it was quantified to be decreased by 
78% compared to the untreated samples (Figure 5.1 C). No DUX4 expression could be 
detected in the control cell line, FSHD-6 (Figure 5.1 B).  
To assess the effects of berberine on viability of FSHD immortalised patient cells the MTT 
assay was performed. The results indicated that berberine significantly reduced cell 
viability of FSHD-A5 myotubes in a dose-dependent manner (Figure 5.1 D). However, a 
large proportion of the cells did not demonstrate any cytotoxic effects leaving 40% (± 
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2.6%) of cells viable at the highest ligand concentration (Figure 5.1 D). Therefore, 
normalising DUX4 expression to a well-established housekeeping gene of FSHD 
immortalised patient cells such a B2M was necessary to ensure that the berberine-
mediated effect on DUX4 expression was not due to the cellular growth inhibition. 
Despite the berberine treatment and increased cytotoxicity, the treated cell populations 
still appear to express high levels of the house keeping gene, whereas the DUX4 
expression becomes significantly downregulated (Figure 5.1 A, B). Therefore, this 
strongly suggests that the effect of berberine treatment is predominately DUX4 specific 
and not due to the cytotoxic effect of the ligand. 
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Figure 5.1 DUX4 expression in FSHD-A5 and -6 cells, and cytotoxic effects of berberine treatment 
Immortalized FSHD-A5 (A.) and -6 (B.) myotubes were treated with berberine in a dose-dependent manner on the 2nd day of differentiation 
and incubated for an additional 48 hours before harvesting the total RNA. (A.) Representative RT-PCR analysis using primers detecting all DUX4 
full-length isoforms in the presence of berberine. B2M was used as the housekeeping gene. The DUX4 mRNA expression was represented as a 
percentage of band intensities normalised to their corresponding housekeeping bands (C.). The RT-PCR gel image (A.) was semi-quantitatively 
analysed using GeneTools showing a significant decrease of DUX4 mRNA level in a dose dependent manner (Syngene). (D.) Immortalized FSHD 
myotubes (which clone) were treated with berberine at the day 2nd of differentiation. The MTT cell viability assay was performed 48 hours after 
treatment.  Treated cells are compared to control cell with no berberine added. Independent treatment at each concentration was performed, 
N=6 (*p<0.05; **p<0.01; ***p<0.001, ****p<0.0001 one -way ANOVA). Error bars represent standard error of the mean (SEM).  
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 Berberine treatment leads to downregulation of DUX4 downstream genes 
DUX4 is a transcription factor that affects expression of several downstream genes. 
Since DUX4 expression levels in muscle tissue are very low and hard to detect, the 
signature expression of these downstream genes can serve as a useful DUX4 biomarker 
(Marsollier et al. 2016). The signature downstream genes that become upregulated by 
DUX4 have been previously determined and include: ZSCAN4, TRIM43 and MBD3L2 
(Ferreboeuf et al. 2014; Geng et al. 2012). These three genes have been selected for the 
RT-qPCR analysis to determine the effects of berberine on their expression. In the FSHD 
positive cell line all of the analysed downstream genes showed a significant 
downregulation at the lowest (5 μM) berberine dose, which was not observable when 
the DUX4 had been detected directly by the RT-PCR (Figure 5.2). The ZSCAN4 was 
significantly downregulated in a dose-dependent manner. In addition, all of the tested 
genes showed a highly statistically significant (p< 0.0001) expression downregulation at 
20 and 25 μM berberine dose. Interestingly, although the expression levels of TRIM43 
were significantly reduced at 10 μM compared to the control, when compared to 5 μM, 
there was an increase in expression of the downstream gene (Figure 5.2). Similarly, the 
MBD3L2 showed no statistically significant change at 10 μM, whereas it appears to be 
downregulated at a lower dose of 5 μM (Figure 5.2). No detectable levels of expression 
in any of the analysed downstream genes could be detected in the FSHD-6 negative 
control cell line (data not shown).
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Figure 5.2 Expression of the genes downstream of DUX4 in FSHD-A5 cells in the presence of berberine 
Expression levels of (A.) ZSCAN4, (B.) TRIM43 and (C.) MBD3L2 were measured by RT-qPCR in FSHD-A5 and -6 myotubes treated with the GQ 
ligand on the 2nd day of and harvested on the 4th day of differentiation. B2M was used as a housekeeping gene. Independent treatment at each 
concentration was performed, N=6 (*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001, one -way ANOVA). Error bars represent SEM. 
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 In-cell western assay to measure DUX4 protein expression 
Although the DUX4 protein is expressed at extremely low levels, it was estimated to be 
present in 1/1000 or 1/200 in primary patents myoblast and myotubes, respectively 
(Snider et al. 2010; Tassin et al. 2013). The first developed 9A12 mouse monoclonal 
antibody against DUX4 has shown to also strongly react with another highly homologues 
protein such as DUX4c (Dixit et al. 2007). More recently, a monoclonal DUX4 rabbit 
antibody (E5.5) targeting the DUX4-specific C-terminus have been developed and tested 
showing positive results in the C2C12 DUX4 transfected cells and cre-inducible DUX4 
transgenic mouse model (Geng et al. 2011; Jones and Jones 2018). Therefore, we asked 
a question whether the E5.5 rabbit monoclonal antibody can also successfully detect the 
DUX4 expression in the FSHD immortalised patient myotubes by using the in-cell 
western assay (ICW) as a readout. ICW is a quantitative immunostaining technique that 
allows to study levels of protein of interest (i.e., DUX4 using the E5.5 mouse monoclonal 
antibody in this case) in cells (Egorina et al. 2006). The normalising signal of the 
corresponding cells was produced by antibody staining of the myosin heavy chain (i.e., 
MF20). Unfortunately, the DUX4 expression could be detected in the FSHD positive (A5) 
myotubes as shown by the Odyssey Imaging system readout (Figure 5.3 A). As expected, 
there was no apparent expression of DUX4 present in the FSHD-6 myotubes either (FSHD 
5.3 A). Although quantification of the DUX4 expression could be detected as a weak 
signal in the FSHD-A5 cells, it was not statistically significantly different from the 
intensities of the DUX4 expression present in the negative control cell line, indicating 
that the measured emission is mostly a background signal noise (Figure 5.3 B).  
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In order to acquire a higher image resolution, to check for the potential DUX4 expression 
at the nuclear level within the FSHD immortalized myotubes, fluorescent microscopy 
analysis was performed. Despite using a relative high antibody concentration (1:100 
dilution), no positive DUX4 nuclei could be found in the patient myotubes using the anti-
DUX4 rabbit monoclonal antibody (E5.5) (Figure 5.4 A).
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Figure 5.3 In-cell western measuring DUX4 protein levels in FSHD patient cells treated with GQ ligand 
Immortalized FSHD-A5 (DUX4 positive) and FSHD-6 (DUX4 negative) myotubes were treated with berberine in a dose dependent manner on the 
2nd day of differentiation. Treated cells were fixed and permeabilized on the 4th day of differentiation. (A.) Representative in-cell western image 
where DUX4 was measured using rabbit anti-DUX4 (E5.5) primary antibody followed by the detection with Goat anti-Rabbit secondary antibody. 
Normalization to number of differentiated cells was performed by staining myosin heavy chain with the mouse IRDye 800CW anti-MF20 primary 
antibody. The plate was scanned on Oddysey Classic Infrared Imaging System (Resolution: 100 μM; Quality: medium; Focus offset: 4.0 mm; 
Intensity: 7 and 8 for 700 and 800 Channel, respectively) (B.) Values of DUX4 intensity were normalised to the MF20, demonstrating no 
statistically significant change in DUX4 expression upon berberine treatment in each cell group. Independent treatment at each concentration 
was performed, N=8 (one -way ANOVA). Error bars represent standard error of the mean (SEM). 
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Figure 5.4 Immunocytochemistry to detect DUX4 protein expression in FSHD-A5 cells treated with berberine 
Immortalized FSHD-A5 (DUX4 positive) myotubes were treated with berberine in a dose dependent manner on the 2nd day of 
differentiation. Treated cells were fixed and permeabilized on the 4th day of differentiation. DUX4 stained using rabbit anti-
DUX4 (E5.5) primary antibody followed by detection with AlexaFluor488 Goat anti-Rabbit secondary antibody. FITC channel was 
used to detect the DUX4. No DUX4 was detected. Scale bar: 100 μm. 
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Figure 5.5 Immunocytochemistry to detect DUX4 protein expression in FSHD-6 cells treated with berberine 
Immortalized FSHD-6 (DUX4 negative) myotubes were treated with berberine in a dose dependent manner on the 2nd day of 
differentiation. Treated cells were fixed and permeabilized on the 4th day of differentiation. DUX4 stained using rabbit anti-
DUX4 (E5.5) primary antibody followed by detection with AlexaFluor488 Goat anti-Rabbit secondary antibody.  FITC channel was 
used to detect the DUX4. No DUX4 was detected. Scale bar: 100 μm. 
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 Berberine increases fusion index of FSHD cells and induces a phenotypic switch 
from atrophic to disorganised myotube morphology 
One of the mechanism by which a rare protein such as DUX4 can cause myopathy is its 
ability to diffuse across the cytoplasm of myotubes to the neighbouring nuclei and lead 
to aberrant activation of many downstream genes (Ferreboeuf et al. 2014).Therefore, in 
order to ensure that the berberine downregulation of the measured DUX4 downstream 
genes (i.e., ZSCAN4, TRIM43 and MBD3L2) was not an indirect effect of the myotube 
formation defect caused by the presence of the ligand, the fusion index of the FSHD 
myotubes (clones –A5 and -6) was assessed. The berberine treated cells were 
immunostained with the antibody specific for the myosin heavy chain (MF20), whereas 
the nuclei were visualised using DAPI (Figure 5.6 A). The nuclei present in the MF20 
positive myotubes were counted and divided by the total number of nuclei present in 
all cells of each filed. The fusion index was expressed as the percentage ratio of myotube 
-related nuclei vs. total number of nuclei (Figure 5.6 B). A statistically significant increase 
in the index fusion was observed across all tested concentrations of berberine, 
suggesting that the downregulation of the DUX4 downstream genes was not caused by 
the impairment of the myotube formation, but it was rather DUX4 specific. This idea was 
further supported by the fact that the negative control cells did not show any statistically 
significant change in the calculated fusion index (Figure 5.7 B).  
Two phenotypes of FSHD primary myotubes were previously reported: the atrophic and 
disorganised (Barro et al. 2010; Tassin et al. 2012). The atrophic phenotype was 
characterised by a narrow elongated myotubes with neatly aligned nuclei, whereas the 
disorganised myotubes were described as giant structures containing large clusters of 
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nuclei. Furthermore, an antisense-mediated downregulation of DUX4 have been 
demonstrated to lead to the prevention of the atrophic, but not disorganised myotube 
phenotype formation in FSHD primary cell culture (Ansseau et al. 2017). Interestingly, 
berberine treatment led to phenotypic switch from atrophic to disorganised state in 
FSHD immortalised myotubes (Figure 5.2.6 A). The clustering of nuclei in the berberine 
treated FSHD negative control cells was not as apparent, suggesting that the phenotypic 
switch could be DUX4 related (Figure 5.2 7 A).
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Figure 5.6 Fusion index of immortalized FSHD-A5 myotubes treated with berberine 
(A.) Immortalized FSHD myotubes were treated with berberine at the day 2nd of 
differentiation. Myosin heavy chain and nuclei were stained at the 4th day of 
differentiation with the MF20 antibody and DAPI, respectively. (B.) For fusion index 
calculation, nuclei were counted in myotubes containing two or more nuclei and were 
expressed as a percentage of total nuclei present. Independent treatment at each 
concentration was performed, N=8 (*p<0.05; **p<0.01; ***p<0.001, one -way ANOVA). 
Error bars represent standard error of the mean (SEM). 
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Figure 5.7 Fusion index of immortalized FSHD-6 myotubes treated with berberine 
(A.) Immortalized FSHD myotubes were treated with berberine at the day 2nd of 
differentiation. Myosin heavy chain and nuclei were stained at the 4th day of 
differentiation with the MF20 antibody and DAPI, respectively. (B.) For fusion index 
calculation, nuclei were counted in myotubes containing two or more nuclei and were 
expressed as a percentage of total nuclei present.  
Independent treatment at each concentration was performed, N=8 (*p<0.05; **p<0.01; 
***p<0.001, one -way ANOVA). Error bars represent standard error of the mean (SEM). 
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 Berberine-mediated downregulation is DUX4 transcript specific 
Since GQ structures have been predicted to prevalently form across the human genome, 
one must bear in mind that berberine could have potential DUX4-unspecific, off target 
effects. Indeed, this work has demonstrated that stable GQ motifs form within multiple 
genomic loci and transcript of DUX4 sequence that could serve as potential targets for 
the ligand (Section 3.2). Furthermore, we have demonstrated that the predicted GQ 
structure within the D4P sequence has a relatively weak effect on regulating the gene 
expression in a transient expression reporter system (Section 4.2.4). Therefore, the next 
question to address was whether berberine-mediated strong inhibition of DUX4 
expression in FSHD patient cells (Figure 5.1 A) was the result of transcript-specific 
targeting by the ligand. To answer this issue, two plasmid constructs were developed, 
where the DUX4 transcript sequence expression was driven by the endogenous D4P 
fragment or the non-native CMV promoter (Figure 5.8 A and B). In addition, a CMV 
driven, eGFP expressing plasmid was used as a control to determine if the berberine 
treatment could affect transfection reaction or influence expression from a plasmid 
deprived of GQ sequences (Figure 5.8 C). The berberine treatment was applied at the 
day of transfection to RD CCL 136 cells for 24 hours before the total RNA was harvested 
for the RT-qPCR analysis. The plasmid DUX4 expression construct driven by the D4P 
begins to show a statistically significant downregulation of the gene expression at 50 
μM of the ligand concentration (Figure 5.8 A). The CMV-driven construct shows a 
significant downregulation of DUX4 expression at lower drug concentration of 20 μM 
(Figure 5.8 B). Furthermore, the DUX4-downregulation from the CMV-containing 
plasmid continued to decrease in dose dependent manner (Figure 5.8 B). Since the CMV 
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promoter does not contain any GQ structures, the effect of berberine could be related 
to binding of secondary structures present within the mRNA and/or the coding sequence 
of the DUX4. This idea is supported by the fact that berberine shows strong binding 
affinity towards the DUX4 RNA GQs (e.g., E1 and SS1 RNA GQs) derived from the 
transcript sequence of the gene (section 3.2.4). The potential mechanisms how 
berberine could downregulate the DUX4 expression on the level of the mRNA are 
discussed in detail in section 5.3. The expression of the negative control plasmid shows 
no change in CMV-driven eGFP at any of the tested concentrations of the ligand, further 
strengthening the idea that the berberine-mediated downregulation of DUX4 is 
specifically related to the gene’s transcript and/or gene coding sequence (Figure 5.8 C). 
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Figure 5.8 Levels of transiently expressed DUX4 transcript at increasing berberine concentrations in RD CCL 136 cells 
Expression levels of DUX4 mRNA was measured using RT-qPCR in rhabdomyosarcoma (RD) CCL 136 cells transfected with 1μg of the pAAV.DUX4 
using LipofectamineTM 3000 (Invitrogen) and simultaneously treated with berberine. Total RNA was harvested 24 hours after transfection and 
treatment. GAPDH was used as a housekeeping gene. (A.) Top: schematic presentation of the transfected plasmid containing DUX4 driven by its 
native promoter sequence (D4P). Bottom: Downregulatory effect of the berberine on DUX4 expression from the transfected plasmid (B.) Top: 
Schematic presentation of the transfected plasmid containing DUX4 driven by a CMV promoter. Bottom: Downregulatory effect berberine on 
DUX4 expression from the transfected plasmid (C.) Top: schematic of the negative control plasmid expression eGFP driven by the CMV promoter.  
Berberine treatment in (A.), (B.) and (C.) was performed independently with N=3; N=6 and N=6, respectively (**p<0.01; ****p<0.0001, one -
way ANOVA). Error bars represent SEM. 
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5.3. Discussion 
Our understanding of the FSHD pathophysiology has advanced significantly in recent 
years (review: (Tawil et al. 2014). The current consensus recognises that the postnatal 
expression of the DUX4 is a key factor causing the disease. The novel finding showing 
that the GQ motifs present within the coding sequence of the gene, could potentially 
lead to further understanding the molecular mechanism that govern expression of the 
DUX4. In this study, we have demonstrated that berberine leads to downregulation of 
the DUX4 mRNA levels in FSHD immortalised patient cells. In addition, the ability of 
berberine to downregulate DUX4 expression could be specifically related to its 
coding/transcript sequence as demonstrated by the reporter studies.  
Since RNA GQs are implicated in mRNA transcription and processing, it is possible that 
the berberine treatment mediates downregulation of DUX4 mRNA by interference with 
these processes. For example, during transcription, the newly produced pre-mRNA 
sequence strand can fold into an intermolecular GQ structure with the coding (sense) 
DNA strand (Zhang et al. 2014). The RNA transcript sequence and the coding DNA strand 
require as little as two tandem G-tracks to form a stable GQ structure (Duquette et al. 
2004). Formation of such a hybrid RNA/DNA GQs has been predicted and confirmed in 
vitro using T7 RNA polymerase transcription, site specific mutagenesis and reporter-
based transient transcription assays (Wanrooij et al. 2012; Zheng et al. 2013). These 
studies conclude that formation of RNA/DNA hybrid GQ structures act as potential in-cis 
elements mediating transcription inhibition. The hybrid GQ structures are thought to be 
also involved in transcription termination as they have been observed to pause RNA 
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polymerase II transcription (Gromak et al.  2006; Skourti-Stathaki et al. 2011). The 
RNA/DNA GQ structures have been predicted to form downstream of poly(A) signals and 
since these motifs are very stable, a helicase Senataxin (SETX) is required to resolve 
these. Binding of SETX, promotes of endonucleolytic cleavage at the poly(A) and finally 
release of the newly synthesised pre-mRNA from RNA polymerase II (Gromak et al. 2006; 
Skourti et al. 2011). Therefore, berberine binding to RNA/DNA hybrid motifs formed 
from the DUX4 transcript and DNA coding strands could potentially prevent functions of 
the specific GQ helicases that ensure the resolution of these structures and 
consequently lead to premature transcription termination and DUX4 downregulation.  
In addition, the transcription termination is tightly linked to the polyadenylation process 
at the 3’end (Mandel, Bai, and Tong 2008). Briefly, the mammalian canonical 
polyadenylation involves pre-mRNA 3’UTR signals recognition (e.g., AAUAAA) by a 
multisubunit protein complex (CFI, CFII, CPSF and CstF). In the case of cellular stress and 
DNA damage, the CstF factor becomes sequestered and the polyadylation regulatory 
complex becomes inactive (Shi and Manley 2015). In the pre-mRNA of TP53, a GQ 
structure proximal to the polyadenylation sequence binds a hnRNP H/F slicing factor 
that in turn recruits and protects CstF from sequestration and allows efficient 
polyadenylation to occur (Decorsière et al. 2011). Perhaps DUX4 3’UTR sequences could 
also aid the process of polyadenylation of the DUX4 transcript, even under cellular stress 
conditions induced by the toxic transcription factor itself. Moreover, the berberine 
binding to the DUX4 RNA GQs could potential prevent formation of the polyadenylation 
complex by interfering with binding of its components (e.g., nhRNP H/F).  
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Three DUX4 transcript isoforms have been detected in primary FSHD myoblasts and 
myotubes (Dixit et al. 2007; Snider et al. 2009). In this study, only the two full-length 
DUX4 transcripts PCR that are thought to be responsible for the formation of the 
functional toxic DUX4 protein have been detected using RT-PCR-. However, there are a 
growing number of reports indicating that the DUX4 can also be alternatively spliced 
into a short isoform (DUX4-s) that would form a truncated protein with a functional DNA 
binding domain but lacking the effector domain (Jones and Jones 2018; Snider et al. 
2009). Therefore, the DUX4-s could potentially have an inhibitory effect on the function 
of the full length toxic protein variant by competing for the DNA target binding site. 
Interestingly, it has been demonstrated that the intronic and exonic RNA quadruplexes 
can be involved in the regulation of alternative splicing (review: Fay et al. 2017). A non-
exhaustive list of physiologically relevant genes that utilise quadruplex motifs to 
regulate splicing of their transcripts, include: B-tropomyosin, hTERT, PAX9, p53, BACE-1 
and FMR1 (Didiot et al. 2008; Fisette et al. 2012; Marcel et al. 2011; Ribeiro et al. 2015). 
Generally, the GQ formation regulates the splicing process by either masking binding 
sites of the target proteins or recruiting GQ-specific biding proteins (e.g., hnRNP protein 
family) (Dominguez et al. 2010). For example, formation of different Fragile X mental 
retardation protein isoforms is regulated by to the exonic GQ structures that provide a 
binding site for a splicing enhancer (Bensaid et al. 2009). By analogy, the GQ structures 
present within the exon 1 of the DUX4 transcript could potentially promote the 
expression of the DUX4-s isoform, which would not be detected by the primers used to 
detect the full-length variant here. Although it is not clear how berberine targeting GQ 
or how these motifs could regulate splicing by of the DUX4 transcript, these are 
interesting questions that could be addressed in the future.   
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The main hallmark of the FSHD molecular mechanism is loss of the epigenetic marks 
within the D4Z4 region leading to chromatin de-repression and DUX4 expression. An 
important epigenetic modificator, EZH2, has been previously found to be enriched 
within the D4Z4 repeat array in healthy primary myocytes, but not in the cells derived 
from the FSHD patients (Cabianca et al. 2012). EZH2 is one of the components of the 
PRC2 complex that acts as an epigenetic transcriptional repressor shown to regulate 
developmental processes and cancer (Sellers and Loda 2002). Interestingly, the EZH2 
has been found to bind to RNA GQs with significantly higher affinity compared to its DNA 
counterparts (X. Wang et al. 2017). It has been now well demonstrated that RNA GQs 
can play an important function in disease pathogenesis by sequestering important RNA-
binding proteins (Cammas et al. 2015). For example, a large hexanucleotide repeat 
expansion within intron 1 that leads to formation of stable RNA GQ structures within 
the pre-mRNA of C9orf72 gene (Reddy et al. 2013). The C9orf72 is a key factor behind 
the pathogenesis of ALS and its transcript’s RNA GQ has been demonstrated to bind and 
sequester important splicing and polyadenylation regulator (e.g., nhRNP H/F), leading 
to a global deregulation of RNA processing evens (Wang et al. 2015). Therefore, an 
interesting hypothesis arises suggesting that the DUX4 transcript could contribute to the 
disease pathogenesis by interfering with the epigenetic pathway regulating D4Z4 array 
repressive chromatin state. Targeting of the DUX4 RNA GQ with small molecules could 
potentially prevent sequestration of important epigenetic modificators (e.g., EZH2) and 
consequently result in DUX4 expression suppression.  
RNA GQ motifs found in open reading frames have also been found to act as 
‘roadblocks’, inhibiting progression of ribosomes along the mRNA, leading to 
significant decrease in protein synthesis efficiency (Endoh and Sugimoto 2016). The 
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RNA GQ downstream of start codon (downstream of 5’UTR) have been found to be 
particularly effective in blocking translation, as demonstrated in the context of KMT2A 
and MLL protooncogenes, where the in line probing combined with the G-A 
mutagenesis and the luciferase assay showed over 75% reduction in protein synthesis 
to be RNA GQ structure related (Thandapani et al. 2015). Presence of stable RNA GQ 
structures within the coding sequence of DUX4 could perhaps also negatively affect its 
translation, providing a potential explanation for the low levels of DUX4 protein 
present in the patient cells.  
Berberine treatment of the FSHD immortalised patient cells has led to significant 
decrease in cell viability. Since the immortalised clones were produced by 
retrotransduction of the hTERT gene, it has been anticipated that berberine could have 
an anti-proliferative effect on these cells (Krom et al. 2012). HTERT is an important 
enzyme involved in lengthening of the telomeric chromosome ends and maintaining 
chromosomal stability (Thorley et al. 2016). However, when overexpressed, it leads to 
cell immortalization and eventually results in wide range of cancers (Cong, Wright, and 
Shay 2002). It has been demonstrated that berberine strongly downregulates expression 
of hTERT and binds to GQ-forming telomeric ends sequences, resulting in growth 
inhibition of cancer cell lines (Fu et al. 2013). Therefore, the primary cause of berberine-
mediated decrease of viability of the patient cells could be a result of interference of the 
ligand with the immortalization pathways. It would be interesting to perform the same 
berberine treatment on primary FSHD patient cell lines to establish whether the 
cytotoxic effects of berberine are specifically attributed to the targeting of the hTERT-
related pathway present in the FSHD immortalised patient cells.  
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Berberine treatment has been demonstrated to lead to DUX4 mRNA downregulation in 
FSHD immortalised patient cells and in RD cells transiently expressing DUX4. 
Furthermore, the shift of the atrophic to disorganised myotube phenotype, could 
further suggest that the treatment is DUX4-specific as it has been previously implied 
(Ansseau et al. 2017). However, since berberine has been found to have a range of 
pharmacological activities, including anti-inflammatory, antimicrobial and anti-tumour 
effects, it is inevitable that berberine has DUX-nonspecific off-target effects (Ganesan 
and Xu 2017). This is also further supported by the fact that berberine, apart from the 
DUX4 transcript, it has a high affinity binding towards the GQ-forming sequences within 
its own enhancer and promoter regions (section 3.2). There is currently no feasible 
method to target specific GQs within the genome, having said that, new small molecule 
chemistries have begun to emerge that have high binding selectivity to GQ over duplex 
DNA or in some cases can even discriminate between RNA and DN GQ structures. Two 
small-molecule ligands have been recently developed able to target RNA GQs, namely 
carboxy pyridostatin and RGB1 (Di Antonio et al. 2012; Katsuda et al. 2016). Since the 
DUX4 transcript’s RNA GQ are demonstrated be a likely target of berberine that leads to 
its mRNA downregulation, it would be interesting to evaluate these RNA GQ specific-
ligands and their ability to suppress expression of the toxic transcription factor. The 
RBG1 is especially interesting candidate molecule, due to its ability to specifically bind 
RNA GQ not only over the DNA counterparts, but also other RNA structures.  
One promising strategy that could potentially address the specificity issue of small-
molecule RNA GQ targeting, is the use of antisense oligonucleotide (AO) chemistries. 
AOs can be designed to target GQ structures based on their sequence, which is the level 
of specificity currently unattainable by any other types of chemical compounds. Indeed, 
228 
 
disruption of RNA GQ folding of the H2AFY’s gene mRNA in human cell line has shown 
to interfere with its translational processes regulating the gene’s expression (Rouleau et 
al. 2015). A number of strategies, utilising various AO chemistries have been deployed 
over the years to regulate mRNA processing, including: interference with 5’-cap 
formation; splicing regulation, degradation of the transcript by the RNase H1-induced 
cleavage or interference with 3’UTR elements; and translation inhibition by interference 
with ribosome access (DeVos and Miller 2013; Marsollier et al. 2016). However, the 
strategy of modulating RNA GQ structures of DUX4 transcript using an AO approach to 
regulate its expression has not been studied. Since the antisense technology shows a 
very promising clinical potential as a treatment for muscular dystrophies, it provides an 
interesting avenue of research for development of novel therapeutic strategy to target 
the DUX4 expression.
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6. Final discussion, evaluation and future directions 
6.1. Summary of results 
The paramount objective of this thesis was to advance our understanding of the 
molecular mechanisms that lead to FSHD pathophysiology. More specifically, it aimed 
to investigate the strength and possible roles of GQ motifs forming within the genomic 
loci (e.g, enhancer and promoter) and transcript of DUX4.  These genetic regions of 
DUX4 were subjected to bioinformatic analyses to assess the potential formation of GQ 
structures. Novel putative GQ-forming sequences were predicted within the enhancer 
and promoter regions. In addition, the DUX4 transcript has been found to be particularly 
enriched in putative GQ motifs. Aided by these bioinformatic results, candidate 
oligonucleotide sequences were selected and analysed for the formation of the GQ 
structures in solution using CD and NMR. The biophysical analysis confirmed that the 
enhancer-, promoter-, and transcript-related putative GQ-forming oligonucleotides had 
indeed formed GQs is solution. Next, a binding interaction of berberine, a small-
molecule known to interact with GQs, with the GQ-forming candidate sequences was 
assessed. Berberine was shown to have a particular high binding affinity towards the 
DUX4 locus enhancer GQ-related sequence. The RNA GQ sequences appear to be 
weaker binders of berberine compared to the DNA counterparts.  
Due to an extensive focus of the scientific literature on promoter-related GQs 
(Balasubramanian et al. 2011), particularly in the context of oncogene expression, the 
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next task undertaken in this thesis was to investigate the role of the GQ-forming 
sequence within the promoter fragment of DUX4. First, substitution of the motif’s 
sequences was performed to disrupt the secondary structure and confirm GQ presence. 
Since the GQ- forming sequences were also predicted to have the potential to form 
alternative non-GQ hairpin structures, both of these putative motif types were disrupted 
by the sequence substitution as shown by the CD and NMR analysis. In addition, the 
mutagenised DUX4 promoter variants with the disrupted secondary structures were 
cloned upstream of an eGFP reporter cassette, to assess their activity to drive gene 
expression. The results demonstrated a statistically significant downregulation of gene 
expression driven by the promoter, with the deprived GQ-forming sequence, whereas 
the presence of hairpin-forming sequence has demonstrated to play no significant role. 
The experimental attempt to demonstrate that stabilisation of GQ-structures of the 
promoter using berberine resulted in enhanced expression was thwarted by the fact 
that berberine and GFP have overlapping emission/excitation wavelengths, which 
produced a significant signal noise in the flow cytometry readout. However, the 
mutagenesis studies, combined with previous literature (Armas et al. 2017) strongly 
suggest that due to the position of the GQ within the DUX4 promoter fragment (i.e., 
coding/positive strand and upstream of the TATA box), this structure could have a weak 
positive effect on transcription by contributing to double helix unwinding, which allows 
easier access of the transcriptional machinery binding. Although we concluded that the 
investigated promoter GQ sequence is a most likely weak, finely tuning in-cis element 
regulating DUX4 expression, its potential to form an intramolecular GQ structure with 
its corresponding enhancer sequence to control the interaction between these two 
crucial transcriptional elements is a very interesting but unexplored possibility. 
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Finally, in chapter 5 the effects of berberine on DUX4 mRNA expression were 
investigated in FSHD immortalised patient cells. The small molecule was demonstrated 
to have a strong downregulatory effect on expression of the toxic transcription factor as 
well as its downstream target genes, without a negative effect on the fusion index 
processes of the treated cells. Furthermore, it has been demonstrated that the potent 
downregulation of the DUX4 expression is likely to be related to berberine-mediated 
interferences of mechanisms mediating transcription and/or transcript processing as 
demonstrated in the reporter-based assay. Considering that the DUX4 transcript is 
enriched in GQ-forming sequences, bound with high affinity by berberine, strongly 
suggest the small-molecule mediated downregulation of DUX4 is a result of its binding 
to the DUX4-specific GQ motifs. Although the molecular mechanisms of berberine-
mediated DUX4 downregulation are not clear at this stage, the potential GQ-related 
pathways of the compound have been discussed in section 5.3. 
6.2. Evaluation and future directions 
The field of GQ epigenetics of FSHD has been previously virtually unexplored. This work 
provides the first comprehensive set of evidence indicating the presence of GQs in DUX4 
genomic loci, and transcript, that could potentially play an important role in the 
regulation of gene expression. The understanding of GQ biology is ever-expanding and 
the novel techniques to evaluate their role are constantly being developed. 
Furthermore, cellular and animal models that help recapitulate FSHD are also emerging. 
Taking advantage of the recent advancements in these scientific fields could significantly 
advance understanding of the FSHD-related GQ function.  
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Since it has been found that the DUX4 DME1 enhancer sequence forms a very stable GQ 
structure that binds berberine with high affinity, it would be interesting to investigate 
the role of the motif in a similar way to that used to examine the promoter elements. 
For example, the enhancer elements could be included in a reporter gene system and 
its intramolecular GQ-forming sequences disturbed through mutagenesis, and/or 
stabilised by small-molecule (e.g. berberine) binding, to determine the potential role of 
the motif on the gene expression regulation. Clearly, if berberine was to be used to 
assess the DME1 enhancer GQ function, an alternative cassette expressing a protein 
would be required with different excitation/emission to spectra to berberine to avoid 
the interference of the signal readout from the flow cytometry seen with eGFP. 
Alternatively, the luciferase reporter system could be used, where the signal is a result 
of an enzymatic reaction, and the reporter product serves as a substrate and therefore 
would not result in formation of a fluorescent activity by berberine.  
Although protein binding to the DUX4 promoter fragment has been previously assessed 
(Sharma et al. 2016), studies describing DUX4 enhancer-associated in-trans factors are 
not currently available. It would be therefore interesting to investigate DUX4 
promoter/enhancer-associated proteins and determine, whether the GQ-forming 
motifs influence these interactions by for example performing ChIP analysis. RNA-
binding proteins associated with the DUX4 transcript could also be investigated and 
evaluated for their potential to interact with the RNA GQ structures.  
The biophysical tools used in this thesis show the formation of GQ structures in isolated 
short sections of a given sequence. However, the bioinformatic analysis has 
demonstrated that the transcript sequence in particular is enriched in multiple 
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(potentially overlapping) RNA GQ sequences. Recently, a method has been developed 
where long stretches of RNA sequences can be footprinted for the presence of GQ by 
performing the 7-deazaguanine substitution (Weldon et al. 2017). The 7-deazaguanine-
substituted RNA is not able to form GQs, which allows differential identification of the 
structures in the control RNA sequences. Therefore, it would be interesting to confirm 
the DUX4 transcript GQ structures identified by bioinformatic and biophysical analyses 
in our studies using this novel foot-printing method. 
Accurate mapping of the DUX4 RNA GQ could also aid rational design of specific AOs 
that could target and potentially disrupt the structures by competitive hybridisation and 
interference with structural components (e.g., G-tetrad sequences) that are essential for 
the formation of the motif. The AO-mediated targeting of the DUX4 RNA GQs could help 
understand their potential role in regulating the transcript processing such as splicing 
and/or polyadenylation. 
Development of animal models for the FSHD has proven difficult over the years. The 
main hurdle behind modelling of FSHD is the fact that the D4Z4 microsatellite repeat 
region containing the DUX4 gene is conserved only to Old World primates, which has led 
to the absence of naturally-arising models of the disease in common animal species used 
in laboratories (Leidenroth and Hewitt, 2010). Attempts to create a mouse animal model 
that carries the contracted FSHD1 or full wild-type D4Z4 allele was performed (Krom et 
al. 2012). However, despite achieving a genetic signature equivalent to the one seen in 
the FSHD patient (i.e. detectable levels of DUX4 and dysregulation of its downstream 
genes) no disease-specific phenotype could be recapitulated in these animals (Krom et 
al. 2012). Recently, a cre-inducible DUX4 transgenic mouse has been created that 
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manifests the FSHD -related myopathy (Jones and Jones, 2018). However, the promoter 
and enhancer elements that have been introduced to drive DUX4 expression in this 
model, were not endogenous to the transcription factor, which eliminates the possibility 
of studying the GQ structures related to these transcriptional elements.  
Another approach to model the FSHD pathogenesis has utilised adeno-associated virus 
mediated delivery of myopathic DUX4 gene constructs in vivo (Wallace et al. 2012). At 
the time of writing of this thesis, it has been decided to deliver the AAV vector expressing 
the DUX4 (kindly provided by Dr Harper, The Ohio State University) into mouse (wild-
type C57BL/6) muscle tissue and investigate if berberine treatment could potentially 
prevent the disease phenotype. Interestingly, the initial results indicate that berberine 
treatment reverses the DUX4- induced histopathological changes of the muscle tissue 
by significantly reducing the central nucleation and fibrotic markers (Dr. Lu-Nguyen, 
Personal communications). In addition, the berberine treatment also reduces the DUX4 
protein levels as well as significantly improving muscle function as demonstrated by the 
improved muscle specific force of the berberine-treated tissue (Dr. Lu-Nguyen, Personal 
communications). It is important to note the DUX4 expression from the AAV vector was 
driven by the non-endogenous CMV promoter that lacks functional GQ motifs (Huang et 
al. 2012; Salvati et al. 2014). Therefore, it can be speculated that the berberine-
mediated DUX4 downregulation is specific to stabilisation of the GQs forming in the 
transcript rather that to the promoter/enhancer-related GQs. This was supported by the 
finding that berberine shows strong binding affinity towards the DUX4 RNA GQs (e.g., 
E1 and SS1 RNA GQs) (section 3.2.4). Even though berberine does not induce structural 
changes to these RNA GQs, as reported in the case of the DUX4 promoter-related GQ, 
strong binding of berberine to the DUX4 RNA GQ structures alone could lead to 
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downregulation of gene expression. The suggested mechanisms explaining DUX4 
downregulation mediated by the berberine biding to the gene’s transcript were outlined 
in section 5.3. 
Considering the vast growth in the scientific advancements of both FSHD and GQ fields, 
multiple exciting opportunities arise for the future research that can combine and 
further explore the two domains of study. 
6.3. Concluding remarks 
The molecular mechanisms that underlie FSHD pathogenesis have been investigated for 
over two decades. Here we make a scientific contribution to the field by showing that 
the GQ structures are novel epigenetic elements involved in regulating DUX4 expression. 
Future work on GQ function in FSHD may facilitate the identification of new drug targets 
and the development of new treatments for the disease as well as fully confirm 
authenticity of the observed GQ structures as important components in the molecular 
pathology of FSHD. 
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APPENDIX: Scientific publications 
Research Article: Antisense targeting of 3’end elements involved in DUX4 
mRNA processing is an efficient therapeutic strategy for Facioscapulohumeral 
Dystrophy: a new gene silencing approach 
Anne-Charlotte Marsollier, Lukasz Ciszewski, Virginie Mariot, Linda Popplewell, Thomas Voit, 
George Dickson, Julie Dumonceaux. 
Hum Mol Genet. 2016 Apr 15;25(8):1468-78 
ABSTRACT: 
Defects in mRNA 3’ end formation have been described to alter transcription 
termination, transport of the mRNA from the nucleus to the cytoplasm, stability of the 
mRNA and translation efficiency. Therefore, inhibition of polyadenylation may lead to 
gene silencing. Here, we choose Facioscapulohumeral Dystrophy (FSHD) as a model to 
determine whether or not targeting key 3’end elements involved in mRNA processing 
using antisense oligonucleotide drugs can be used as a strategy for gene silencing within 
a potentially therapeutic context. FSHD is a gain-of-function disease characterized by 
the aberrant expression of the DUX4 transcription factor leading to altered pathogenic 
deregulation of multiple genes in muscles. Here we demonstrate that targeting either 
the mRNA polyadenylation signal and/ or cleavage site is an efficient strategy to 
downregulate DUX4 expression and to decrease the abnormally high pathological 
expression of genes downstream of DUX4. We conclude that targeting key functional 
3’end elements involved in pre-mRNA to mRNA maturation with antisense drugs can 
lead to efficient gene silencing and is thus a potentially effective therapeutic strategy for 
at least FSHD. More over polyadenylation is a crucial step in the maturation of almost 
all eukaryotic mRNAs, and thus all mRNAs are virtually eligible for this antisense-
mediated knockdown strategy. 
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Book Chapter: Antisense Oligonucleotide Targeting of 3’-UTR of mRNA for Expression 
Knockdown 
 
Golnoush Golshirazi, Lukasz Ciszewski, Ngoc Lu-Nguyen, Linda Popplewell 
 
‘Exon skipping and Inclusion Therapies’ Methods Molecular Biology, Vol 1828, ISBN:978-1-
4939-8650-7 
 
Abstract: 
 
With the recent conditional approval of an antisense oligonucleotide (AON) that 
restores the reading frame of DMD transcript in a subset of Duchenne muscular 
dystrophy patients, it has been established that AONs sharing similar chemistry have 
clear clinical potential. Genetic diseases, such as facioscapulohumeral dystrophy (FSHD), 
can be the result of gain-of-function mutations. Since mRNA processing in terms of 
termination of transcription, its transport from the nucleus to the cytoplasm, its stability 
and translation efficiency are dependent on key 3’UTR elements, it follows that targeting 
these elements with AONs have the potential to induce gene silencing. Aberrant 
expression of the Double homeobox 4 (DUX4) transcription factor and the downstream 
consequences of such expression is the hall-mark of FSHD. Here we describe the 
bioinformatic strategies behind the design of AONs targeting polyadenylation signals 
and the methodologies relevant to their in vitro screening for efficacy and safety, 
including analysis of expression at the transcript and protein level of the specific target 
and downstream genes, and measurement of the effect on the fusion index of 
myotubes. The targeting of permissive DUX4 and MSTN are used as examples. MSTN 
encodes for myostatin, a negative regulator of myogenesis; the downregulation of 
MSTN expression has the potential to address the muscular atrophy associated with 
muscular dystrophies, sarcopenia, cancer and acquired immunodeficiency syndrome. 
